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Abstract 
NON-TRANSFERRIN-BOUND IRON AND PROTEIN GLYCATION IN TYPE 2 DIABETES  
Desley Louise White 
Background and Methods 
The involvement of iron in the risk for, and complications of, type 2 diabetes has 
generated substantial interest over the past 15 years, initially sparked by an 
association with raised serum ferritin, and the observation that people with iron 
overload diseases frequently develop diabetes.  Considerable advances have since 
been made in understanding the effect glucose has on molecules, cells, and tissues; 
and the role that oxidative stress plays in the development of the pathologies of long-
term diabetes. Poorly liganded iron is potentially both a contributor to, and 
consequence of, these complications. 
In vitro experiments with glucose-incubated transferrin by earlier workers have 
demonstrated loss of function with increasing glycation, leading to the suggestion that 
the failure of this key iron-binding protein may contribute to diabetic pathology, via 
the presence of redox active non-transferrin-bound iron (NTBI). In vitro glycated 
transferrin is examined here by ultrafiltration, to assess loss of function and possible 
oxidative fragmentation. Mass spectrometry is used to identify a range of amino acid 
glycation sites on in vitro glycated transferrin for the first time. Finally, several groups 
have previously measured NTBI in people with diabetes, finding little agreement in 
results.  NTBI is measured here in a cohort of people with type 2 diabetes, using a new 
adaptation of earlier NTBI assays. NTBI is also assessed in pre-dialysis chronic kidney 
disease (CKD) stages I to III for the first time. 
Results and Conclusions 
Experiments with glycated transferrin in vitro demonstrate oxidative fragmentation, 
explaining the loss of function reported by earlier groups. In vitro glycated transferrin 
examined by mass spectrometry reveals a substantial number and range of amino 
acids subject to glycation. Comparison with in vivo glycated transferrin suggests that 
many of the in vitro glycation sites are not glycated in vivo, and that there are many 
oxidized methionine residues which are potential artefacts, or likely to be repaired by 
methionine sulphoxide reductases in vivo. A study of people with type 2 diabetes finds 
no direct association between NTBI and protein glycation. Unexpected correlations 
between NTBI and LDL, and LDL and haemoglobin with increasing protein glycation, 
are reported for the first time. NTBI is suggested to be iron sourced from haemoglobin 
or haem, from erythrocyte haemolysis prior to sample collection. In people with pre-
dialysis CKD stages I to III no significant difference in NTBI level compared to controls is 
seen, or correlations with markers of renal function. No link between NTBI and kidney 
function at this stage of disease is indicated.  
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 Chapter 1. Introduction and Background 
 
“A faint magenta tinge, due to the greater exposure of the reduced iron bearing 
clay, is apt to show where the glaze runs thin on the edge of bowls…This ‘life’ in the 
old glazes is due in large measure to the presence of elements in the raw material 
which the old potters either did not know how, or did not desire, to eliminate. The 
most common was a small percentage of iron.” 
Bernard Leach 
“A Potter’s Book” 
Introduction 
The evolutionarily successful Homo sapiens has built a world where, for some, the 
modern environment predisposes for an energetically unbalanced life-style. The 
consequence of this are metabolic diseases characterised by obesity, inflammation, 
high blood pressure, and cardiovascular risk; and globally the prevalence of one 
consequence - type 2 diabetes - is reaching epidemic levels. It is paradoxical that as 
a species gifted in adaptability we are suffering at our own hands from our success, 
and that the influence of modern spatial and nutritional environments are 
frequently greater than an individual’s capacity for beneficial change. 
Much research activity has focused on defining dietary risks for type 2 diabetes (in 
addition to a surfeit of kilocalories).  Other research aims to define the processes 
that drive development, and the later complications of, type 2 diabetes. These 
complications are life-threatening – heart disease, stroke, renal disease, blindness, 
and neuropathies. Oxidative stress-related damage, from errant oxygen and 
nitrogen species, is likely to be involved in at least the pathologies of advanced 
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disease, and possibly the disease itself; and in biology it seems, where oxidative 
stress is found, the abundant element iron will soon be suspected of involvement.  
A substantial literature exists for the many aspects of iron and risk for diabetes; and 
iron and links to its later complications. This thesis aims to identify the links for 
both of these which have the firmest evidence base, and for the former, suggest a 
scenario by which some of the threads are drawn together. For the latter, 
experimental work has been undertaken that clarifies some effects reported in 
vitro by other groups, but suggests they may not be as relevant to the in vivo 
reality. Finally, in collaboration with The Diabetes and Vascular Medicine Research 
Group in Exeter, a cross-sectional investigation is made of the presence of reactive 
non-transferrin-bound iron in type 2 diabetes, its association with pathologies, and 
with a range of physiological parameters. 
Background 
1.1 Type 2 diabetes  
1.1.1 Prevalence and impact of diabetes 
Globally, the burden of all forms of diabetes now stands at 347 million people, with 
increases in age standardized prevalence from 8.3% of men and 7.5% of women in 
1980, to 9.8% of men and 9.2% of women in 2008. The highest levels are seen in 
Oceania, approaching 16% of the population (Danaei et al 2011). Within the UK 
Danaei et al find prevalence to be generally stable, with 7.8% of men and 5.7% of 
women affected, compared with 8.1% of men and 5.7% of women in 1980. 
However our population is growing and increasingly elderly, and actual numbers 
have risen from 1.4 million in 1996 to 2.6 million in 2009. By 2025, the number is 
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estimated to be 4 million people (Quality and Outcomes Framework 2009, Diabetes 
UK 2010).  
In the UK around £9 billion a year (10% of the NHS budget) is spent on diabetes, 
including the cost of one in five coronary heart disease, renal, and foot admissions 
(DH 2006, NDST 2005). Of sufferers, 90% will have type 2 diabetes, which will be up 
to six times more prevalent in people of South Asian descent, and up to three times 
more prevalent in people of African and African-Caribbean origin, compared to 
Caucasians (DH 2007, DH 2001). 
Type 2 diabetes has long been associated with obesity and dyslipidaemia (Gordon 
et al 1977), with obesity being the most critical risk factor (Kahn et al 2006). In UK 
children, rising levels of obesity are leading to a rapid increase in prevalence of type 
2 diabetes, from an estimated 0.21 per 100,000 (0.00021%) in 2000 (Ehtisham et al 
2004), to 3.0 per 100,000 (0.003%) in England for 2009 (RCPCH 2009). Rates are set 
to continue rising as obesity levels increase, from 11% of boys and 12% of girls aged 
2 to 15 years in 1995, to 16% of boys and 15% of girls in 2009 (HSCIC 2010) 
1.1.2  The pathophysiology of diabetes 
In essence, diabetes is a cellular resistance to the action of insulin, and/or the 
inability of pancreatic β-cells to produce insulin. As insulin is required for the 
uptake of glucose from plasma its insufficiency results in high plasma glucose 
levels, and dependence for energy metabolism on fats and protein. In adipocytes 
and myocytes glucose uptake follows insulin-receptor binding, which stimulates 
translocation of, mainly, GLUT4 storage vessels within the cell to the cell surface for 
20 
 
glucose transportation into the cell. Over time, persistently raised blood glucose 
levels lead to the complications of advanced diabetes. 
Type 1 diabetes is a genetically acquired disease, affecting the HLA region of 
chromosome 6, but also requiring an unknown environmental trigger or triggers. It 
is an autoimmune disease causing the inflammatory destruction of β-cells.  
Type 2 diabetes also has a genetic component, but is not HLA-related. Obesity is a 
considerable risk factor for type 2 diabetes, and onset of disease can be delayed by 
lifestyle changes leading to weight loss (Klein et al 2004). The disease progresses 
from obesity, to insulin resistance, hyperinsulinaemia (with normal glucose 
tolerance), diminished insulin secretion, to type 2 diabetes. Approximately 90% of 
diagnosed patients have an islet cell defect, and increased peripheral insulin 
resistance (Watkins 2003).  
A higher risk of disease is seen with abdominal fat distribution, reflecting the link 
between adipocyte release of non-esterified fatty acids, which induces insulin 
resistance, and inflammatory cytokine release, which is involved in islet cell 
damage. A feedback system modulates insulin expression in response to insulin 
sensitivity, which increasingly fails as type 2 diabetes develops (Kahn et al 2006). 
Risk factors for type 2 diabetes are: 
 Age ≥45 years 
 Overweight (BMI > 25 kg/m2, but may vary with ethnicity) 
 Family history of diabetes 
 Habitual physical inactivity 
 Ethnicity 
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 Previously identified impaired fasting glucose or impaired glucose 
tolerance 
 History of gestational diabetes, or delivery of a baby weighing > 4 kg 
 Hypertension (≥140/90 mmHg in adults) 
 Dyslipidaemia HDL cholesterol 0.91 mmol/l and/or a triglyceride level 
≥2.82 mmol/l 
 Polycystic ovary syndrome 
 History of vascular disease 
(Klein et al 2004) 
1.1.2.1 The metabolic syndrome 
Suggested to affect ~25% of Western adults (Reaven 2002), the metabolic 
syndrome describes a cluster of conditions associated with obesity, namely, 
hypertension, dyslipidemia, insulin resistance, non-alchoholic fatty liver disease 
(NAFLD), and chronic, low-grade inflammation, and which gives an increased risk 
for type 2 diabetes and cardiovascular disease (Hotamisligil 2006, Achike et al 
2011). Shared pathogenic factors are likely between metabolic syndrome 
conditions and NAFLD, and a review of population studies for the USA, Italy, and 
Japan suggests that approximately 22% of lean, and 76% of obese individuals have 
prevalent NAFLD, and 10% to 25% of these may have the progression of this, non-
alcoholic steato-hepatitis (NASH) and fibrosis or cirrhosis (Farrell & Larter 2006). 
1.1.2.2 WHO criteria for the diagnosis of diabetes 
1. Symptoms of diabetes plus random venous plasma glucose ≥ 11.1 mmol/l. 
The classic symptoms of diabetes include polyuria, polydipsia, and 
unexplained weight loss 
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2. Fasting plasma glucose ≥ 7.0 mmol/l or whole blood  ≥ 6.1 mmol/l 
3. Two hour plasma glucose ≥ 11.1 mmol/l during oral glucose tolerance test 
using 75 g glucose load 
In the absence of symptoms these criteria should be confirmed by repeating testing 
on a different day. If the fasting or random values are not diagnostic, the 2 hour 
value post-glucose load should be used. 
1.1.2.3 Diagnostic fasting plasma glucose values 
Normal: < 5.6 mmol/l 
Impaired fasting glycaemia:  ≥ 5.6 and < 6.1 mmol/l; 2-h post glucose load < 6.7 
Impaired glucose tolerance: < 6.1 mmol/l; 2-h post glucose load ≥ 6.7 and < 10.0 
Diabetes (provisional diagnosis): ≥ 6.1 mmol/l; 2-h post glucose load ≥ 10.0 
 (préci of Alberti et al 1999, WHO) 
 
1.1.2.4 Complications of advanced diabetes 
Chronic exposure to high glycaemia leads to hypertension, microvascular 
complications affecting the eyes, kidneys, and nerves, and macrovascular diseases 
including coronary artery disease, strokes, and peripheral vascular disease.  A 
prospective study of 3642 type 2 diabetes patients followed for 10 years (Stratton 
et al 2000) found that, after controlling for confounding factors, for every 1% (1 
mmol/mol) reduction in HbA1c: 
 Microvascular complications decreased by 37% 
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 All micro and macrovascular endpoints relating to diabetes decreased by 
21% 
 Deaths related to diabetes decreased by 21% 
 Myocardial infarctions decreased by 14% 
 
The links between hyperglycaemia and the complications of diabetes are complex 
and multifactorial, and orchestrated by the combination of inflammation and 
oxidative stress. The main mechanisms involved are given in outline over the 
following pages.  
1.1.2.5 Vascular disease 
In the UK, cardiovascular disease (CVD) accounts for around 33% of all deaths in the 
general population (Scarborough et al 2010), and type 2 diabetes gives an 
additional risk for CVD of two to fourfold compared with normal glycaemic control 
(Wood et al 2005). 
Vascular disease results from the effects of hyperglycaemia, insulin resistance, and 
free fatty acids on the endothelial layer between the bloodstream and the smooth 
muscle cells of the vessel wall (Creager et al 2003). Central to this pathology is a 
reduction in the bioavailability of nitric oxide (NO) produced by endothelial NO 
synthase, and required for vasodilation and degradation of oxygen-derived free 
radicals. NO level reflects the balance between NO production and inactivation by 
reactive oxygen species (ROS). In the vascular wall, NO binds to Fe2+-haem groups 
in the enzyme guanylate cyclase in smooth muscle cells, activating them to produce 
more cyclic GMP, and lowering intracellular Ca2+. This relaxes muscle and dilates 
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blood vessels. Most NO is removed from the vascular system following reaction 
with haemoglobin (Halliwell & Gutteridge 2007). NO also protects blood vessels by 
controlling proinflammatory transcription factor nuclear factor kappa β (NF-κβ), 
and subsequently reducing leukocyte adhesion molecules, chemokines and 
cytokines, all involved in the development of atherosclerotic plaques via monocyte 
and smooth muscle cell migration into the intima layer, and the formation of 
macrophage foam cells within.  
Increased circulating free fatty acids from adipose tissue, and reduced uptake by 
myocytes, induce very-low-density lipoprotein (VLDL) production and cholesterol 
ester synthesis by the liver, and a decrease in high density lipoprotein (HDL), 
resulting in dyslipidaemia and increased atherosclerosis risk (Adiels et al 2005). 
Dietary fats also contribute to the lipid profile, and inflammation. The balance of 
the types of polyunsaturated long chain fatty acids (LC-PUFA) consumed influences 
inflammation, as dietary n-3 LC-PUFA can moderate the production of 
inflammatory eicosanoids, cytokines, ROS, and adhesion molecules, if sufficient 
levels are consumed. Essentially, n-3 PUFAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are metabolised to anti-inflammatory 3-, and 5-series 
eicosanoids, and inflammatory n-6 PUFA linoleic acid and arachidonic acid are 
metabolised to pro-inflammatory 2-, and 4-series eicosanoids, by a shared pool of 
cell membrane-based cyclooxygenase (COX) and lipoxygenase (LOX) processes, 
therefore the relative concentrations of the different PUFAs determine the type of 
eicosanoids produced (Calder 2006). 
25 
 
In type 2 diabetes, risk for myocardial infarction (MI) in people who have not 
previously had an MI is 20.2%, similar to that of someone without diabetes who 
has previously had an MI (18.8%) (Haffner et al 1998). Haffner et al suggest lipid 
profile as being a possible reason, although their diabetes groups had significantly 
less LDL than the non-diabetes groups. Blood pressure was higher in the diabetes 
groups. Carotid artery intimal wall thickness in diabetes and non-diabetes, and with 
and without coronary artery disease, suggested that the diabetes subjects with 
coronary artery disease had accelerated atherosclerosis compared with the other 
groups. 
1.1.2.6 Retinopathy 
Diabetes-related damage to the retina is caused by microvascular occlusion, 
breakdown and leakage. Small haemorrhages occur as dots and blots on the retina. 
Exudates of lipid deposits can build up around the haemorrhage, and retinal 
oedema may occur. Ischaemia may lead to the formation of new vessels, which are 
more prone to haemorrhage. In type 2 diabetes blindness is mainly caused by 
macular exudate build up, retinal oedema, and ischaemia.  
1.1.2.7 Peripheral neuropathies 
Damage to distal peripheral nerves, mainly in the legs and feet, is common in type 
2 diabetes. Sensory loss may lead to small injuries being unnoticed, which can 
become ulcerated and septic, and resistant to treatment.  
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1.1.2.8 Autonomic neuropathies 
These include diarrhoea, gastroparesis, postural hypotension, tachycardia, erectile 
dysfunction, and respiratory attack (discussed by Watkins 2003). 
1.1.2.9 Diabetic nephropathy 
Diabetic nephropathy develops in around 40% of people with diabetes, and is 
associated with increased cardiovascular mortality. Genetic susceptibility increases 
likelihood of disease. Renal function impairment progresses from microalbuminuria 
to macroalbuminuria, with decreasing glomerular filtration rate, and increasing 
serum creatinine and hypertension. See Appendix 1.i for UK clinical classification of 
stages.  
Diabetic nephropathy occurs as glomerulosclerosis, with a thickening of the 
glomerular basement membrane, diffuse mesangial (smooth muscle cells 
surrounding the glomerular capillaries) sclerosis, hyaline arteriosclerosis (a build-up 
of proteinaceous material within the extracellular matrix, causing thickening of 
arteriolar walls). Nodular mesangial expansion (Kimmelstiel-Wilson nodules) is seen 
in 40 to 50% of patients with proteinuria (Gross et al 2005).  Basement membrane 
thickening and mesangial expansion can be seen in all stages of albuminuria, and 
severity of lesions is related to glomerular filtration rate and urine albumin 
excretion, diabetes duration, glycaemic control, and genetic factors (Gross et al 
2005). Reduced perfusion of the kidney results in secondary, renovascular 
hypertension.  
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1.1.3 Treatment of type 2 diabetes 
The NICE Guidelines for the treatment of type 2 diabetes (2008) recommend that, 
because the disease is a progressive long-term condition that can largely be self-
managed, and successful management can achieve optimal outcomes, all patients 
should be offered a structured educational program about the disease at the time 
of diagnosis. Nutritional advice should be central to management, with the aims of 
stabilising blood sugar levels, weight loss, lowering hypertension, and optimising 
cardiovascular risk. Emphasis should be on a healthy balanced diet, with low 
glycaemic index carbohydrates, fruit, vegetables, whole grains and pulses; low-fat 
dairy protein and oily fish; and controlling intakes of high fat and high salt foods, 
and  saturated and trans fat acids. Use of foods manufactured specifically for 
people with diabetes should be discouraged. Individual recommendations for life-
style modification should be given, including weight loss and physical activity 
advice. 
HbA1c should be monitored, and individual goals set at or above 48 mmol/mol 
(6.5%). 
Oral glucose control therapies include metformin, that reduces the rate of 
gluconeogenesis by the liver (Hundal et al 2000), and can stimulate cell glucose 
uptake in the presence of a high level of free fatty acids (Adnitt et al 1973); and 
sulphonylureas, that stimulate the pancreas to secret insulin, for example 
gliclazide. Insulin analogues include the fast-acting lispro, and aspart; long-acting 
detemir, and glargine; and mixed types for example NovoMix 30, and Humulin 
30/70. Insulin sensitizers may be used, which bind to cell peroxisome proliferator-
activated receptors (PPARs) that increase cell sensitivity to insulin, and can inhibit 
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inflammatory cytokine expression. The safety of some of these has been 
questioned in recent years, and use of one glitazone (Rosiglitazone) has been 
suspended in the UK.  
Statins are used to treat dyslipidaemia by blocking a rate-limiting step in hepatic 
cholesterol synthesis. Acetyl salicylic acid (aspirin) is used to prevent myocardial 
infarction and strokes by inhibiting thromboxane production and blood clotting. 
Hypertension may be treated by renin-angiotensin system blockade with 
angiotensin-converting-enzyme (ACE) inhibitors such as lisinopril, and ramipril; and 
angiotensin II type I receptor blockers (ARB) such as ibesartan, and valsartan. 
1.2 Oxidative stress 
The many metabolic pathways and cellular and molecular processes of the body 
produce a constant stream of oxidant species, which are held in check by 
endogenous and exogenous antioxidants. This is a delicate balance, as some degree 
of oxidation is necessary, for instance, for the regulation of some cellular processes 
by oxidation and reduction, and cross-talk for phosphorylatory cell signalling. Sies 
(1991) describes oxidative stress as “a disturbance in the prooxidant-antioxidant 
balance in favour of the former, potentially leading to damage”. Whilst oxidative 
challenge may be a part of the normal cellular environment, oxidative stress 
requires a combination of factors to be present. For example, a lack of dietary 
antioxidant availability alone may not constitute oxidative stress, but combined 
with increased hydrogen peroxide formation and a lack of glutathione, oxidative 
damage may occur (Sies 1999).  
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The free radical species involved have been defined as “any species capable of 
independent existence that contains one or more unpaired electrons” (Halliwell & 
Gutteridge 2007). These are reactive oxygen species (ROS), such as superoxide  
(O2
-), the highly reactive hydroxyl (HO·), carbonate (CO3
2-), carbon dioxide (CO2), 
peroxyl (RO2
·), and alkoxyl (RO·). Whilst it is a ROS, hydrogen peroxide (H2O2) is a 
non-radical species. Reactive nitrogen species (RNS) are also produced, such as 
nitric oxide (NO·), and nitrate (NO3
·). Sulphur-based free radicals thiyl (RS·), and 
perthiyl (RSS·) also occur, and single hydrogen (H·), and chlorine atoms (Cl·). 
Transition metal ions are also free radicals by this definition, and may donate or 
accept electrons depending on their electron state. 
The effects of oxidative stress on cells are numerous. Many cells respond to mild 
oxidative stress by increasing proliferation, or by adapting defence systems to 
protect against damage. Oxidative cell injury can damage lipids, DNA, protein, and 
carbohydrate. Following injury, the cell repairs or replaces damaged molecules, or 
survives with persistent damage, or DNA damage may trigger cell death by 
apoptosis or necrosis. On DNA, free radical damage can produce base 
modifications, particularly to guanine, and double strand breaks that are difficult to 
repair and can lead to insertions and deletions from the DNA sequence, and 
chromosomal translocations (Halliwell & Gutteridge 2007).  
Lipid peroxidation occurs by addition of a reaction species, or more usually by 
abstraction of H from methylene group (-CH2-) by a reactive species. In either case 
a carbon radical results (·CH or C·). The most likely fate of this in aerobic conditions 
is for the carbon radical to combine with O2 inside the membrane, forming a 
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peroxyl radical (ROO· or RO2
·). Peroxyl radicals can then abstract H. from an 
adjacent fatty acid side chain, in the propagation stage of lipid peroxidation. New 
peroxyl radicals are formed and so the chain reaction of lipid peroxidation 
continues. The RO2
· combines with the H· that it abstracts to form a lipid 
hydroperoxide (or lipid peroxide) ROOH. Consequently a single initiation event has 
the potential to generate multiple peroxide molecules by a chain reaction (Halliwell 
& Gutteridge 2007). 
Evidence of damage by RS occurring in vivo includes, on lipids, presence in tissues 
and body fluids of specific end-products of peroxidation, for example isoprostanes, 
isofurans, HNE-adducts, with levels increasing during oxidative stress. On proteins, 
increased carbonyls and other amino acid modifications are seen, low levels of 
which are detected in healthy animal tissues and body fluids. Nitrotyrosines, 
products of attack by RNS on tyrosine, have been detected in many normal body 
fluids at low levels, and at higher levels in diseased tissues. On DNA, low levels of 
oxidative base damage products present in DNA isolated from all aerobic cells.  
Levels often increase in animals with cancer or chronic inflammatory diseases, or 
subjected to oxidative stress by toxins. Some base damage products are excreted in 
urine, in part from DNA repair processes. 
Within the vascular system, NO (itself a radical) is a source of oxygen radicals which 
may react with superoxide to form peroxynitrite, decaying to become the hydroxyl 
radical. Loss of nitric oxide by reaction with superoxide is thought to be involved in 
the development of hypertension, and therefore linked to risk for CVD and renal 
disease (Bender 2002). NO can also scavenge free radicals, such as the hydroxyl 
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radical, is a powerful inhibitor of lipid peroxidation, and also binds to ferrous iron – 
decreasing reactivity with hydrogen peroxide and thus hydroxyl radical production.  
Many antioxidant systems exist to control reactive species and maintain 
homeostasis. Reactive species can be removed by a specific agent, for example the 
cellular enzymes superoxide dismutase (SOD), and catalases, that detoxify 
superoxide and hydrogen peroxide respectively; or they may repair other 
antioxidants, for instance oxidized glutathione may be reduced by glutathione 
peroxidases. Lipid membrane-based antioxidants, including tocopherols and 
carotenes, and some phenolic compounds intercept chain reactions of electron 
loss, preventing greater damage occurring.  Antioxidants in the aqueous phase 
include ascorbate, glutathione, urate, and selenium. Many antioxidants work 
indirectly, for example plasma metal-binding proteins transferrin and albumin, 
prevent transition metal catalysed development of HO·.  
1.2.1 The role of oxidative stress in diabetes  
1.2.1.1 Introduction 
Whilst oxidative stress is generally believed to be involved in both the 
development, and subsequent complications of diabetes, reviewers have in the 
past been reticent to attribute redox toxicity to specific events, as many of the 
processes involved were not fully elucidated. Scott & King, in a 2004 review, found 
it unlikely that oxidative stress causes initiation of microvascular pathologies, 
although it may well accelerate the processes involved in their development. 
Halliwell & Gutteridge (2007) write that oxidative stress is thought to contribute to 
atherosclerosis, and possibly also to renal damage, neuropathy, cataract, and 
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retinopathy. They conclude that, in diabetes, oxidative stress stems from raised 
plasma glucose, with the development of atherosclerosis appearing to be linked to 
lipid oxidation and formation of non-enzymatic glycation products, and the 
development of neuropathy possibly via oxidative stress as a result of decreasing 
nerve glutathione levels.  
Our understanding of the mechanisms linking oxidative stress, hyperglycaemia, and 
diabetes continues to grow, and a number of well-supported scenarios have been 
proposed. Tissue and cell types shown to be at particular risk include:   
In the development of type 2 diabetes: 
 Pancreatic β-cells, which are at increased risk of oxidative damage due to 
particularly low antioxidant levels (Grankvist et al 1981, Lenzen et al 1996). 
In the development of complications: 
 Endothelial, neural and kidney mesangial cells, which have insulin-
independent glucose uptake and are unable to reduce glucose influx during 
hyperglycaemia (Kaiser et al 1993).  
 Tissues at risk from protein glycation and therefore oxidative stress, 
including long-lived vascular and nonvascular collagen and lens crystalline, 
and low density lipoprotein (LDL) (Ulrich & Cerami 2001).  
 Neurons, retinal, endothelial, and vascular cells that contain aldose 
reductase and can switch to polyol pathway metabolism in hyperglycaemia 
(Lorenzi 2007).  
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Some authors place great emphasis on the importance of oxidative damage in 
diabetes, and it has been suggested as a link between the various pathologies 
involved. Nishikawa et al (2000), and Brownlee (2005), propose that over-
production of superoxide by mitochondria results from increased substrate 
availability for ATP production, leading to electron ‘leakage’ from the electron 
transport chain. How this leads to cell deterioration is described under 
‘Mitochondrial source of oxidative stress in diabetes’.  
The importance of oxidative stress in vascular disease is well supported, and roles 
include the overproduction of ROS by vascular cells, which then mediate 
inflammation signalling pathways, and oxidize LDL (reviewed in Madamanchi et al 
2005).  The oxidation of LDL is believed to be integrual to the pathogenesis of 
atherosclerosis, with an extensive literature, yet as Steinberg (2009) points out, a 
number of questions remain unanswered. Where does LDL oxidation occur – 
intravascularly, or within the endothelium? And why have large scale clinical trials 
with antioxidants generally failed to improve cardiovascular outcomes? Halliwell 
and Gutteridge (2007) suggest part of the answer this last question lies with the 
experimental design of many of the large scale studies that have been done. Rather 
than categorise subjects into groups depending on physiological level of the 
antioxidant in question, and intervene and test the deficient group alongside a 
Control group,  as would occur for example in an anti-hypertension medication, 
instead blanket supplementation is given to all, regardless of need. Consequently, 
when the results are pooled for analysis the results of those who have benefited 
from supplementation are diluted by those who have not, and perhaps erased by 
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those for whom unnecessary supplementation has had a detrimental effect on the 
measured endpoint.  
1.2.1.2 Mitochondrial sources of oxidative stress in diabetes: The Brownlee 
Hypothesis  
Proposed as a unifying link for diabetic complications (Brownlee 2005), Brownlee’s 
group report that hyperglycaemia in cells that are unable to limit glucose intake in 
conditions of extracellular hyperglycaemia, leads to increased availability of 
electron donors NADH and FADH2 for oxidative phosphorylation within the electron 
transport chain (ETC). The voltage gradient across the mitochondrial membrane 
subsequently increases until a critical threshold is reached, and electron transfer 
within complex III of the electron transport chain is blocked, causing electrons to 
be donated from coenzyme Q to molecular oxygen, generating superoxide. This 
would normally be converted to H2O2 by MnSOD, but the mitochondrial antioxidant 
capacity is apparently insufficient in these conditions.  This group also found that 
insulin resistance led to increased free fatty acid flux from adipocytes into arterial 
endothelial cells, leading to β-oxidation of fatty acids, with the same result - 
increasing NADH and FADH2, and electron leakage from the ETC. 
Brownlee suggests that increased mitochondrial superoxide causes DNA strand 
breaks in the nucleus, activating poly-(ADP-ribose) polymerase (PARP) a repair 
enzyme that makes polymers of ADP-ribose. PARP utilises NAD+ to make ADP-
ribose, which accumulates on nuclear proteins including the key glycolytic enzyme 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH). GAPDH activity is inhibited, 
increasing levels of all upstream glycolytic intermediates, with the following effects: 
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 Increased glyceraldehyde-3 phosphate activates AGE formation as the major 
intracellular AGE precursor methylglyoxal is formed from glyceraldehyde-3 
phosphate. 
 Increased glyceraldehyde-3 phosphate also activates protein kinase C (PKC), 
by increasing formation of diacylglycerol (DAG), a precursor of PKC. This 
activates a signalling cascade leading to effects including reduced 
vasodilation, increased vasoconstriction, up-regulated NF-КB and 
inflammatory responses, and increased ROS formation (Brownlee 2005, 
Scott & King 2004). 
 Increased glucose causes activation of the polyol pathway, with subsequent 
reduction of NADPH level limiting GSH formation, lowering cell antioxidant 
status. 
 Increased fructose-6-phosphate causes activation of the hexosamine 
pathway, leading to production of N-acetyl glucosamine, which can attach 
to transcription factors, causing modified gene expression, and resulting in 
dysfunction in cells such as glomerular cells and cardiomyocytes. Activation 
of the hexosamine pathway is also found to induce oxidative stress and 
deterioration of pancreatic β-cell function (Kaneto et al 2001). 
The presence of methylglyoxal (MGO) and glyoxyl (GO) is known to cause 
mitochondrial deterioration, and Rabbani & Thornalley (2008), and Morcos et al 
(2008) have produced work that shows that protection from glycation of 
mitochondrial proteins by MGO and GO prevents oxidative and nitrosative protein 
damage and extends life in nematodes. However, there is a gap in Brownlee’s 
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hypothesis, in that it does not account for how mitochondrial superoxide – a fairly 
unreactive ROS - damages nuclear DNA. To speculate, trace amounts of labile 
cellular iron, perhaps originating from ferritin or hemosiderin, would be immensely 
damaging in the presence of increased levels of superoxide from high intracellular 
glucose as described above. Such a combination would be capable of destroying β-
cells, and would explain the loss of insulin production in secondary diabetes of iron 
overload conditions, where iron is known to be stored in the pancreas (Rahier et al 
1987). 
1.2.1.3 Oxidative stress, β-cells, and the development of type 2 diabetes 
Pancreatic β-cells are at increased risk of oxidative damage due to particularly low 
antioxidant levels (Grankvist et al 1981, Lenzen et al 1996). Tiedge et al (1997) for 
instance found that insulin-producing cells in rats produced less catalase, 
glutathione, and glutathione peroxidase than other tissues, and when challenged 
by high glucose, high oxygen, and heat shock treatment, they were unable to 
respond by up-regulation of antioxidants. Lenzen (1997) proposes that this 
increased sensitivity to reactive species allows β-cells to integrate their role of 
insulin biosynthesis and exocytosis with a metabolic requirement for glucose, and 
initiation of glucose-induced insulin secretion. The cell needs to ensure sufficient 
glucose for its own energy needs, whilst enabling signal generation for insulin 
secretion (a function of glucose metabolism). In order to sense glucose, and 
produce insulin, the β-cell needs an environment rich in glucose and oxygen but 
this increases opportunity for ROS activity. If the redox balance of the cell changes, 
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and ROS or RNS are over-produced, the β-cell is unable to protect itself and is 
ultimately vulnerable to cell death. 
1.2.2 Oxidative stress in the development of diabetes complications 
1.2.2.1 Cell types at particular risk from hyperglycaemia 
Glucose entry into some cell types (including endothelial, and some neural and 
kidney cells) is independent of insulin action, and utilises transporter proteins in a 
concentration-dependent facilitated diffusion process. The GLUT4 transporter, 
found in insulin-sensitive skeletal and cardiac muscle and brown and white fat, is 
down-regulated by high levels of circulating glucose (Klip et al 1994). Other 
transporters, for instance GLUT1, are ubiquitously expressed throughout the body, 
in insulin-dependent and non-dependent cells, including erythrocytes. GLUT1 
activity is enhanced by raised extracellular glucose concentrations, by either, 
increased activity, increased expression, or translocation from intracellular sites to 
the plasma membrane (Heilig et al 1995). The inability to decrease glucose uptake 
when appropriate means that intracellular glucose concentrations may approach 
extracellular levels in hyperglycaemia, with subsequent effects on polyol pathway 
activation and possible mitochondrial dysfunction. Pancreatic β-cells utilise GLUT2 
transporters which have the capacity to increase in proportion to extra and 
intracellular glucose, and so do not become rate limiting in tissues for which it is 
the predominant transporter (Kahn 1992). 
1.2.2.2 The polyol pathway  
In conditions of high glycaemia, in tissues that contain the enzyme aldose 
reductase, surplus cellular glucose causes activation of the polyol pathway of 
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glucose metabolism, and inhibition of the pentose-phosphate pathway. Tissues 
affected include epithelium, aortic endothelium and smooth muscle cells, lens and 
retina, Schwann cells of peripheral nerves, and a number of kidney cell types (Kern 
et al 1981). The pentose-phosphate pathway is the major cellular source of 
nicotinamide adenine dinucleotide phosphate (NADPH), which required for 
reducing and repairing glutathione (GSH), a vital antioxidant for cell protection. 
Glucose is reduced to sorbitol by aldose reductase (AR) using NADPH as a cofactor, 
leading to further NADPH depletion in addition to loss of production. In the second 
step, sorbitol is converted to fructose via NAD+ reduction to NADH. The overall 
effects of increased glucose metabolism via the polyol pathway at the expense of 
the pentose phosphate pathway are to cause cellular depletion of NADPH and 
NAD+, enhancing reactive oxygen species accumulation and subsequent oxidative 
damage, due to insufficient NADPH availability for reducing glutathione (GSH) level. 
GSH depletion therefore impairs cell redox balance, increasing vulnerability to 
oxidative stress (Bravi et al 1997).  
1.3 Protein glycation and advanced glycaemic end product (AGE) formation 
 
 
 
 
 
 
 
Nomenclature 
‘Glycation’ refers to the reaction between glucose or other sugars and amino 
groups of proteins, whether enzymatically catalysed or formed via a Schiff’s 
base and Amadori rearrangement. ‘Glycosylation’ refers specifically to an 
enzymatically catalysed reaction (IUPAC-IUB 1984). 
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Figure 1. Isomers of glucose, % occurring in aqueous solution 
Reprinted and adapted with permission from Zhu, Y. Zajicek, J. 
Serianni, A. (2001) Acyclic forms of [1-13C]aldohexoses in aqueous 
solution:  quantitation by 13C NMR and deuterium isotope effects on 
tautomeric equilibria. Journal of Organic Chemistry 66 (19): 6244 – 
6251. Copyright 2001 American Chemical Society. 
 
In aqueous solution, glucose exists almost entirely in the pyranose (ring) form, with 
less than 0.40% in the furanose ring form, and less than 0.01% in the open-chain 
aldehyde form (Bubb et al 2003)(Figure 1). Acyclic glucose is transient and reactive, 
due to its carbonyl (C=O) double bond, and a reaction with the open-chain form 
results in a ring-form converting to take its place, with the four ring forms 
transforming into each other via the open-chain, until equilibrium is reached (Robyt 
1998). Reactions involving the ring-form can include the replacement of OH groups 
at C-2 and C-6 by hydrogen or amine groups; however the C1 carbonyl of the chain-
form is the most active. 
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Carbonyl groups on sugars such as glucose and fructose react with the –NH2 amine 
group on proteins, DNA, and lipoproteins, to form glycated proteins. This non-
enzymatic glycation is the first stage of the Maillard reaction, also responsible for 
browning reactions between carbohydrates and amines in cooked food. Changes 
are reversible in the initial stages, forming Schiff bases followed by Amadori 
products, which are then oxidised by reactive oxygen and nitrogen species to 
become irreversible advanced glycation endproducts (AGE). Glycation rate 
increases with glucose concentration, and AGE formation is dependent on the 
presence of reducing sugars and reactive oxygen species, in fact, ROS have been 
described as ‘fixatives of glycation’ (Halliwell & Gutteridge 2007, Ahmed & 
Thornalley 2007, Forbes 2008). For diagrams of AGE compounds and their routes of 
formation see Ahmed (2005), and Ahmed & Thornalley (2007). 
The development of AGE products is a normal part of ageing, but is accelerated in 
diabetes (Ulrich & Cerami 2001). They form over months and years, and are 
present until the protein is ultimately degraded. HbA1c, the commonly used 
measure of glycaemia over the previous 6 - 12 week red blood cell life-span, 
measures glucose Amadori product on haemoglobin beta-chain. Tissues at 
particular risk are those that are long lived, such as vascular wall tissue, 
nonvascular connective tissue such as tendon collagen, and lens crystallin. Skin 
collagen for example has a half-life of 15 years, and cartilage collagen has an 
estimated half-life of 117 years (Verzijl et al 2000). Lens crystallin may last for the 
entire life time. Low density lipoproteins are also at risk of glycation, as both the 
amino groups and the lipid groups are potential sites. 
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There are two main routes for glucose to attach to proteins (Hunt et al 1988): 
covalent Amadori attachment, and autoxidative glycosylation – transition metal 
catalysed oxidation of glucose producing hydroxyl radicals and ketoaldehydes. The 
processes are not clear cut however, and Amadori products can also oxidise, 
becoming either carboxymethyllysine (CML) or pentosidine (for review see Ahmed 
& Thornalley 2007). CML is also produced via lipid peroxidation (Fu et al 1996), and 
this is thought to be important in the atherosclerotic complications of diabetes 
(Singh et al 2001). Glycated proteins are themselves redox active, and can catalyse 
lipid peroxidation (Fu et al 1996). 
1.3.1 Functional effects of AGE products 
AGE products and their precursors are heterogeneous in nature, and have many 
varied deleterious effects. Immunohistochemistry of human, non-diabetic, post-
mortem and biopsy tissue (Ling et al 1989) has identified AGE (carboxymethylysine 
(CML), and fluorolink (a fluorescent cross-linked AGE structure), distributed widely 
throughout the body. AGE are evident intracellularly, in the cytosol and 
compartments, including the nuclei, mitochondria, golgi complexes, and cell 
membrane, in the extracellular matrix, within numerous blood vessel endothelial 
cells, in blood cells, and in various organs including the heart. 
Much of the evidence of links with pathologies is indirect, and relies on in vitro 
work. Intracellularly, AGE precursors can bind to and modify gene transcription 
proteins, impacting on protein synthesis (Brownlee 2005), and bind to fibroblast 
growth factors, reducing mitogenic activity (Goldin et al 2006). Finding that in vitro 
culture of β-cells with AGE reduced β-cell function, Tajiri et al (1997) suggested an 
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alteration of transcription factors would be compatible with the effects seen on 
protein synthesis and insulin mRNA. Within the mitochondria, in vitro treatment of 
vascular smooth muscle cells with methylglyoxal (MGO) – an α-oxoaldehyde AGE 
precursor – has been found to impair ATP synthesis and MnSOD activity, whilst 
increasing mitochondrial ROS production (Wang et al 2009). Electron transport 
chain impairment can result from glycated proteins causing electron ‘leakage’ and 
superoxide formation (Halliwell & Gutteridge (2007), and Brownlee’s hypothesis 
may describe only one route to mitochondrial impairment and ROS formation in 
diabetes. 
In cells that utilise the polyol pathway, glucose is metabolised to sorbitol, and 
subsequently to fructose. The rate of AGE production is enhanced in the presence 
of fructose and its derivatives, compared with glucose in vivo (Goldin et al 2006), 
and this is thought to contribute to diabetic retinopathy development (Lorenzi 
2007).  
Shangrai & O’Brien (2004) have demonstrated that Amadori dicarbonyl glyoxal 
(GO) was cytotoxic to hepatocytes, via lipid peroxidation of the mitochondrial 
membrane. GSH oxidation, and ROS formation were also evident, and damage 
could be prevented by ROS scavengers. Human vascular endothelial cells, when 
exposed to 50 - 5000 µM GO in vitro, produced inflammatory cytokine activation, 
swelling, and decreased cell density (Yamawaki & Hara 2008). For comparison, 
plasma GO levels in 20 healthy controls are: (mean ± SD) 12.5 ± 0.5 µg/l, and 
methylglyoxal (MGO), 8.5 ± 0.5 µg/l. Plasma levels in 12 patients with chronic renal 
failure receiving peritoneal dialysis were: GO, 22.6 ± 3.0 µg/l, and MGO, 17.5 ± 6.9 
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µg/l (Lapolla et al 2005) (1 µM glyoxal = 58.04 µg/l). The involvement of GO, MGO, 
and other AGE within endothelial cells in atherosclerosis are reviewed by Basta et 
al (2004), and include receptor-mediated inflammatory responses to RAGE binding, 
increased membrane permeability, and increased intracellular oxidative stress. 
AGE precursors may diffuse out of the cell, interact with nearby molecules, and 
affect cell surface receptors and signalling (Monnier et al 2008), for instance by 
binding to plasma proteins such as albumin, which then bind to and activate AGE 
receptors (RAGE), triggering inflammatory responses involved in vascular pathology 
(Brownlee 2005). 
In the extracellular matrix, evidence is clearer for the pathological effects of AGE, 
and is reviewed by Monnier (2008). For example, CML in skin collagen predicts the 
risk of future diabetes-related pathologies (Genuth et al 2005). Vascular basement 
membrane collagen is modified by MGO, and impairs endothelial cell survival by 
detachment of cells and apoptosis (Dobler et al 2006). Dobler et al glycated human 
type IV collagen under physiological conditions, identified the arginine residues 
involved in the protein-protein interaction with integrin, and described how the 
modified arginine (Arg390) would be unable to form a hydrogen bond with the 
integrin His258. Prevention of MGO formation was achieved with 500 µM 
aminoguanidine. Cross-linking occurs between glycated proteins, most importantly 
forming glucosepane. Cross-linking leads to tissue matrix stiffening and decreasing 
elasticity, leading to damage to the lens, within the collagen layer of blood vessel 
walls, and to the kidney basement membrane (Ulrich & Cerami 2001, Halliwell & 
Gutteridge 2007). AGE cross-link with collagen. Through cross-linking and redox 
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effects, AGE and ALE (advanced lipoxidation end-products) are also involved in the 
progression of diabetic nephropathy, generalised vascular disease, atherosclerosis, 
diabetic retinopathy, and neuropathy. In the eye lens, cumulative modification of 
crystallin proteins by glycation, oxidation, deamidation and other changes cause 
crystalline aggregation, which gradually lead to cataract formation and blindness 
(reviewed by Sharma & Santhoshkumar 2009). 
In plasma, AGE products on LDL have pro-oxidant effects, acting as free radicals by 
accepting a hydrogen atom from LDL, leading to LDL peroxidation and subsequent 
involvement with macrophages and the atherosclerotic process (Ulrich & Cerami 
2001). Bucala et al (1994) demonstrated that AGE-modified LDL, at the same 
degree of modification as seen in in vivo diabetes, in mice, had impaired plasma 
clearance due to non-recognition by tissue LDL receptors, leading to increased 
plasma LDL, dyslipidaemia, and the potential for increased time within the 
subendothelium, macrophage take-up, and foam cell formation in the arterial wall. 
In addition to this, and the inflammatory response by AGE receptors to AGE on 
albumin, AGE formation on LDL reduces NO production (Goldin 2006), decreasing 
vasodilation whilst matrix cross-linking causes vascular stiffness, adding to 
increasing cardiovascular risk.  
In plasma proteins, Miyata et al (2000) have observed that AGE and ALE accumulate 
in uraemic renal patients with and without diabetes, and propose that increased 
oxidative stress plays a role in uraemia by enhancing formation of reactive carbonyl 
compounds (RCO), which then react with protein residues to form AGE and ALE.  
Thornalley (2005) suggests that the degradation of glycated proteins and the 
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formation of “glycation free adducts” via cellular proteolysis leads to the build-up 
of MGO-derived hydroimidazolones, which are subsequently filtered by the 
glomerular and reabsorbed or excreted. Two studies by Thornalley’s group 
examined the fate of proteolytic degradation products in disease. Ahmed et al 
(2005) found profound increases in plasma concentration and urine excretion of 
glycation free adducts in 21 type 1 diabetes patients with normal creatinine 
clearance, compared with 12 healthy controls. Over a range of glycation adduct 
types, plasma concentrations were increased by four- to ten-fold, and urinary 
excretion levels increased by two- to fifteen-fold. Plasma protein CML adducts 
correlated with HbA1c. The authors conclude that the increases are not due to 
changes in protein turnover but to changes in protein modification, as glycation of 
albumin has no effect on half-life, and little difference is seen in red blood cell life-
span in diabetes (although Cohen et al, 2008, found the average life span of 
diabetic red blood cell is 56 days, compared to 60 days for controls). In 
nephropathy, glycation free adducts are insufficiently cleared from plasma (Agalou 
et al 2005). In people with mild chronic renal failure, Agalou et al found plasma 
glycation free adducts increased up to 5 times that of healthy controls, and 
correlated with the decline in renal clearance. Amounts in peritoneal dialysis 
patients were up to 18 times, and haemodialysis up to 40 times greater. Many 
glycation-free adducts are known to be uraemic toxins, including CML, MGO, GO, 
fructoselysine, and pentosidine (Vanholder et al 2003). 
Comparing intra- and extracellular effects, Johansen et al (2006) collated protein 
glycation data from the literature, and used their findings to predict, from the 
glycation potential of the protein primary structure, and the physiological role of 
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the protein, a scale of the impact of glycation in different functional realms. 
Overall, the intracellular environment was more prone to glycation than the 
extracellular, with the regulation of protein kinase activity, and transferase activity, 
the most affected realms. Whether this translates to actual effects on health is not 
known. Extracellular matrix proteins were less prone to glycation, as predicted by 
the model, and this is borne out by the findings of Zhang et al (2011), who found 
more glycated peptides from erythrocytes than human plasma. Johansen et al 
suggest this is due to evolutionary pressure disfavouring extracellular protein 
glycation, as extracellular matrix proteins such as collagen have a long half-life, and 
thus being exposed to glucose over a longer period have a greater need to deter 
glycation. 
1.4 Iron in the body 
1.4.1 Characteristics of iron binding 
Iron has a co-ordination number of 6, therefore it is capable of six bonds within its 
4s, 4p, and 4d orbital levels, irrespective of its ionic state. Bonds between atoms of 
iron and other molecular species (or ligands) are of a dative covalent nature, where 
a co-ordination bond is formed between a donor and an acceptor (the iron), of a 
shared electron pair. A unidentate ligand has one bond with the iron, bidentate, 
tridentate etc. ligands have two or three bonds. A chelate is a ligand with at least 
two bonding positions (IUPAC 1997). Table 1 lists the main plasma-iron ligands in 
humans, their size, and typical concentration.  
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1.4.2 Role, uptake, transport, and storage 
The transitional nature of atomic iron, due to its incompletely filled 3d orbital shell, 
makes it an extremely useful physiological ligand and catalyst. For oxygen carrying, 
ferrous (Fe2+) iron is bound to four nitrogen ions at the centre of haem, and a 
dioxygen molecule. Four haem structures make up haemoglobin, with between 200 
and 300 million molecules of haemoglobin per red blood cell. Oxygen storage in 
muscle is facilitated by myoglobin, which also contains a haem group. In the 
electron transport chain, iron cytochromes alternate between the ionic states of 
ferric (Fe3+) and ferrous iron, transferring electrons along the chain in the 
generation of ATP. Iron is also utilised as the active site in many enzymes, including 
cell lipid membrane lipoxygenases (for full review see Crichton 2009).  
In healthy adults, approximately 1 - 2mg of iron per day is absorbed, equal to 
average losses via menstruation and sloughing of cells. In the modern diet, 0 - 2mg 
per day is consumed via haem iron (from meat, fish, and poultry), and 12 - 18mg of 
iron per day is available via non-haem iron (vegetables, pulses, fortified cereals) 
(Hunt 2005). (See section 1.4.2, and Appendix 1.iii for more information). 
Non-haem dietary iron is in the ferric form. An intestinal haem carrier protein 
(HCP1) been identified by Shayeghi et al (2005), although this is thought to be a 
folate transporter (Qiu et al 2006). HCP1 is highly expressed in the duodenum, and 
post-transcriptionally regulated in response to body iron stores. HCP1 mRNA 
increased in response to hypoxia, but it was unclear whether this was a direct effect 
on HCP1 mRNA. Following translocation across the brush border membrane, haem 
is then degraded by haem oxygenase (HO) yielding ferrous iron. Non-haem iron 
absorption is better established, requiring conversion to ferrous iron by reductase 
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enzyme duodenal cytochrome b (Dcytb) prior to uptake by divalent metal 
transporter-1 (DMT-1) in gut enterocyte cells (McKie et al 2001).  
Within the cell, ferrous iron is either oxidised and bound to ferritin, or transported 
across the basolateral membrane by ferroportin. Haem iron also joins this cellular 
pool. Release of iron to plasma by ferroportin in regulated by hepcidin, which binds 
to ferroportin leading to its internalisation and degradation within the cell. Hepcidin 
therefore regulates iron uptake by the body, as ferritin bound iron within the cell is 
(if not required) is lost when the enterocyte is sloughed from the villi tip. Once 
across (or prior to crossing - Evans & White unpublished work) the basolateral 
membrane, ferrous iron is oxidised to ferric iron by hephaestin and bound to 
transferrin, for transportation within the bloodstream. Ceruloplasmin (a homologue 
of hephaestin) performs this role in complex with lactoferrin. Two binding sites are 
available per molecule, and in healthy people, 20-45% of available transferrin 
binding sites are normally filled. The iron is then stored in cells bound to ferritin, 
around 4000 atoms per molecule. More ferritin is produced in situations of excess 
iron. Normally, 75% of absorbed iron is bound to haemoglobin (~80-90% 
Fairweather-Tait 2001), and 10-20% is recycled through erythropoiesis, and stored 
in bone marrow (Dooley & Worwood 2000). A healthy male body may typically hold 
around 4g iron in total, a female around 3g. Serum ferritin levels have been found 
to correlate with iron stored in bone marrow in healthy people, and 1 µg/l serum 
ferritin is equivalent to approximately 8 mg of stored iron (Walters et al 1973, in 
Aggett et al 2010). 
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Iron in excess of physiological requirements is stored by ferritin, which is most 
abundant in the liver and muscle, but ferritin-bound iron may be also be deposited 
in the pancreas, pituitary gland, and joints (Rahier et al 1987). When iron 
absorption exceeds storage and transporter capacity non-transferrin-bound iron 
(NTBI) results. NTBI is potentially toxic as it is vulnerable to free radical reactions, 
and subsequent oxidative damage to lipids, proteins and DNA (Gutteridge et al 
1981).  
Other than by blood loss or foetal growth, no regulatory method exists for the body 
to reduce iron stores once it has passed through the gut epithelia, therefore 
regulation of ferroportin and hepcidin production is closely maintained in response 
to need, as is the regulation of transport and storage proteins.  
Table 1. Plasma iron ligands, size and typical concentrations 
Ligand Molecular mass Plasma level 
Albumin1 66 kDa 35 – 50 g/L 
Transferrin2 80 kDa 2.07 - 3.10 g/L 
Phosphates2 <  0.05 KDa 25 - 45 mg/L (~1000 µM) 
Citrate2 <  0.2 kDa ~18mg/L (100 µM) 
Haemoglobin2 68 kDa 0.3 - 8.9 mg/L 
Pyruvate2 0.046 KDa ~2.8 mg/L (~60 µM) 
Lactoferrin3 80 kDa 1 mg/L 
Acetate4 0.06 kDa < 1.2 mg/L (<  20 µM) 
Ferritin5 450 kDa 10 - 447 µg/L 
1Roche et al 2008, 2 Lentner 1984, 3Farnaud & Evans 2003, 4Skutches et al 1979, 5Knovich et al 
2008 
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1.4.3 Dietary iron, adult recommendations and sources 
In the UK, the recommended nutrient intake of iron for males 19 plus years is 8.7 
mg/day; for females 19 to 50 years, 14.8 mg/day; females 50 plus years, 8.7 
mg/day (DH 1991). In healthy adults, approximately 1 to 2mg of iron per day is 
absorbed, equal to average losses via menstruation and sloughing of cells. In the 
modern diet, 0 to 2mg per day is consumed via haem iron (from meat, fish, and 
poultry), and 12 to 18mg of iron per day is available via non-haem iron (fortified 
cereals, pulses, vegetables) (Hunt 2005). The biggest dietary contributors of iron in 
the UK are cereals and cereal products (44 to 55%), and meat and meat products 
(13 to 19%) (NDNS 2008/9), giving 10 to 15% haem iron (absorbed at 20 to 50% 
efficiency), and 85 to 100% non-haem iron (absorbed at 0.1 to 35% efficiency) 
(Dainty et al 2003, Hunt 2005). High consumers of red and processed meat (> 90 
g/day cooked weight) should consider reducing their intakes to the adult 
population average of about 70 g/day (SACN 2010). 
Rates of absorption of both haem and non-haem iron varies depending on the 
composition of the rest of the diet, and on the iron status of the individual, 
although this variation is more pronounced for non-haem iron (Hallberg et al 1997). 
Non-haem iron is more highly adjustable to requirement (Cook 1990, Hunt 2005), 
although Hallberg et al have demonstrated that, in a mixed diet over 5 days, 
approximately 40% of both types were absorbed by iron depleted people, but as 
total absorbed iron decreased the ratio of haem to non-haem altered, becoming at 
the lowest levels 20:5%, and 15:2.5%. This work showed that although haem iron is 
absorbed more efficiently than non-haem iron, it is not possible for high meat 
intakes to lead to accumulating iron stores in healthy people, as absorption was 
significantly related to ferritin status. They also found that 50% of ferritin variation 
was unrelated to iron stores, and may therefore be due to other roles, such as up-
regulation in response to inflammation. It is not clear why non-haem iron is more 
adjustable to demand, however there appear to be differences in the mechanism 
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for absorption into gut enterocytes, and haem iron is thought to be absorbed as an 
intact porphyrin structure, possibly via endocytosis (Hunt 2005).  
Various dietary components are known to influence iron absorption, for instance 
alcohol, ascorbic acid, and haem iron enhance non-haem iron absorption, and 
unidentified factor(s) in meat, poultry, and fish enhance haem iron absorption, 
proposed to be peptide fragments by Storcksdieck et al (2007). Phytic acid, calcium, 
iron-binding polyphenols, soy protein and egg can inhibit non-haem absorption 
(Hunt 2005). Other influences on enhanced absorption include erythropoiesis, 
pregnancy, hypoxia, and inflammation. 
1.4.4 Non-transferrin-bound iron 
The redox active nature of iron requires that it is tightly controlled by the body, to 
avoid unwanted reactions, and generation of ROS. In particular, the production of 
the hydroxyl radical is dangerous, and can occur via the following sequences: 
Fe3+ + O2
-  Fe2+ + O2 
Fe2+ + H2O2  Fe
3+ + OH· + OH- 
O2
- + H2O2  O2 + OH
· + OH- 
In cells, a constant stream of superoxide is produced by mitochondria during ATP 
production. Superoxide and hydrogen peroxide are also produced during the 
respiratory burst prior to phagocytosis (Dahlgren & Karlsson 1999). Ferric iron (for 
example from ferritin) can then accept an electron from the superoxide, producing 
ferrous iron and oxygen. The Fenton reaction, between ferrous iron and hydrogen 
peroxide, can then produce the hydroxyl radical (Halliwell & Gutteridge 2007), 
which can participate in oxidative damage to lipid membranes, proteins, DNA, and 
lipoproteins, as described earlier. Even trace amounts of redox available iron (or 
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copper) can produce a range of damaging effects to the functioning of proteins, 
cells, and tissues, therefore numerous mechanisms exist for the safe transport and 
storage of iron. The interruption or disruption of these can result in the appearance 
of irregular and toxic “non-transferrin-bound iron”.  
Non-transferrin-bound iron (NTBI) is a generic term for any plasma iron that is 
redox available, irrespective of its source or form. Redox inactive forms may also 
occur. It was initially observed in patients with iron overload and transferrin 
saturation, by Hershko et al (1978), is seen following intravenous and oral iron 
supplementation, and exists in numerous physiological conditions (see Appendix 
1.ii for a compilation of relevant studies, and see 2009 for a review). NTBI can 
appear without transferrin saturation, although its existence may be transitory. Its 
chemical nature is not fully defined, and there are thought to be a number of 
isoforms, which vary with disease state. Studies in mice demonstrate at least three 
different fractions of NTBI (Simpson et al 1992), with a range of molecular masses 
from less than 10 kDa, to 150 kDa or greater, relating to the plasma component 
with which it is (loosely) bound. Suggested ligands include citrate, the similarly 
structured Heidi, albumin, albumin-citrate, acetate, pyruvate, and phosphates 
(Hider 2002, Evans et al 2008, Silva & Hider 2009). Different NTBI species may be 
taken up by cells by a variety of mechanisms, possibly accounting for the 
differences seen in organ iron loading and distribution in various iron overload 
syndromes (Evans et al 2008).  
Despite its known existence in many pathological conditions, there is little 
consensus on physiological levels of NTBI within different diseases, and a lack of 
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standardised assay methodology (Jacobs et al 2005). Different assays may be 
measuring iron attached to different ligands.  These factors, and the difficulties 
inherent in collecting and quantifying reactive iron without interference from safely 
transferrin-bound iron, have prevented NTBI measurement becoming a useful 
clinical tool.  
1.4.4.1 Non-transferrin-bound iron and type 2 diabetes 
Levels of non-transferrin-bound iron in type 2 diabetes have been investigated by 
several groups, using different methods and reporting a range of results. A 
discussion of these forms part of the Background to Chapter 4. 
1.4.5 Iron as a risk factor for type 2 diabetes 
Genetic iron overload disease, haemochromatosis, is a risk factor for secondary 
diabetes (McClain et al 2006) due to impaired insulin secretion, as a consequence 
of pancreatic-iron deposition (Rahier et al 1987). This has led to a great deal of 
investigation of iron status as a risk for diabetes, although the presence of 
increased pancreatic iron has not been demonstrated in non-haemochromatosis 
type 2 diabetes, and the iron marker of choice is serum ferritin, which is up-
regulated in inflammation, and clinically more useful for measuring iron deficiency 
(Knovich et al 2008). Two lines of research have fuelled these studies: physiological 
iron status and risk for disease, and dietary iron intake and risk for disease. The 
latter is discussed in section 1.5.  
Evidence for a link to risk for diabetes was first put forward by Salonen et al (1998), 
reporting positive serum ferritin correlations with serum insulin and blood glucose, 
without controlling for inflammation. Similar findings are reported by Ford & 
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Cogswell (1999), Fumeron et al (2006), and Sharifi et al (2008), using C-reactive 
protein (CRP), and Jehn et al (2006), who use an inflammation score to control for 
inflammation. Using CRP alone does not fully account for inflammation, (Rajpathak 
et al 2009, DePalma et al 2010, and see Table 28), and the results of studies 
controlled thus may still include inflammation as a factor in the level of risk seen. 
Jiang et al (2004b) followed 32,826 females for one year, comparing the 698 who 
developed diabetes with matched controls, using both serum ferritin and soluble 
transferrin receptor (sTfR) to ferritin ratio to assess iron status. The sTfR:ferritn 
ratio relies on increases of STfR seen during iron-deficient erythropoiesis (Skikne 
2008). Using serum ferritin with multivariate adjustments including for CRP they 
found an increased relative risk for type 2 diabetes in the highest quintile of serum 
ferritin to be 2.61 (95% CI 1.68 to 4.07), P < 0.001 for trend.  Occupation of the 
lowest quintile for sTfR:ferritin ratio gave a relative risk for diabetes of 2.40 (95% CI 
1.55 to 3.71), P = 0.02 for trend.  
Fernandez-Real et al (2005) found a protective effect of repeated venesection has 
been used as on risk for diabetes in a small study of 21 regular blood donors, 
however, other studies disagree.  Zheng et al (2007) found no significant difference 
in risk between frequent donors (> 8 per 2 years) and infrequent donors (1-2 per 2 
years). The results of the largest study of this kind (Jiang et al 2004b) do not 
support a link between blood donation and risk for type 2 diabetes, following 
33,541 men for 12 years. The highest quintile of donation (≥ 30 in 30 years) gave a 
relative risk of 1.12 (95% CI 0.78 to 1.61), P = 0.70 for trend. 
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In summary, increased iron status, as measured by serum ferritin, and sTfR:ferritin 
ratio, has a positive association with risk for type 2 diabetes. This risk does not 
appear to be reduced by regular blood donation, and the adaptability of the gut to 
adjust iron absorption to physiological need may lead the body to respond to 
venesection by absorbing more iron.   
As an anabolic peptide, insulin stimulates the cellular uptake of various nutrients 
besides glucose, including iron (Davis et al 1986). Davis et al demonstrated up-
regulation of cell-surface transferrin receptors (TfR) in adipocytes in response to 
insulin. This would imply a reduced take-up of iron by insulin sensitive cells where 
insulin is lacking, perhaps raising plasma levels and predisposing non-insulin 
sensitive cells (such as endothelial, and some neural and kidney cells) to receiving 
the iron. Transferrin receptor regulation is also stimulated by hypoxia, via hypoxia-
inducible factor (HIF-1) (Tacchini et al 1999), and the case could be made for a 
further source of iron uptake by cells, where intracellular hyperglycaemia leads to 
an increased cytosolic ratio of NADH to NAD+, and subsequent cell 
“pseudohypoxia” (Williamson et al 1993). Hypoxic responses might then promote 
TfR expression and increased iron uptake. 
1.4.5.1 Iron and the metabolic syndrome 
Using data from 6,044 adults contributing to the Third National Health and 
Nutrition Examination Survey (NHANES III), Jehn et al (2004) have found a positive 
association between serum ferritin quartile and prevalence of the metabolic 
syndrome. Multiple regression analysis including CRP as a variable, for post-
menopausal women, found an OR for the metabolic syndrome in the highest 
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quartile of serum ferritin (> 168 µg/l) compared to the lowest (≤ 54 µg/l), of 2.7 
(95% CI 1.7 to 4.1, P < 0.001 for trend). For men, the highest quartile of serum 
ferritin (> 231 µg/l) compared to the lowest (≤ 86 µg/l), gave an OR of 1.6 (95% CI 
0.9 to 2.7, P < 0.11 for trend). The results for men is non-significant, and reflects 
the OR for the third quartile of serum ferritin (146 to 231 µg/l), of 1.6 (95% CI 0.8 to 
3.2), the same as the fourth quartile but with a larger confidence interval, 
suggesting that the association between ferritin and the metabolic syndrome for 
men is weak. 
1.4.5.2 Insulin resistance-associated hepatic iron overload 
Hepatic iron loading, associated with overweight, dyslipidemia, hypertension, and 
glucose intolerance, and separate from genetic iron-overload disease, was first 
identified by Moirand et al (1997). Termed ‘insulin resistance hepatic iron overload’ 
(IR HIO), or ‘dysmetabolic iron overload disease’ (DIOS), it is seen in about a third of 
patients with NAFDL and the metabolic syndrome (Dongiovanni et al 2011).  
IR HIO is associated with raised serum ferritin, independently of CRP, and increased 
liver iron, seen in periportal hepatocytes and less frequently in sinusoidal Kupffer 
cells (Moirand et al 1997).  Altered iron regulation is seen, in association with 
subclinical inflammation (Dongiovanni et al 2011), and increased hepatic hepcidin 
expression correlates positively with hepatic iron concentration, whilst transferrin 
receptor mediated iron uptake is not associated with iron accumulation in NAFLD 
(Aigner & Datz 2008). Altered iron homeostasis may also be linked to low copper 
bioavailability, as copper is required for ceruloplasmin and hephaestin ferrioxidase 
activity (Aigner & Datz 2008). Aiger et al (2008) found an inverse relationship 
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between iron and copper stores in patients with NAFDL. Whether or not this is 
dietary in origin is unknown, but dietary sources of copper are broad, and include 
legumes, potatoes, nuts and seeds, beef, cereal grains including breads and 
breakfast cereals, and poultry (Ma & Betts 2000). Data from the 2008/2009 UK 
National Diet and Nutrition Survey find UK adults to have sufficient copper intakes 
(NDNS 2008/2009).  
Whilst increased stored liver-iron is thought to cause insulin resistance, the 
mechanisms by which it does so are undefined (Dongiovanni et al 2011). In a 
review of insulin resistance and liver disease, Bugianesi et al (2005) give peripheral 
muscle rather than the liver as the primary site of insulin resistance in NAFLD, with 
the most likely mechanism to be cytokine-induced serine rather than tyrosine 
phosphorylation of insulin receptor substrate, IRS-1. Bugianesi et al suggest the 
likely progression of peripheral insulin resistance to be hyperinsulinemia, increased 
lipolysis, influx of fatty acids to the liver, and increased liver triglycerides, followed 
by hepatic steatosis and hepatic insulin resisitance. The major source of 
intrahepatic fat, contributing to fatty liver disease, is plasma free fatty acids from 
adipose tissue (Donnelly et al 2005, in Bugianesi et al 2005), and therefore it 
appears that, following inflammation, peripheral insulin resistance and 
hyperinsulinemia drives adipocyte lipolysis, which causes hepatic fat deposits, and 
subsequent liver disease.  
Hepcidin upregulation as a result of chronic inflammation might be suggested to 
lead to less hepatocyte-iron build up, via less enterally absorbed dietary iron, 
however Aiger & Datz (2008) propose that hepcidin upregulation is a consequence 
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of hepatocyte-iron accumulation, as iron is a stimulus for hepcidin production, and 
persistently high hepcidin levels would induce iron deficiency, which is not seen in 
biopsies of patients with NAFLD. Iron depletion therapy has been shown to 
increase peripheral and hepatic insulin sensitivity, increase pancreatic insulin 
sensitivity, reduce HbA1c, improve liver function tests, and ameliorate low-grade 
inflammation, in patients with IR HIO, by numerous studies (see reviews by Aigner 
& Datz 2008, and Dongiovanni et al 2011). 
As around a third of NAFLD and metabolic syndrome patients will have IR HIO, and 
these conditions are strong risk carriers for diabetes, a proportion of people with 
type 2 diabetes could be expected to have hepatic iron overload. Very few studies 
have measured liver iron in type 2 diabetes, however. Dineen et al (1994) finds, in 
15 diabetes patients, and 17 age-matched controls, no significant difference in 
mean hepatic iron (1,303 vs 1,349 µg Fe/g dry weight of liver; P = 0.87, in diabetes 
vs controls consequetively). To compare with other conditions, Moirand et al 
(1997) found, in 65 IR HIO patients median liver iron concentrations of 4,760 µg 
Fe/g dry weight of liver, and in 65 controls with haemochromatosis, matched for a 
range of serum ferritin levels from 398 to 1,691 µg/l, 2,016 µg Fe/g dry weight of 
liver. Liver iron content of healthy controls (n = 20) was found to be 636.1 ± 203.4 
µg Fe/g dry weight of liver by Aiger et al (2008). Given the low numbers of 
participants in Dineen et al’s (1994) study, it is possible that they did not include 
any patients with hepatic-iron overload, and it may be the case that a particular 
genotype or types predisposes for liver-iron-loading.  George et al (1997) found 
that heterozygosy for the haemochromatosis gene mutation Cys282Tyr was 
associated with increased hepatic iron, but not serum ferritin, in 16 non-alcoholic 
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steatohepatitis patients (NASH) with the mutation, compared to 35 NASH patients 
without the genotype. 
 1.5 The link between dietary iron and risk for type 2 diabetes 
1.5.1 The historical perspective: Dietary adaptation theory of diabetes 
Humans evolved from a plant-eating ancestor living 2 to 4 million years ago. The 
adaptation to hunting, and a diversely mixed diet of animals in addition to plants, 
appears to be linked to global cooling and ice ages, and the expansion of drier open 
savannah in place of forests (Brand Miller & Colagiuri 1994). What the diet of early 
man consisted of has been revealed by a number of methods, including 
comparative studies of the diets of hunter-gatherer societies today. Work by 
Cordain et al (2000) looking at current hunter-gatherers finds a reliance on meat, 
fish, and other tissues for between a third to two thirds of their diet, preferring to 
obtain at least half of their energy from animal foods when possible. In some 
cultures protein intakes reach 86% of total energy intake. Evidence from fossil 
isotope and tooth enamel studies indicate large quantities of grazing animal meat 
in ancient diets (reviewed in Mann 2000), and comparison of gut physiology with 
other mammals also suggests that meat contributed a significant amount to the 
diet of early hominids (approximately 1.8 million years ago). Diets would have 
varied depending on environment, season, and latitude; and carbohydrate intake 
would have consisted of foods such as fibrous vegetable roots and tubers, berries, 
honey, and fruits when available (Brand Miller & Colagiuri 1994; Leach et al 2006).  
As man evolved the human brain size increased threefold over a period of 3.5 
million years (Mann 2000), to represent 2% of total body weight, approximately 1.3 
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to 1.4 kg. This would have required long chain polyunsaturated fatty acids (PUFA), 
particularly arachidonic acid and docosahexaenoic acid (DHA) for its composition 
(whole brain is 10 to 12% lipid, McIlwain & Bachelard 1985), and increased energy 
intake for brain metabolism (nine times higher per kg than human tissue as a 
whole). O’Dea (1991) and Wendorf & Goldfine (1991) have proposed that insulin 
resistance would have been of benefit to people faced with periods of food scarcity, 
conserving what glucose was available for brain and reproductive functions. Insulin 
resistance in tissues such as muscle would have preserved glucose for these vital 
functions, and as a survival advantage, insulin resistance may have been genetically 
selected for throughout human evolution. Periods of starvation would have also led 
to a bottleneck effect in populations, where survival only by those with the best 
insulin resistance would have ensured the genotype was passed on to future 
generations.  
Mechanisms involved in the initiation of insulin resistance by nutrients in plasma 
have been demonstrated by a number of groups. Postprandial levels of amino acids, 
particularly branched chain, interfere with insulin signalling in animals (Patti et al 
1998), and in humans (Krebs et al 2002), by inhibiting the early stages of post-
insulin receptor activity, preventing phosphorylation of insulin receptor substrates 
(IRS) and subsequent protein kinase C and other kinase sub-units, consequently 
interfering with GLUT4 translocation to the cell membrane (reviewed by Zierath et 
al 2000). This cell signalling pathway is also inhibited by plasma free fatty acids 
(Dresner et al 1999, Griffen et al 1999), and up-regulated by exercise and hypoxia 
(Zierath et al 2000). 
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Protein initiated insulin resistance would have benefited hunter-gathers, where low 
glucose intakes would be the norm, and a protein rich meal could inhibit muscle 
glucose uptake, conserving available glucose for the brain, and allowing peripheral 
cells to metabolise lipids and protein for energy. For modern man this advantage 
has become a disadvantage. Brand Miller & Colagiuri (1994) propose that cultures 
that adopted agriculture early, such as the Near East, Mediterranean and Europe, 
have been adapting to dietary change over a 12,000 year period, consequently 
eating less meat, of altered fat type, and relying on domesticated animals and 
cultivated grains. Brand Miller & Colagiuri suggest that these people now have less 
type 2 diabetes than cultures such as the American Pima Indian, Australian 
Aboriginal, and Inuit peoples, who have only recently adopted Western lifestyles, 
and have rates of diabetes several times higher than European populations. This 
period of time is known to be sufficient to alter gene frequency, they argue, as 
adult expression of lactase has developed in European people over the same 
period. In support of this, Mann (2000) report that when urbanised diabetic 
Australian Aborigines return temporarily to their traditional diet, their condition 
improves.  
In the western world in recent centuries, changes in the quality of dietary 
carbohydrate as a result of the industrial revolution and the milling of grains, as 
well as the introduction of potatoes to our diets, has led to meals of higher 
glycaemic load, requiring higher postprandial insulin levels. Brand Miller & Colagiuri 
suggest that the modern diet has a higher carbohydrate intake, of a different 
quality, than the body has evolved to cope with, and that one physiological effect of 
this is the requirement of pancreatic β-cells to produce increased volumes of 
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insulin, beyond the capacity required in the past. Many other aspects of lifestyle 
have also changed of course, and many factors influence the body’s progression 
towards diabetes. We live longer, and have decreased energy expenditure, 
increased portion sizes, increased energy intake from fats, and changed intake of 
fatty acid types. A lower ratio of n-3 to n-6 PUFA in the modern diet for instance 
promotes an inflammatory cellular environment (Calder 2006).  
Clearly type 2 diabetes is a disease of lifestyle and environment at odds with the 
human body as it has evolved to be, and a review of how dietary iron fits into this 
picture is relevant, given the reports of a positive association of haem iron intake 
and risk (Rajpathak et al 2006; Lee et al 2004; Jiang et al 2004, for example), and 
the growing evidence claiming disordered iron homeostasis in the diabetic 
condition. 
1.5.2 Dietary haem iron intakes – ancient and modern 
Considering whether there is any relevance to links between changes in iron intakes 
and development of insulin resistance, it is evident that historically, humans would 
have had a plentiful supply of iron from diets rich in muscle tissue from meat and 
fish. Why then has haem iron intake been so positively associated with risk for type 
2 diabetes? It seems unlikely to be due to elemental iron itself, considering the high 
levels consumed in ancient diets, and the body’s ability to regulate dietary 
absorption of both haem and non-haem iron to match requirement (Hallberg et al 
1997). Hallberg et al’s work showed that whilst haem iron is more efficiently 
absorbed, high intakes do not lead to accumulating iron stores in healthy people. 
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Although absorption of both types are influenced by iron status, the effect on non-
haem iron is greater.  
One explanation may relate to other factors present in the source of haem iron 
rather than the iron itself. Cordain et al (2002) in their ethnographical study of 229 
hunter-gatherer societies, found that of the 55 to 65% of daily energy from animal 
foods (haem iron providers), half would be derived from aquatic animals, and half 
from terrestrial animals.  This would provide a fatty acid profile significantly 
different from that seen in the typical modern diet, with a saturated fat content of 
7% energy compared with between 9 and 19% today (Salmeron 2001), and an n-3 
to n-6 ratio of 1:1.5, compared with >1:15 today (Simopoulos 2006). In support of 
this, Hu et al (2001) in a review of cohort studies of dietary fat, carbohydrate, and 
risk for diabetes, found that higher intakes of PUFA, and possibly n-3 PUFA, could 
be beneficial, but there was no general consensus on proportions of total fat or 
carbohydrate as a risk factor for diabetes. Substituting a high saturated fat diet for 
a high monounsaturated fat diet has been shown to improve insulin sensitivity in 
162 healthy men and women over a 3 month period, by Vessby et al (2001), 
however they failed to show any benefit in fat type substitution for individuals with 
a high fat intake (>37%), or with the addition of n-3 fatty acids. A review by Riccardi 
et al (2004) also found consistently positive associations between saturated fat and 
hyperinsulinaemia, though again, n-3 supplementation had no effect on insulin 
action. On the other hand, Steyn et al (2004) do report two epidemiological studies 
that found an inverse relationship between fish intake and glucose tolerance, and 
positive links between total fat, and saturated fat and diabetes risk. They 
recommend total fat intakes not exceeding 30%, and saturated fat not exceeding 
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7% total energy intake as beneficial to diabetes risk. They did not include iron or 
meat intakes as part of their review. 
1.5.3 Review of cohort studies linking haem iron intake and risk for diabetes 
A closer look at the studies that have reported haem iron intakes to be positively 
associated with risk for type 2 diabetes finds no clear picture of any risk associated 
solely with red meat over other sources of haem iron.  For instance, Lee et al (2004) 
found multivariate adjusted relative risk (RR) for diabetes increased from 1.0 to 
1.28 across quintiles of haem iron intake, and from 1.0 to 1.2 for red meat only, in 
35,698 postmenopausal females over 11 years (The Iowa Women’s Health Study). 
Jiang et al (2004b) followed 38,394 men for 12 years, finding relative risk increased 
from 1.0 to 1.28 over the quintile range for total haem iron intake (in support of Lee 
et al), however no increased risk was found to be associated with haem iron from 
other sources. Rajpathak et al (2006) followed 85,031 females for 20 years (The 
Nurses’ Health Study), finding relative risk increased from 1.0 to 1.28 over the 
quintiles for total haem iron intake, but that red meat and other haem iron 
providers both independently raised risk, agreeing with Lee et al. It should be noted 
that Rajpathak et al, and Jiang et al, in their dietary analysis interpret red meat 
intake as being solely haem iron, but in fact it has a significant proportion of non-
haem iron (from ferritin and mitochrondria). For example in beef muscle meat 64% 
of total iron is in the haem form (Valenzuela et al 2009). Other studies have used a 
factor of 0.6 (Monsen et al 1978) to calculate non-haem iron in meat. Incorporating 
this attributes greater weight to a link with haem iron by Rajpathak et al, and Jiang 
et al. 
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On balance, it is not clear from these studies whether it is haem iron, as red meat, 
or total haem iron (red meat, poultry and fish), which increases risk for diabetes. 
Jiang et al also calculated RR for total iron, which over the quintitles increased from 
10 to 1.16. This suggests that the iron content per se is less influential than dietary 
haem iron intake and risk for diabetes, and that other factors related to red meat, 
poultry and fish are affecting this.  
An obvious possibility might be saturated fat - common in red meat products - but 
data analysis included adjustment for saturated fat by Jiang et al, animal fat by Lee 
et al, and polyunsaturated fat to saturated fat ratio by Rajpathak et al, ruling this 
possibility out. Two other factors have been proposed by Schulze et al (2003) as 
potential risk enhancers in relation to haem iron intake: dietary nitrites, and dietary 
advanced glycation end products (AGE). Both of these are found in high levels in 
processed meat products, and a number of cohort studies have found processed 
meat intake to be a stronger indicator of diabetes risk than total red meat (Schulze 
et al 2003; Song et al 2004), or dietary fat intake (van Dam et al 2002). It may be 
queried that these studies of processed meat intakes may be reflecting a less 
healthy life-style generally, however results were reported following adjustment for 
variables such as exercise, smoking, and intakes of alcohol; total energy; fibre; 
magnesium; and a range of fat types.  
1.5.4 Processed meats, nitrites and dietary advanced glycation end products 
Looking at haem iron intake from a different perspective, there is strong evidence 
for a link between processed red meat intake and incident type 2 diabetes. Using 
data from The Nurses’ Health Study II, Schulze et al followed-up 91,246 young and 
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middle-aged females over 8 years, and analysed the data for processed meat 
intake. They found total red meat increased RR, from 1.00 to 1.58 for intakes of < 
1/week to ≥ 5/week, but increased processed meat intake to be more strongly 
associated with risk for diabetes, with RR increasing from 1.0 to 1.91 for intakes of < 
1/week to ≥ 5/week. They found no independent associations attached to fish 
intake, but poultry intakes decreased RR from 1.00 to 0.78 for intakes of < 1/week 
to ≥ 5/week. Data were adjusted for BMI, and dietary fatty acids and cholesterol. 
This work has been updated (Pan et al 2011), consolidating the findings, and 
distinguishing between total and unprocessed red meat, leading to an estimation 
that substitution of 100g/d unprocessed, or 50 g/d processed red meat, for one 
serving of nuts, low fat dairy, and whole grains per day would reduce risk for 
diabetes by 16 to 35%. 
Song et al (2004) evaluated 37,309 females aged 45 or older, finding red meat 
increased RR for type 2 diabetes, from 1.00 to 1.29 for intakes of < 1/week to ≥ 
5/week, and increased processed meat intake to increase RR from 1.0 to 1.43 for 
intakes of < 1/week to ≥ 5/week. Only processed meat remained significantly 
associated with risk when all other nutrient factors had been adjusted for, with 
bacon and hot dogs having the highest association with risk compared with a mixed 
group of other processed meats. Confirmation of this comes from a meta-analysis 
of 20 studies investigating red and processed meat, and risk for coronary heart 
disease, stroke, or type 2 diabetes (Micha et al 2010), which found that 
unprocessed red meat was not associated with CHD, diabetes or stroke, but 
processed red meat was associated with CHD (RR per 50g/d, 1.42, 95% CI 1.07 to 
1.89), and diabetes (RR 1.19, 95% CI 1.11 to 1.27), but not stroke. Further to these, 
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Lajous et al (2012) looked at unprocessed and processed red meat intake and 
incidence of type 2 diabetes in a cohort of 66,118 healthy French women, finding 
an association with processed meat only (hazard ratio for one serving/day, 1.29, 
95% CI 1.14 to 1.45).  
Aune et al (2009) performed a systematic review and meta-analysis of 12 cohort 
studies assessing meat consumption and risk of type 2 diabetes. Their findings had 
a large degree of heterogeneity, however overall results suggest that red meat 
consumption does increase the risk of type 2 diabetes. They did not include the 
large scale dietary iron intake studies of Jiang et al (2004b), and Rajpathak et al 
(2006) in their analysis. For total meat consumption, RR of high vs low intake is 1.17 
(95% CI 0.92 to 1.48); red meat consumption, RR of high vs low intake 1.21 (95% CI 
1.07 to 1.38); and processed meat consumption RR of high vs low intake 1.41 (95% 
CI 1.25 to 1.60). Assessed intake frequencies varied between studies, but were 
typically servings equal to or more than two a week versus less than one a week, or 
two to five servings a week versus less than 1 a month. Red meat portion size was 
set at 120 g; processed meat portion size was set at 50 g. 
Processed meat clearly gives the greatest risk, and Song et al, and Schulze et al, 
propose dietary nitrites, and/or dietary advanced glycation end products, as 
possible reasons for the increased risk attached to processed meats. Nitrites are 
commonly used to preserve meats, and are transformed in the gut by reaction with 
amines and amides to become N-nitroso compounds nitrosamines and 
nitrosamides. Nitrites have been linked to the development of type 1 diabetes 
(Akerblom et al 2002), although the mechanism involved is unclear. 
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1.5.5 Dietary AGE and type 2 diabetes risk 
The term ‘advanced glycation end product’ refers to a heterogeneous group of 
compounds known to have pro-oxidant and pro-inflammatory effects in the body 
(Uribarri et al 2005). AGE occur following reaction between carbonyl groups on 
sugars and amine groups on proteins, DNA, and lipoproteins, to form glycated 
proteins. This non-enzymatic glycation is the first stage of the Maillard reaction, 
also responsible for browning reactions between carbohydrates and amines in 
cooked food. Proteins can also be modified by lipid peroxidation, becoming 
advanced lipoxidation end products (ALE). Within the literature discussing dietary 
AGE, the term ‘AGE’ is often used as a generic term for any non-enzymatic protein 
modification, i.e. for reactions involving either carbohydrate or lipids. 
1.5.6 AGE in meat 
For the role of dietary AGEs in diabetes risk, support for earlier work by Schulze’s 
group (van Dam et al 2002), is put forward by Peppa et al (2002), who propose that 
dietary glycoxidation products are the link between animal fats; meat; and 
diabetes; as the highest levels of AGE and ALE (advanced lipoxidation endproducts) 
are seen in animal products high in protein and fat, with industrially processed 
animal products such as frankfurters and bacon containing large amounts. 
Formation is increased by higher cooking temperatures and method of cooking, and 
meats cooked with a high dry heat such as grilling, frying, and roasting have the 
highest AGE values (Uribarri et al 2005). (Tables of AGE levels in common foods are 
available, see Goldberg et al 2004).  The label ‘AGE’ for these products is 
misleading, as they refer to εN-(carboxymethyl), and εN-(carboxyethyl)lysine (CML 
and CEL), downstream products of glycation that can occur between lipids and 
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protein, independently of the Amadori compound fructolysine (Fu et al 1996). 
Consequently, the presence of glucose (or fructose) is not essential for their 
formation, and meats and cheese for example can have high levels, despite having 
very little or no intrinsic carbohydrate content. One common route of formation is 
from PUFA, where oxidation of a double bond causes fatty acid cleavage and 
formation of a 4-hydroxy-2-nonenal (4-HNE) moiety, which can then bind to a 
protein lysine residue, forming a protein carbonyl (Estevez 2011). 
The proposal of AGE as the link between animal fats, meat, and diabetes can be 
extended to explain the positive association between haem iron intake and risk, 
with perhaps an involvement by N-nitroso compounds. It also raises the question of 
whether or not the formation of AGE products within these foods is enhanced by 
the presence of elemental iron, as shown to be the case in vitro with copper, LDL, 
and PUFA formation of CML (Fu et al 1996), and suggested within the body by 
Stadtman & Levine (2000); or whether some other factor(s) present in haem is 
influential, alongside the effects of heat during processing. The mechanical process 
of mincing meat for example breaks down tissue, exposing myoglobin and haem, 
and oxidation of the ferrous iron to ferric occurs when the reducing environment of 
the tissue surrounding the exposed myoglobin is exhausted. With storage, 
unsaturated fatty acids oxidize and produce free radicals that can oxidize the 
myoglobin (Claus 2007). Protection against meat protein oxidation by dietary 
antioxidants is able to compensate for high levels of PUFA in pasture fed lamb, 
compared with grain fed (Sante-Lhoutellier et al 2007). The potential for haem iron, 
and ferric iron from ferritin, to catalyse reactions has received some investigation 
by the meat industry, and myoglobin is found to be a good predictive marker for 
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protein carbonyl formation, however, relative contributions from different iron 
forms have not been determined (Estevez 2011). Several studies have compared 
the production of thiobarbituric acid reactive substances (TBARS) (a marker of lipid 
peroxidation) on stored raw and cooked muscle meats. Levels were low in chicken 
and pork compared with beef, and all increased with cooking, with myoglobin 
content best explaining the difference (Rhee & Ziprin 2007), later agreed with by 
Peiretti et al (2012). Again, no iron ‘factor’ has been drawn, by which the 
contribution of iron to lipid oxidation can be estimated. 
When cooking red meat, incidentally, the darkening of colour is due to denaturing 
of the globin and oxidized haem iron, forming a hemichrome (Claus 2007).  
1.5.7 Dietary AGE in the body 
Approximately 10% of dietary advanced glycation end products are absorbed, 
directly proportional to the amount consumed (Koschinsky et al 1997), and a 
growing body of evidence describes their deleterious effects on the body. For 
example, Uribarri et al (2007) found that a single AGE drink led to a significant 
increase in serum AGE, and significantly decreased flow-mediated dilation of the 
brachial artery in both diabetic and healthy subjects, at 90 minutes post 
administration. The authors suggest that elevated circulating AGE may alter 
vascular endothelium response by reducing cellular nitric oxide production, or 
inhibiting nitric oxide activity. Vlassara et al (2008) have linked AGE intake to 
increased oxidative stress and inflammation, and reductions in dietary AGE to 
improved flow-mediated vasodilation in diabetes patients. A high AGE meal 
compared to a low AGE meal results in a marked increase in circulating markers of 
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endothelial function (VCAM-1 and E-selectin) in type 2 diabetes patients (Stirban et 
al 2008). Dietary AGE products have also been found to activate cell membrane 
AGE receptors (RAGE), triggering MAP kinase activation of pathways for 
inflammation, cell proliferation, and tumour growth (Zill et al 2003).  
1.5.8 AGE and insulin  
Of direct relevance to risk for diabetes, evidence that AGE can cause changes that 
predispose for diabetes has come from a number of studies from Vlassara’s group, 
using the insulin resistant mouse model db/db(++). Dietary AGE restriction whilst 
maintaining other nutrient values (including kcals) improves insulin resistance, with 
the mice fed a low AGE diet demonstrating a doubling in glucose uptake by 
abdominal tissue compared with those receiving a high AGE diet (Hofmann et al 
2002). Sandu et al (2005) found that high fat and high AGE diets led to increased 
visceral fat, plasma 8-isoprostane, plasma glucose and plasma insulin; altered 
pancreatic islet structure, with fewer insulin and glucagon producing cells; and 
increased diabetes. Less adiponectin (the mediator for transcription factor 
peroxisome proliferator-activated receptor γ) was also apparent.  
Impaired insulin secretion in type 2 diabetes is thought to be due to cell function 
impairment and cell loss by apoptosis (Cunha et al 2008). β-cell apoptosis is 
thought to result from endoplasmic reticulum (ER) stress (Xu et al 2005), which can 
be induced by high glucose and free fatty acids in type 2 diabetes, and 
inflammatory cytokines in type 1 diabetes (Kharroubi et al 2004) (although Cunha 
et al propose the effect on ER in type 2 to be primarily lipotoxic rather than 
glucotoxic). Functionally, the cell signalling pathways that result in insulin 
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regulation in β-cells are not fully elucidated, but are known to involve transcription 
factor pancreatic duodenal homeobox factor-1 (Pdx-1), with a possible negative 
feedback inhibitory action by protein kinase CK2 (Meng et al 2010).  
Sandu et al, above, did not speculate on the mechanism connecting AGE to insulin 
resistance, however later work (Zhao et al 2009) has described a link, whereby AGE 
inhibit ATP production in islet β-cells, subsequently inhibiting insulin secretion. In 
db/db mice, Zhao et al used glycated bovine serum albumin (AGE[CML]-BSA; 50 
mg/ml BSA incubated in 0.5M glucose, at 37°C, for 8 weeks), administered intra-
peritoneum for 2 weeks. Serum insulin, glucose tolerance, and insulin tolerance 
were all significantly impaired in a dose-dependent manner with AGE-BSA. Few 
morphological changes in islet structure were seen, but the isolated cells dose-
dependently contained significantly less insulin. Fresh islets were isolated from 
healthy mice and treated with AGE-BSA for 48 hours. Inducible nitric oxide 
synthase (iNOS) mRNA was induced in a dose-dependent manner, accompanied by 
nitric oxide (NO) release in parallel. NO is thought to regulate mitochondrial oxygen 
consumption by inhibiting cytochrome c oxidase (the final enzyme in the electron 
transport chain) activity (Cooper & Guilivi 2007), therefore Zhao et al treated cells 
with aminoguanidine, which selectively inhibits iNOS, and found that cytochrome c 
oxidase activity was restored. Inhibition of iNOS also restored ATP production and 
insulin secretion, leading the authors to conclude that AGE inhibits insulin secretion 
via iNOS up-regulation (via cell membrane AGE receptor signalling cascade and 
nuclear factor-κβ activation) and NO up-regulation; inhibiting cytochrome c 
oxidase-dependent ATP production. ATP production is stimulated by cellular 
glucose, and increase in the ratio of ATP to ADP closes ATP-dependent K+ channels 
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to depolarize cell membranes prior to insulin secretion. If ATP production is 
interrupted insulin secretion cannot take place.   
1.5.9 Summary 
It is known that diet contributes to the bodily pool of AGE and ALE products, and, as 
is described elsewhere in this thesis, endogenous AGE and ALE products (and 
perhaps redox active iron), are co-involved in the complications associated with 
diabetes. It can be seen from the literature that the emphasis on iron intake alone 
as accounting for the positive association between haem iron intake and risk for 
diabetes (Jiang et al 2004, and Rajpathak et al 2006) does not do justice to the real 
picture. A more detailed analysis of the haem iron intake of these earlier cohort 
studies, to include dietary AGE (ALE form) intake via processed meats and cooking 
methods, would clarify this. Although man has evolved with the capacity for large 
amounts of red meat (by modern Western standards) to safely contribute to our 
diet, the combination with dietary AGE from other components of the diet may well 
explain the apparent link with diabetes, and whole diet AGE intakes should be 
included as a factor when regression analyses are performed on red meat intakes.  
In conclusion, from consideration of the studies discussed here, processed meat 
intake is associated with increased risk for type 2 diabetes, more than red meat, 
haem iron, or elemental iron. Meta-analysis by Micha et al (2010) finds that relative 
risk for diabetes per 50 g/day processed red meat is 1.19, with no significant 
increase with red meat.  
Aune et al (2009) found processed red meat intake gave a RR of 1.57 per 50 g/day. 
The link may very plausibly be ALE products produced by food processing, with 
74 
 
meat PUFA content and heat facilitating their composition. A mechanism has been 
described that defines the link between dietary AGE(CML)-products and insulin loss 
(Zhao et al 2009). High red meat intakes may also increase risk for type 2 diabetes, 
to a lesser degree. The level of contribution from iron to dietary protein oxidation 
and AGE is not known, but experimental laboratory testing of this should be 
relatively straight-forward to carry-out, in meats with varying lipid contents, and 
between red meat and other dietary AGE. 
1.6 Inflammation: BMI, and central adiposity 
Conversely to the situation suggested in type 2 diabetes, obesity is generally 
associated with depleted iron stores. This has been suggested to be linked to 
hepcidin – the “master regulator” of iron metabolism, itself regulated by iron 
levels, inflammation, and erythropoeitic activity. Inflammation, from cytokine 
release by adipocytes, leads to increased hepcidin production, which then down-
regulates iron absorption by the gut (McClung & Karl 2009). Ruivard et al (2009) 
have suggested a possible 3-step response by the body to weight gain, whereby 
initial increased iron availability and hepatic iron loading is followed by visceral 
adiposity, inflammation, and hepcidin up-regulation, leading to the iron deficiency 
associated with obesity (Yanoff et al 2007).  
1.7 Iron involvement in AGE development and the pathologies of advanced 
diabetes 
Based on the evidence for AGE development in the long-term pathologies of 
diabetes, the role of reactive oxygen species in AGE development as “fixatives of 
glycation” (Halliwell & Gutteridge 2007), and the potential for iron to participate in 
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the generation of oxidative stress, and glucose autoxidation, poorly liganded iron 
has come under investigation for involvement in diabetic pathology.  
Metal catalysed oxidation in diabetes was first proposed by Wolff & Dean (1987), 
following on from the work of Thornalley et al (1984) who identified that 
monosaccharides could oxidize haemoglobin to methaemoglobin (Hb-Fe3+), at pH 
7.4 and 37°C. Wolff & Dean found that the metal chelator DETAPAC (10 µM to 1 
mM) inhibited the formation of glucose attachment to bovine serum albumin (10 
mg/ml BSA in 25 mM glucose in a 100 mM potassium phosphate buffer). However, 
the effect was biphasic, suggesting two routes of formation, and the addition of 
Cu2+ did not increase the reaction, suggesting saturation of the reactive component 
to the authors. The optimum inhibition of glucose attachment was 45%, achieved 
with 100 µM DETAPAC, in a system with no added Cu2+. The authors do not say 
where the metal had come from to catalyse glycation, presumably the source was 
trace levels in the buffer used, as reported by Halliwell & Gutteridge (2007). 
Later in vitro studies on rat collagen supported a role for Fe2+ and Cu2+ in catalysis of 
the formation of glycated protein and cross-linking, which could be inhibited by the 
metal chelator diethylenetriaminepentaacetic acid (DTPA) (Chace et al 1991), and 
shown to involve hydrogen peroxide as the reaction could be inhibited by catalase. 
Sajithlal et al (1998) used rat tail collagen incubated in 250 mM glucose and 5 to 
500 µM Cu2+ for one week. AGE formation was estimated by ELISA, and found to be 
concentration-dependent with copper. The reaction could be inhibited by a range 
of free radical scavengers, suggesting the oxidation of glucose to be involved, and 
aminoguanidine, suggesting carbonyls or dicarbonyls to be involved. Xiao et al 
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(2007) incubated rat tail collagen in 250 mM glucose for four weeks, with Fe2+ 
ranging from 0 to 300 µM. AGE-collagen was then incubated with human umbilical 
vein endothelial cells (HUVECS) and primary human monocytes for up to 60 hours, 
resulting in increasing losses of cell viability at 60 hours of 5.3% of total cells in 
HUVECS, and 8.6% in monocytes, demonstrating that the AGE-collagen was 
cytotoxic.  
Further evidence for the role of metals in AGE formation comes from Miyata et al 
(2002), who found that angiotensin II receptor (AIIR) antagonists (olmesartan, 
candesartan, irbesartan, losartan, and valsartan) lower in vitro formation of AGE, 
and have metal-chelating activity which accounted for their results. They found 
that aminoguanidine traps AGE precursors reactive carbonyl and dicarbonyl 
compounds, and that the AIIR antagonists inhibit and block hydroxyl and carbon 
radicals mostly at the pre-Amadori stages.  
1.8 Redox-active iron as a consequence of AGE-products  
The studies above demonstrate how AGE development may be initiated and 
maintained by available redox-active iron, or copper. However, they have not 
speculated on the origin of such metals in the body. A number of studies have 
shown that glycation of key iron-binding proteins damages their structure and 
impairs their function, and thus sources of reactive iron in diabetes are presented 
that may contribute to the complications of advanced diabetes. Redox active iron 
apparently has the potential to be both the cause and the effect of glycation. 
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1.8.1 Haem proteins 
Gutteridge (1986) first demonstrated that iron can be released from haemoglobin 
by H2O2, and promote oxidative damage via the Fenton reaction. Subsequently, 
Khoo et al (1994) reported that glycation of haemoglobin A1c causes altered 
electrophoretic motility due to being more negatively charged, and that 
deoxygenated haemoglobin can be glycated twice as rapidly as oxygenated. Khoo 
et al argued that if the conformational state of haemoglobin plays a part in the 
formation of HBA1c, then its enzymatic properties may also be modified, which they 
demonstrated by reaction with H2O2 and 5-aminosalicylic acid. The peroxidase 
activity of glycated haemoglobin was lessened compared to non-glycated, in the pH 
range 4.5 to 6.0. Kar & Chakraborti (2001) confirmed this, and, since the presence 
of iron in the haem moiety is obligatory for peroxidase activity, examined the effect 
of H2O2 on iron release in HbA0 and HbA1c isolated from blood samples of diabetes 
patients. They found a greater, dose-dependent, loss of iron with glycated 
haemoglobin. Reaction with H2O2 and nitroblutetrazolium produced greater levels 
of ferric-form methaemoglobin (a promoter of superoxide formation and 
erythrocyte membrane damage), with HbA1c compared with HbA0, and, when 
reacted with H2O2, HbA1c also produced more lipid peroxidation (measured by 
malondialdehyde), which could be prevented by catalase, and metal chelation, 
confirming the sources of the oxidation. Similar results were also reported for 
myoglobin (Roy et al 2004), although myoglobin glycation is not found significantly 
within muscle. Sen et al (2005) later identified structural alterations in HbA1c 
suggested to represent an unfolding of α-helices and exposure of tryptophan 
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residues. They propose steric alterations to cause a weakened haem-globin linkage, 
providing a vulnerable target for H2O2 degradation and iron release. 
In unglycated haemoglobin, degradation of haem was shown to be dependent on 
ferrous haemoglobin and not ferric methaemoglobin, by Nagababu & Rifkind 
(2000), as degradation could be inhibited by compounds that reacted with ferryl 
haemoglobin, and electron paramagnetic resonance showed that reaction between 
ferrylhaemoglobin and H2O2 involved a one-electron oxidation to superoxide. H2O2 
reacting with methaemoglobin undergoes a two-electron oxidation, producing 
oxygen. Using spectrophotometry to assess the effects of glycation of 
methaemoglobin and metmyoglobin on haem proteins, Cussimanio et al (2003) 
found that the Soret band of maximum absorption for haem (410 nm) was 
completely destroyed, which did not occur with the haem group of cytochrome c. 
Cussimanio et al used 1 M glucose in 0.4 M phosphate buffer with 0.02% azide, 
over 20 days at 37°C, however they did not use an iron chelation agent such as 
Chelex 100, therefore, if trace levels of metals were present in the buffer then 
initial low levels of protein oxidation damage may have escalated following any 
initial haem release during the incubation process, producing the level of damage 
seen. They did not find the haem group in cytochrome c to be damaged, which has 
a ferric iron, although a rapid reduction to ferrocytochrome took place. Cussimanio 
et al suggest the reason for the lack of degradation in cytochrome c may be due to 
inaccessibility of the haem iron to H2O2 produced during glycation, as a methionine-
sulphur ligand is specific to cytochrome c at the sixth coordination position of the 
iron. Alternatively, they propose the cytochrome c haem group to be more securely 
attached due to its covalent bond with globin, unlike in haemoglobin and 
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methaeomglobin, where the bonds are reversible and dissociate easily. Cussimanio 
et al raise the implications for haem degradation in red blood cells of diabetes 
sufferers, but point out the extensive intracellular antioxidant capacity of catalase 
and glutathione peroxidase. They suggest the extracellular matrix, with no 
established antioxidant enzymes, as being more vulnerable to the oxidative threat 
from free iron originating from degraded haemoglobin. 
1.8.2 Haptoglobin 
About 10% of red blood cells are haemolysed intravascularly (Garby & Noyes 1959, 
in Ashleh & Levy 2005), degrading to free, prooxidant haemoglobin. This is dealt 
with in the body by haptoglobin binding, producing a stable, high affinity complex, 
which is subsequently recognised and taken-up by the CD163 macrophage 
scavenger receptor (reviewed in Zuwala-Jagiello et al 2006). CD163 is recycled, the 
haem is degraded to biliverdin and bilirubin, and the iron is either stored as ferritin 
or transported out of the cell by ferroportin (Carter & Worwood 2007). 
Haptoglobin comprises two α-chains, and two β-chains, and is coded for by two 
distinct genes, Hp1, and Hp2. Whilst the β-chains are identical to each, the α-chains 
are longer in Hp2, and can form a variety of cyclic multimers. Three genotypes 
therefore exist: Hp1-1 (86 kDa); Hp2-1 (86 to 300 kDa); and Hp2-2 (170 to 900 kDa) 
(Ashley & Levy 2005, Langlois & Delanghe 1996). Genotypes vary globally, with 
frequency of Hp1 ranging from around 0.07 in India, to over 0.7 in parts of West 
Africa and South America. The mean Hp1 frequency in Europe is 0.38 (Carter & 
Worwood 2007). 
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In diabetes, haptoglobin genotype is a determinant of risk for micro- and 
macrovascular complications, with Hp1-1 being resistant to diabetic retinopathy, 
nephropathy, and cardiovascular disease, Hp2-1 having an intermediate risk, and 
Hp2-2 having greatest risk, with a five-fold increase in risk for cardiovascular 
disease compared with Hp1-1 (Melamed-Frank et al 2001). In the healthy 
population, evidence for differences in risk for these and other diseases due to 
genotype is not clear, and normally a 400 molar excess of haptoglobin to free 
haemoglobin results in no significant effect on function of the haptoglobin types 
(Ashleh & Levy 2005, Carter & Worwood 2007). Ashleh & Levy suggest a molecular 
basis for risk in diabetes linked to an increased clearance rate of Hp1-1-
haemoglobin complexes by CD163 receptors, and a subsequently increased 
production of anti-inflammatory IL-10 compared with Hp2-2-Hb. The smaller Hp1-1 
can more easily enter the sub-endothelial space, the site of vascular injury, to 
scavenge free haemoglobin; and additionally, they found that the oxidative effect 
of glycated haemoglobin on LDL is greater than that of unglycated haemoglobin, 
and is not completely blocked by binding to haptoglobin. Finally, they also report 
finding a profound lack of monocytes expressing CD163 receptors in people with 
diabetes.  
Ashleh & Levy’s theory that Hp2-2 size prevents it accessing free haemoglobin in 
the sub-endothelial space implies that the same must also be occurring in people 
without diabetes, for whom no increased vascular risk is established. The 
difference in vascular risk may therefore be explained by either: more haemoglobin 
being present as a result of increased red blood cell degradation (diabetic 
erythrocytes on average exist for four days less than non-diabetic, Cohen et al 
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2008), increased LDL oxidation by glycated haemoglobin, or increased LDL 
oxidation by haem from degraded glycated haemoglobin, or a combination of 
these.  
In order to gauge the effect Hp genotype might have on vascular risk in diabetes 
compared to non-diabetes, a very rough comparison can be made between rates of 
CVD in populations with low versus high rates of Hp2 genotype. The Indian urban 
population has a high rate of diabetes (Gupta et al 2007), and the highest global 
Hp2 rate (~0.93). CVD accounts for 52.9% of deaths in the diabetic population, and 
24.2% of deaths in the non-diabetic population (Mohan et al 2006). In London, 
where the (European) Hp2 rate is 0.62 (a moderate global rate), in type 2 diabetes 
the rate of cardiovascular mortality is 63.5%, with around 33% of deaths caused by 
CVD in the general population (Morrish et al 2001, Scarborough et al 2010). In both 
countries, CVD deaths in diabetes are approximately double those seen in the 
general population, which, if Hp only has an influence on diabetic CVD risk, implies 
that there are other factors at play. 
A direct comparison of all UK deaths between 1985 and 1986 of people with type 2 
diabetes, between South Asian born people (Indian Hp2 rate ~0.93), and African 
Caribbean born people (African Hp2 rate ~0.3, the global lowest), with diabetic 
people born in England and Wales (Hp2 rate 0.62), was carried out by Chaturvedi & 
Fuller (1996). They did not include Hp genotype data. They found highly significant 
and very highly significant increases in CVD and stroke in both immigrant ethnic 
populations, compared to people born in England and Wales. When population 
rates of Hp are considered, no consistent effect by Hp rate is indicated. For CHD 
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mortality however, a very highly significantly increased risk was seen in the South 
Asian population, with no difference in men and only a small increase in women for 
CHD death by the African Caribbean group, in some agreement with the increased 
risk suggested by Hp genotype. The African Caribbean group however might have 
been expected to have a decreased risk compared to the indigenous population, by 
Hp genotype rate alone, which was not seen. These results echo the general UK 
population trends, with CHD being highest in South Asian people, and stroke being 
highest in African Caribbean people (Scarborough et al 2010). Hp genotype does 
not therefore explain the different cardiovascular risks seen, and many factors 
could influence this, such as diet, apolipoprotein and other genotypes, parental 
health and epigenetic changes, and heathcare prior to and age at migration. A 
comparison between ethnic populations with and without diabetes, and correcting 
for different factors, would provide more information on the causes of CVD, and 
the contribution from Hp genotype in different populations.  
In search of a link between Hp genotype, haemoglobin clearance, and 
atherosclerosis, two studies have studied iron deposition in plaques by Hp 
genotype. Moreno et al (2008) looked at 189 aortic plaques from 21 male type 2 
diabetic, and 16 male control cadavers, comparing Hp1-1 and Hp2-1 against Hp2-2, 
and measuring iron as being present or not by Perl’s stain.  They found that in both 
diabetes, and non-diabetes, Hp2-2 resulted in a larger number of plaques with iron, 
with the effect being greater in diabetes. In non-diabetes, Hp1-1 and Hp2-1, 11.1% 
of plaques had iron, with Hp2-2 being 26.8%; in diabetes Hp1-1 and Hp2-1, 11.8% 
of plaques had iron, with Hp2-2 being 46.2%.  
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More recently, Lioupis et al (2011) measured hemosiderin-iron deposits in carotid 
atherosclerotic plaques from subjects undergoing surgical plaque removal 
operations. Single plaques from each subject were used, 27 with diabetes (diabetes 
type unspecified), comparing Hp1-1 and Hp2-1 (n = 16), with Hp2-2 (n = 11); and 43 
non-diabetic plaques, Hp1-1 and Hp2-1 (n = 20), Hp2-2 (n = 23). Iron was measured 
in every plaque from the diabetes Hp2-2 group, unlike the other three groups. 
Within the diabetes group, they found a highly significant increase in Perl’s iron 
stain in the Hp2-2 group (p = 0.008), and a non-significant increase in Hp2-2 
compared with Hp1-1 and Hp2-1 in the non-diabetes group (p = 0.197). No other 
tests were performed on the plaque material, and so it is not possible to say if the 
presence of iron correlated with oxidative stress measures, or plasma 
malondialdehyde or antioxidants. Plaque iron correlated with serum homocysteine 
(r = 0.354, p <  0.05), and it would be interesting to know if plaque iron or serum 
homocysteine correlated with plaque length or depth, as homocysteine is known to 
autoxidize in the presence of ceruloplasmin, and thus iron too, and in the presence 
of human serum, and is injurious to endothelia (Starkebaum & Harlan 1986). The 
presence of homocysteine in the vascular extracellular matrix would be particularly 
prooxidant if NTBI was present. It seems perplexing that the Hp2-2 plaques had 
more iron, if the problem with Hp2-2 is thought to be its lack of monocyte 
recognition and take-up, and so this appears to support Ashleh & Levy’s theory that 
the larger Hp2-2 is unable to access haemoglobin in the sub-endothelial space, 
leaving it vulnerable to plaque incorporation. Alternatively the Hp2-2-glycated 
haemoglobin complex might enter the plaque independently of macrophages, from 
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a raised plasma pool due to lack of monocyte scavenging. Inflammatory responses 
to Hp2-2-glycated haemoglobin would also play a role in plaque development.  
It can be seen from the two studies above that Hp2-2 clearly leads to plaque iron 
development in diabetes and non-diabetes, with greater effect evident in diabetes. 
Although neither group looked at the oxidative nature of the plaque contents, 
Lapenna et al (2007) have done this, in a study that compared serum ferritin with 
low molecular weight iron, and lipid peroxidation products, in 38 plaques from 38 
carotid artery surgical plaque removals. Following plaque homogenation, iron was 
measured by centrifugation and ultrafiltration through 10,000 kDa filters, then by 
spectrophotometric reaction to ferene. Lipid peroxidation was measured by Fox 
assay, and spectrofluorescence. Plaques were categorised into groups by stenosis 
(less than or greater than 90%); and by contralateral stenosis (occurrence or not). 
Plaque iron and lipid peroxidation measures were all significantly higher in the > 
90% stenosis and contralateral stenosis groups. A significant correlation was seen 
between plaque iron and the oxidation measures in the > 90% stenosis group, 
which was non-significantly associated in the < 90% group. Serum ferritin 
significantly correlated with plaque iron throughout. Lapenna et al demonstrated 
that plaque iron was present, associated with redox active plaque tissue, and more 
concentrated in more severe atherosclerosis.  
This suggests that the iron seen in non-diabetic Hp2-2 plaques will be redox active, 
the effect of which might be to further lipid peroxidation, inflammation, and plaque 
expansion, and, that iron might contribute to cardiovascular risk in non-diabetic 
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Hp2-2 genotype, although the effect of free glycated haemoglobin in the sub-
endothelial space is evidently stronger. 
1.8.3 Transferrin 
Glycation of transferrin in vitro has been shown to decrease its ability to bind ferric 
iron (Fujimoto et al 1995, Van Campenhout 2004 for example), and this is discussed 
in depth in Chapters 2 and 3. 
1.8.4 Albumin 
Human serum albumin represents around 60% of the plasma proteome, and 
estimates for rate of glycation range from 1% normally to 10% in diabetes (Peters 
1996). Garlick & Mazur (1983) reported 10 – 12% normally glycated. In vivo 
glycated albumin reduces its ability to bind fatty acids and bilirubin, and 
demonstrates conformational changes, shown by a reduction in tryptophan 
fluorescence at 295 nm suggesting the sole tryptophan residue had become more 
hydrophobic, and presumably more buried due to the protein contracting (Shaklai 
et al 1984). Qian et al (1998) investigated the ability of glycated albumin to bind 
iron and copper in vitro. They found a pronounced binding affinity for both metals, 
compared with controls, which maintained redox activity in situ. The mechanism 
for this was not clear, but did not involve carbonyls or aldehydes, the authors 
argue, as reduction of the glycated proteins with borohydride did not affect 
binding.  
The number of iron atoms capable of being bound by albumin is not agreed, but 
may be one (Xu et al 2008), two or three (LØvstad 1993), or nine (Loban et al 1997). 
Albumin-iron-citrate ternary complexes can be formed (LØvstad 1993), and a high 
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affinity copper-binding site exists at the N-terminal peptide Asp-Ala-His (Roche 
2008). 
Silva & Hider (2009) used mass spectrometry to measure the influence of oxidation 
and glycation of human serum albumin on iron binding. Both modifications 
increased iron binding, with glycation having the stronger effect. Albumin glycation 
of up to 16% of available primary amine groups led to 99.8% of iron being bound 
from a 1 µM solution, compared with 0.6% by normal albumin. At 50 µM iron 
concentration, 96.1% was bound by glycated albumin, compared with 4.8% by 
normal. Unlike Qian et al however, Silva & Hider found the glycated albumin-iron 
was resistant to interaction with other compounds. They pointed out that 
physiological levels of citrate should be used when incubating albumin with 
glucose, which were not present in Qian et al’s experiment, as the citrate acts as a 
counter ion in the ternary complex. It is not clear whether this accounts for the 
difference in findings for the two groups.  
Silva & Hider (2009) suggest that the sites for iron-liganding on glycated albumin 
may be the carboxylic acid end groups on AGE-products carboxymethylysine (CML) 
and carboxyethylysine (CEL), which lie at the distal end of the residue to the 
protein backbone. If this is the case, other CML- or CEL-glycated proteins might also 
acquire a capacity for iron binding, if glycation isn’t destructive to the protein as 
appears to be the case for haem-proteins. It is not known if citrate forms a bond or 
bonds with the CML-iron; if coordination is provided by neighbouring CML hydroxyl 
groups; or if the iron is subsequently redox available. CML are redox active species 
(Fu et al 1996) and the proximity of the iron ion to the carbonyl group of CML may 
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further the risk of oxidative reactions. The proteolysis of glycated proteins 
produces free glycation adducts which can be measured intra- and extracellularly, 
as discussed earlier, and the inclusion of iron with these degraded species, which 
are exposed to vascular endothelia and subject to renal filtration, provides a 
mechanism by which iron could be damaging to these tissues.  
Iron and AGE - summary 
Copious literature exists hinting at the potential for iron to be involved in diabetic 
pathology via the instigation and the effects of AGE products. Evidence for a direct 
link between iron and AGE development relies on their inhibition by chelators in 
vitro. Evidence for the involvement of glycation in development of redox active iron 
in vivo is more circumstantial. Haptoglobin Hp2-2 genotype is associated with risk 
for vascular complications in diabetes, and the presence of iron in carotid artery 
plaques, probably by poor sub-endothelial scavenging, and subsequently increased 
LDL oxidation by glycated haemoglobin, presumably also in the sub-endothelia. 
Glycated haemoglobin is unstable in vitro, and a potential source of haem in 
plasma. Glycated albumin binds more iron than unglycated albumin, and degrades 
to an unstable uraemic toxin, and other proteins may do the same.  
It is not certain whether the increased cardiovascular risk seen in type 2 diabetes is 
completely accounted for by Hp genotype, but it is evidently an important factor, 
and might perhaps occlude the risk from other sources of reactive iron. It is 
unknown if Hp genotype influences other diabetes pathologies, and this would be 
useful research to do. 
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1.9 Iron and diabetes summary 
Mechanisms exist which could lead from high iron status to risk for diabetes, if 
surplus dietary iron is absorbed and subsequently deposited in the pancreas. A 
meta-analysis of red meat intakes finds an increased relative risk (RR) for type 2 
diabetes of 1.20 per 120 g/day, with processed red meat intake giving a higher RR 
of 1.57 per 50 g/day (Aune et al 2009). A different meta-analysis finds RR per 50 
g/day processed red meat of 1.19, and no significant increase with red meat (Micha 
et al 2010). As described in section 1.5, dietary iron, when combined with advanced 
lipoxidation endproducts, could lead to β-cell loss and type 2 diabetes. Pancreatic 
iron, in the presence of increased levels of superoxide, as proposed by Brownlee 
and others, might drive β-cell damage. Measurement of pancreatic iron in people 
with and prior to type 2 diabetes but without iron overload disease would inform 
this.   
Increased physiological iron status, as measured by serum ferritin, and sTfR:ferritin 
ratio, finds a positive association with risk for type 2 diabetes, but this does not 
appear to be reduced by regular blood donation. Studies that assess physiological 
iron status and risk for diabetes by using serum ferritin alone, and which control for 
inflammation with CRP, may be inadequately controlling for inflammation.  
In the pathologies of advanced diabetes many possible routes exist for iron to be 
involved, via oxidative damage and development of AGE, as described above. Iron-
binding proteins are altered by glycation, and may consequently be impaired in 
their various functions, resulting in plasma and sub-endothelial redox active non-
transferrin-bound iron. Such iron forms are capable of contributing to endothelial, 
and renal diabetic pathologies, and possibly others, although direct evidence of 
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their involvement is elusive. The following chapters are concerned with iron in 
established diabetes and its possible association with pathology. The potential 
source of one form of non-transferrin-bound plasma iron, from glycated 
transferrin, is explored in depth. The measurement of (probably another form of) 
NTBI is made in people with type 2 diabetes, and compared with controls. 
Assessment of diabetic pathologies are reported, and their association with NTBI, 
alongside measures of antioxidant status and lipid peroxidation. 
1.10 Aims of this project 
 To investigate the effects of in vitro glycation of transferrin, and, using 
ultrafiltration, determine whether loss of transferrin-iron-binding capacity is 
due to protein fragmentation.  
 Using two mass spectrometry systems as a model only, to evaluate potential 
differences between in vitro and in vivo glycated transferrin, in position and 
extent of glucose modifications, which may be relevant to the protein 
fragmentation seen in vitro or other loss of function. 
 To evaluate non-transferrin-bound iron in people with type 2 diabetes and 
controls, and to assess its association with haemoglobin glycation, lipid 
peroxidation, antioxidant status, and other iron parameters.  
 To compare non-transferrin-bound iron in people with and without 
diabetes, and with and without cardiovascular and renal disease
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Chapter 2. In vitro study of glycated transferrin 
2.1 Aim 
To investigate the effects of in vitro glycation of transferrin, and, using 
ultrafiltration, whether loss of transferrin-iron-binding capacity is due to protein 
fragmentation.  
2.2 Background 
The observation by Austen et al in 1987 that, like other plasma proteins, transferrin 
became glycated in vivo, coupled with an interest in the role of iron in diabetes, has 
led several groups to investigate transferrin glycation in vitro.  The interest has 
been in the effect glycation might have on transferrin-iron-binding, with the 
speculation that a functional loss may contribute to diabetes complications such as 
cardiovascular disease, via a reduction in antioxidant capacity, and the potential 
occurrence of redox-active plasma iron (Fujimoto et al 1994, Van Campenhout et al 
2003, Goodarzi et al 2010). In 1987 Austen et al had observed in 5 people with 
diabetes (with HbA1c between 12% and 19.7%), that transferrin was 5.2% glycated 
on average, compared with 1% in a single control (HbA1c 4.3%). This was done by 
separating glycated and unglycated plasma protein fractions on a Glycogel B 
affinity column, then quantifying them by electrophoresis and densitometry.  
Three groups have previously carried out in vitro glycation experiments with 
transferrin (Table 2). 
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Table 2. In vitro glycation of transferrin by other groups 
Fujimoto et al 
(1994) 
 
Bovine 
holotransferrin  
(hTf) & 
apotransferrin 
(aTf) (Wako Pure 
Chemicals) 
Incubation method 
10 mg/ml protein in 0 or 1 M glucose, 
50 mM phosphate buffer pH 7.4, 37˚C 
for 10 days.  
hTf also received 9 mM & 34 mM 
incubations 
Glycation assessment method 
Thiobarbituric acid reaction using 
5-hydroxymethyl-2-furfural 
(HMF) as a standard compound 
Glycation (mean±SD nmol HMF 
equivalent/mg protein, n=3) 
0 M: Not reported 
1 M: hTf, 17.43±4.02;   
         aTf, 20.4±3.42 
9 mM: hTf, 0.6±0.1 
34 mM: hTf, 2.9±0.6  
(P<0.01 compared with 9 mM) 
Unsaturated iron binding 
capacity (ng/mg) 
aTf: 0 M, 1013±82.6 
        1 M, 480±82.5 (P<0.001) 
hTf: 0 M, 25±8.2 
        1 M, 0.0 
 
Van Campenhout 
et al (2003) 
 
Human 
apotransferrin 
(Sigma) 
Incubation method 
5 mg/ml protein in 0, 5.6, 13.9, 22.2, 
33.3, or 1000 mM glucose, 0.1 M 
sodium phosphate buffer pH 7.4, 37 ˚C 
for 14 days   
Glycation assessment method 
Fructosamine measured by 
reaction with nitrotetrazolium-
blue (Roche kit 109893), with 
fructosamine standard 
Glycation (mean±SD, μmol 
fructosamine/g aTf, n=8-26) 
0 mM, 1.1±0.7   
5.6 mM, 4.9±3.4*** 
13.9 mM, 6.2±1.0*** 
22.2 mM, 9.6±1.5*** 
33.3 mM, 13.4±3.0*** 
1000 mM, 157.4±57.8***      
(***P<0.001, vs 0 mM) 
Total iron binding capacity 
(mean±SD, μg/g aTf, n=8-26) 
0 mM, 0.726±0.089 
5.6 mM, 0.696±0.083 
13.9 mM, 0.672±0.069** 
22.2 mM, 0.667±0.056* 
33.3 mM, 0.585±0.079*** 
1000 mM, 0.011±0.010*      
(*P<0.05; ** P<0.01; ***P<0.001, 
vs 0 mM) 
Goodharzi et al 
(2010) 
 
Human 
apotransferrin 
(Sigma-Aldrich) 
Incubation method 
5 mg/ml protein in 0, 50, 100, 150, 
200 mM glucose in 0.1 M PBS, pH 7.4, 
at RT for 10 & 20 d   
Glycation assessment method 
Thiobarbituric acid reaction using 
HMF as a standard compound 
Glycation  
(μmol HMF/mg aTf) 
0 mM: 10 d, 5.06±1.10 
             20 d, 6.08±1.09* 
50 mM: 10 d, 20.95±1.17 
               20 d, 25.02±1.26* 
100 mM: 10 d, 28.64±1.54 
                 20 d, 34.04±1.16* 
150 mM: 10 d, 39.04±1.10 
                  20 d, 45.10±1.21*  
200 mM: 10 d, 51.04±1.32 
                 20 d, 58.02±1.17* 
(*P=0.029 vs 10 d) 
Antioxidant capacity  
(μM vitamin C equivalence) 
0 mM: 10 d, 43.85±1.2 
             20 d, 41.79±1.19* 
50 mM: 10 d, 39.90±1.21 
               20 d, 36.90±1.13* 
100 mM: 10 d, 34.76±1.23 
                 20 d, 30.72±1.17* 
150 mM: 10 d, 28.82±1.19 
                  20 d, 23.79±1.25*  
200 mM: 10 d, 21.66±1.12 
                 20 d, 15.83±1.18* 
(*P=0.029 vs 10 d) Results are 
from 2 triplicate experiments 
Key: PBS: Phosphate buffered saline; RT: Room temperature; HMF: 5-hydroxymethyl-2-
furfural  
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Protein glycation in vitro is essentially straightforward to achieve, and a range of 
glucose concentrations up to 1 M have been used, with protein incubations of 
between 10 and 20 days, at 37˚C (Fujimoto et al 1994, Van Campenhout et al 2003) 
or room temperature (Goodarzi et al 2010) (Table 2). At the end of this period 
samples are buffer exchanged through Sephadex G-25 columns, or by dialysis 
against glucose-free buffer.  Degree of glycation was assessed by these groups by 
measurement of fructosamine, a stable product of the Schiff base reaction and 
Amadori rearrangement, or alternatively, 5-hydroxymethyl-2-furfural (HMF), which 
is related to available lysine.  
All three groups found positive associations between glucose concentration, 
degree of glycation, and reduction in function, with significant differences between 
glucose concentration and controls, and between different concentrations, or 
increased incubation time. Fujimoto et al used denaturing electrophoresis to 
further examine the samples, finding that substantial fragmentation of the protein 
could be seen only in the glycated holotransferrin sample. This is interesting 
because they reported a higher level of glycation in the apo-sample compared to 
holo (which might be expected due to the iron-free form having a more open 
structure). They also tested the capacity of the different samples to generate 
superoxide and the hydroxyl radical, in a system with phenylalanine and 
hypoxanthine-xanthine oxidase, finding a significant increase in activity with the 
holotransferrin compared to apotransferrin and both controls. These findings all 
suggest that oxidative damage is occurring in the presence of holotransferrin and 
that the iron bound to the glycated holotransferrin is redox-available, and 
therefore the iron-binding ability of transferrin is impaired by glycation. 
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Van Campenhout et al (2004) supported this by studying the rate of transferrin-
iron-binding in solution, using spectrophotometry at 450 nm. Lyophilised human 
serum transferrin was incubated in SPB with a range of glucose concentrations 
from 0 to 33.3 mM, which, following buffer exchange, were incubated with iron-
nitrilotriacetic acid solutions calculated to achieve 32%, 64%, and 96% of total iron-
binding capacity. Glycation impaired binding at all levels of iron-loading, compared 
with freshly made-up and SPB with no added glucose, although they conclude that 
glycation facilitates the initial binding to iron, but that when high amounts of iron 
are present iron-binding is impaired. They referred to the work of Qian et al (1998) 
to propose that the resulting chelate was more loosely bound, however whilst Qian 
et al did find this to be the case with in vitro studies of albumin, gelatin, and elastin, 
they did not study glycated transferrin, and the nature of the two specific iron 
bonds in transferrin and lactoferrin are entirely different to the non-specific 
binding seen in other proteins (Aisen et al 1967, Roche et al 2008).  
Van Campenhout et al (2004) hypothesised that, as glycation of apotransferrin in 
vitro decreased its total iron-binding capacity, in addition to its capacity to prevent 
lipid peroxidation (Van Campenhout et al 2003), the increased lipid peroxidation in 
diabetes might be due to poor iron-binding by glycated transferrin.  
To add to these findings, Goodarzi et al (2010) found that transferrin antioxidant 
capacity reduced with glycation when tested against the thermal decomposition of 
2,-2’-AZO bis-dihydrochloride (AAPH), and AAPH-induced lipid peroxidation of 
erythrocytes. 
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In order to gain further insight into the effects of glycation on transferrin, and to 
confirm Fujimoto et al’s 1994 suggestion that protein fragmentation was taking 
place, transferrin glycation studies were undertaken as part of this PhD work. 
Protein fragmentation was measured by ultrafiltration through Amicon Ultra filter 
units (Merk-Millipore), which uniquely can be reversed to recover the retentate. 
This is a novel approach to this question, and no other report of ultrafiltration for 
this purpose can be found in the protein oxidation literature. 
2.3 Experimental methods 
2.3.1 Equipment list 
Burkard Koolspin 6S refrigerated centrifuge BS-CAT/006D/K, serial number 81140 
CamSpec M302 UV/vis spectrophotometer 
Beckman Microfuge 11 
Thorn Electrim 10W heat mat 
Mettler Toledo AB 104 balance  
Eppendorff pipettes, calibrated prior to start of experiment 
Merke-Millipore Amicon Ultra filter units 30 kDa & 10 kDa 
Bio-Rad Mini-Protean II electrophoresis system, with a Bio-Rad PowerPac  
2.3.2 Laboratory solutions 
0.1 M Sodium phosphate buffer (SPB) pH 7.4, to make 500 ml: 
Na2HPO4 14.505 g in 405 ml Milli-Q H2O 
NaH2PO4 1.482 g in 95 ml Milli-Q H2O 
pH to 7.4 with 1 M HCl 
 
1 M glucose solution: 
D-glucose (Sigma-Aldrich) 0.9008 g in 5 ml Milli-Q H2O 
Dilute as necessary in SPB 
 
Protein precipitation solution: 
0.6 M trichloroacetic acid (TCA) and 0.4 M thioglycollic acid, made up in 1 M HCl 
(To 9.803 g TCA add a small volume 1 M HCl. Add 3.76 ml 98% thioglycolic acid. Make 
up to 100 ml with 1 M HCl) 
Iron chromogen:  
0.5 mM 3-(2-pyridyl-5,6-bis-[2-(5-furyl sulphonic acid)]-1,2,4-triazine (ferene)  
in 1.5 M sodium acetate (20.412 g sodium acetate trihydrate in 100 ml di H2O) 
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Iron Saturating Solution:  
100 µM ferric chloride solution in 5 mM HCl.  
Made up from a 1:10 dilution of stock ferric chloride solution 1 mM in 50 mM HCl 
2.3.3 Laboratory protocols 
Protein assay (Lowry et al 1959) 
Solutions: 
Lowry A: 2% Na2CO3 in 0.1 M NaOH 
Lowry B: 1% CuSO4 in diH2O 
Lowry C: 2% sodium potassium tartrate (NaKC4H4O6∙4H2O) 
 
Lowry stock reagent: 
49 ml Lowry A 
0.5 ml Lowry B 
0.5 ml Lowry C 
Folin’s reagent: Phenol reagent – 2N (Folin-Ciocalteau reagent). Dilute 1:1 in diH2O 
before use. 
Procedure: 
1) To 50 µl sample, bovine serum albumin (BSA) standards and blank add 1 ml 
Lowry stock reagent 
2) Incubate at room temperature for 30 minutes 
3) Add 100 µl of diluted Folin’s reagent to each tube 
4) Incubate at room temperature for 30 minutes 
5) Read in a spectrophotometer at 595 nm 
 
The coefficient of variance for the Lowry protein assay, compiled from repeated 
standards, is given in Table 3, shown in Figure 2. 
 
Table 3. Lowry protein assay, compilation of bovine serum albumin (BSA) 
standards  
BSA μg/ml Mean (AU) SD n = CV 
100 0.044 0.012 37 0.26 
250 0.117 0.021 40 0.18 
500 0.243 0.040 40 0.17 
1000 0.347 0.050 40 0.14 
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Figure 2. Lowry protein assay 
Lowry protein assay, compilation of standards, mean & SD (n = 37 to 
40, see Table 3). 
 
2.3.4 In vitro glycation of transferrin 
Human apo-transferrin (Sigma T4382-100 mg, 98% purity, 049K15511), 8 mg, was 
dissolved in 200 µl of freshly made sodium phosphate buffer (SPB) pH 7.4. Four 50 
µl aliquots of this were added to glucose solutions plus SPB to give 1 ml of 0, 500, 
750, and 1000 mM glucose concentration. Protein concentrations were therefore 2 
mg/ml. Glucose concentrations were chosen to correspond with those used by 
earlier groups, and give an amplified degree of glycation for detection of effects. 
SPB was made with Milli-Q HPLC grade water, and all plastic tubes and tips were 
autoclaved and stored in sealed containers prior to use. Tubes were incubated at 
37˚C, on a heat mat, in a closed, insulated, incubation box, for 14 days. Tubes were 
vortexed at the start and on Day 7. The experiment was carried out between 
January and August 2011. The temperature within the incubation box was tested 
by thermometer at the start, and mid-way through the project, and found to be 
37˚C on both occasions.  
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Further filtration studies used Sigma apo-transferrin T4382-100 mg, 98% purity, lot 
# 031M19551V. 
2.3.5 Buffer exchange 
On Day 15 samples were removed from the incubation box and placed on ice, prior 
to buffer exchange into glucose-free SPB. Buffer exchange was through a 5 ml 
Sephadex G-25 column, made-up in the lab. This volume was found to give the 
optimum separation of protein from glucose, with 1 ml samples. Tests using bovine 
serum albumin (BSA) had established that a mean of 86% of a 1 mg/ml protein 
solution would be recovered in the first three 500 μl collections, following the 1 ml 
run-on from application of a 1 ml sample. The recovery of protein following buffer 
exchange, and the separation of protein from glucose are shown in Figure 3 and 
Figure 4. 
 
Figure 3. The recovery of bovine serum albumin 
Recovery of serum ferritin following application of 1 mg/ml of 
protein through a 5 ml Sephadex G-25 column, in the development 
of the glucose-buffer exchange process. 
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Figure 4. The separation of bovine serum albumin  
The separation of bovine serum albumin from glucose, following 
application of 1 mg/ml of protein in 1 M glucose in 0.1 M SPB buffer, 
through a 5 ml Sephadex G-25 column, in the development of the 
glucose-buffer exchange process.  
 
2.3.6 Assessment of glycation 
Glycation is a condensation reaction between the acyclic glucose hydroxyl (OH) 
group and the protein primary amine (NH2). Degree of glycation was assessed by 
measurement of NH2 groups. 
Following buffer exchange into 0.1 M SPB, protein concentration was measured by 
the method of Lowry et al (1951). A solution of fresh apotransferrin was made up in 
SPB (1 mg/ml), to act as a further control. Degree of glycation was measured by 
trinitrobenzene sulphonic acid (TNBSA) assay (also known as picrylsulphonic acid), 
which reacts with NH2 groups at pH 8, to form adducts detectable at 335 nm. 
TNBSA is specific for primary amine groups (Satake et al 1959). Solutions of L-lysine 
were used as standards for quantification, and results are reported as lysine 
equivalent NH2 groups (μM/mg/ml). The assay was a scaled-down and adapted 
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version of that used by Silva & Hider (2009), described by Satake et al (1959), and 
Cabot & Tainturier (1996):  
To 25 μl of glycated apotransferrin, and L-lysine standards and blank, the following 
were added: 25 μl 4% Na2HCO3; 25 μl 0.1% TNBSA. The sample was incubated at 
37˚C for 2 hours, then the following were added: 25 μl SDS, 12.5 μl 1 M HCl, and 
787.5 μl diH2O, to make a final volume of 900 μl. The absorbance of the resulting 
solution was read immediately, at 335 nm. 
Table 4. TNBSA assay of NH2 groups, compilation of L-lysine standards, read 
at 335 nm, absorbance units (AU) 
Lysine μM Mean (AU) SD n = CV 
10 0.015 0.016 3 1.05 
25 0.016 0.01 11 0.64 
50 0.032 0.009 15 0.29 
100 0.055 0.01 18 0.19 
250 0.12 0.023 19 0.19 
500 0.242 0.029 14 0.12 
750 0.37 0.023 6 0.06 
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Figure 5. Compilation of L-lysine standards 
Compilation of L-lysine standards, showing NH2 groups by TNBSA 
assay (mean & SD, n = 3 to 19, see Table 4). 
 
2.3.7 Measurement of total iron  
(Adapted from Bothwell et al 1971). 
To 350 μl glycated transferrin sample, iron standards (10 to 100 µM), and SPB 
blank, was added 350 μl protein precipitation solution. This was mixed thoroughly 
for 1 minute, and then heated at 56˚C for 15 minutes in a water bath. Samples 
were then centrifuged at 1,000 x g for 5 minutes, and 350 μl of the resulting 
supernatant was removed, and added to 350 μl of 0.5 mM ferene solution. After 
incubation for 5 minutes at room temperature absorbance was read at 593 nm. 
2.3.8 Measurement of total iron-binding capacity  
(Method of Ramsay 1957). 
To 350 l samples of the protein solutions (n = 2) was added 350 l of iron 
saturating solution. This was mixed and left for 5 minutes at room temperature. To 
this was added 35 mg light magnesium carbonate, in the form of Mg(OH)2.3H2O. 
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This was agitated frequently and thoroughly for 40 minutes, and then centrifuged 
at 1,000 x g for 5 minutes. The supernatant was removed and re-centrifuged at 
1,000 x g for 5 minutes. The resulting supernatant was removed and analysed for 
iron as in the measurement of total iron methodology. 
2.3.9 Measurement of glucose  
Glucose separation was determined by the dinitrosalicylic colorimetric method of 
Miller (1959). The compilation of results for glucose standards is given in Table 5, 
and shown in Figure 6. 
Table 5. Glucose assay, compilation of standards read at 575 nm, 
absorbance units (AU) 
 Glucose concentration (mM) 
 100  200 500 750 1000 
n =  5 6 7 3 2 
Absorbance at 575 (AU, mean) 0.04 0.19 0.35 0.58 0.83 
Absorbance at 575 (SD) 0.02 0.040 0.03 0.03 0.00 
 
  
Figure 6. Glucose assay, compilation of standards 
Glucose assay, compilation of standards, mean and SD (r = 0.993, n = 
range 2 to 7, see Table 5). 
2.3.10 Measurement of glucose in samples, post buffer exchange 
To assess the adequacy of the buffer exchange process for the removal of glucose 
from the buffer containing the glycated transferrin, the method of Miller (1959) 
[Glucose] (mM) 
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was used to measure glucose. Results are given as glucose (mM). A lyophilized apo-
human transferrin samples was freshly dissolved in SPB, and included as a control. 
Results for glucose concentration in SPB following buffere exchange are given in 
Table 6 and Figure 7. 
Table 6. Glucose in glycated transferrin solutions post buffer exchange 
 
 
 
 
Figure 7. Glucose present in glycated transferrin solution  
Glucose present in glycated transferrin solution post buffer 
exchange, Batches A to C, mean ± range (r = 0.467, n = range 1 to 3, 
see Table 6). 
 
The samples that were tested for glucose post buffer exchange were all found to 
have mean glucose present in excess of 101.6 mM. Transferrin freshly made-up in 
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Glucose concentration (mM) 
Fresh 0 500 750 1000 
n = 1 3 3 3 3 
Glucose (mM, mean) 97.2 122.2 127.6 135.7 112.4 
Glucose (mM, ± range) 0 20.6 13.0 35.9 5.9 
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SPB, and transferrin incubated in SPB with no added glucose, which could be 
expected to have no glucose, had levels ranging from 97.2 to 142.8 mM.  
A positive trend with glucose incubation level was seen (r = 0.467), suggesting that 
the buffer exchange process assay may able to measure glucose adducts. There 
may be contamination from the buffer exchange process, if the 1.5 ml protein 
collection also collected part of the glucose elution, however as the fresh sample 
(which did not undergo buffer exchange) also had glucose present this would not 
appear to be the case. The compilation of standards shows little variation in results 
at 100 µM glucose (Figure 6), and therefore the assay appears to be reliable, 
suggesting that whilst a positive trend for glucose may be associated with glucose 
incubation concentration, someother factor may be causing interference with the 
assay.  
2.3.11 Assessment of iron-binding by spectrophotometry  
Four incubated samples of transferrin (0, 500, 750, 1000 mM glucose) were 
compared to freshly dissolved transferrin. Each 900 μl sample was adjusted by the 
addition of SPB to have ~500 μg/ml protein, dissolved in SPB pH 7.4. Each received 
50 μM (50 μl of 1mM) iron:nitrilotriacetic acid (Fe:NTA), and 1.5 mM (50 μl of 30 
mM) sodium bicarbonate (NaHCO3). Fe:NTA and NaHCO3 were added after the first 
reading at 0 minutes. All samples were read concurrently, in a seven position 
spectrophotometer, optical pathway 1 cm. Quartz cuvettes were used for the 
ultraviolet measurements. Absorption readings were taken against a blank SPB 
sample containing 50 μl Fe:NTA and 50 μl NaHCO3 set at zero the start of every run 
of 6 readings. 
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2.3.12 Ultrafiltration  
Following buffer exchange, protein quantification, and NH2 group quantification, 
protein samples were placed on ice, in a refrigerator, overnight. The following day 
three aliquots of transferrin solution, volumes varying depending on transferrin 
concentration, were taken from each of the five transferrin samples (0, 500, 750, 
1000 mM glucose and Fresh), and placed in Eppendorf tubes. SPB was added to a 
inal volume of 450 μl volumes with an approximately equal protein concentration 
in each. 50 μl of each was then taken for protein quantification.  
Tubes were designated Run 1, 2, or 3, and samples for Runs 2 and 3 were placed on 
ice until required. All runs within a batch were performed on the same day. 
Each of the 5 samples for Run 1 received 50 μM (50 μl of 500 μM) iron atomic 
absorption standard solution (25 μl of 990 μg/ml Fe in 1 wt. % HCl, added to 861 μl 
distilled H2O) (gift from R. Evans), plus 50 μl of 500 μM (50 μM) NaHCO3. Samples 
were incubated at room temperature for 30 minutes. The pH of the protein-iron 
solutions were measured on the first day of filtration, and were found to range 
from pH 7.43 to pH 7.48. 
Millipore Amicon Ultra filter units 500 μl, 30 kDa (Merke Millipore),  were pre-
washed in 500 μl dH2O, spun at 6,000 x g for 10 minutes at 4°C, and the effluent 
discarded. Filters were then inverted and spun for a further 5 minutes at 2,500 g to 
empty them, before being placed inside clean, dry, individually weighed filtrate 
collection tubes. Samples were centrifuged at 13,000 x g for 30 minutes, at 4 ˚C. 
The filtrate tubes were collected, and the retentate was recovered by centrifuging 
into a second set of weighed collection tubes, at 6,000 x g for 10 minutes, at 4 ˚C.  
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Filtrate tubes, and retentate tubes, were re-weighed, the volume of solution in 
each calculated, and adjusted to 500 μl by the addition of SPB. Protein 
quantifications were repeated, and expressed as μg/500 μl. 
Filter units were reused for each of the 3 runs on the day, keeping filters to the 
same glucose concentration sample type each time, before being discarded. 
Iron in each fraction was measured by the method of Bothwell et al (1971), see 
section 2.3.7 for method.  
This procedure was repeated for each run. Four separate incubation batches (A to 
D) were tested by this method, giving 12 runs at each glucose incubation level in 
total. Samples were treated individually for statistical purposes.  
2.3.13 Electrophoresis  
Denaturing, SDS-urea gel electrophoresis was carried out following the method of 
Blackshear (1984), in Bollag et al (1996), with 8.4% acrylamide gel, and 6 M urea. 
Samples consisted of 20 µg protein, in buffer containing 10 mM dithiothreitol and 6 
M urea. Gels were run at 170 V over 45 minutes, and stained for 1 hour with 
coomassie blue, and destained overnight. 
2.3.14 Statistical analysis 
Statistical analyses were performed in Excel (Microsoft 2010). Differences were 
tested by unpaired, two-tailed Student t-test for equal variance (unless stated), 
with significance set at P ≤ 0.05 in all cases. Excel can be used without reservation 
for this method (Dale 2001). Correlations were by Pearson’s correlation test, with 
two-tailed P-value significance set at ≤ 0.05. Significance testing was not used for 
small sample size (n = 5), non-parametric, correlations. 
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2.4 Results 
2.4.1 Iron-binding by spectrophotometry  
To investigate whether in vitro glycation of transferrin has an effect on iron-
binding, a time course of spectrophotometry at 470 nm was undertaken. The rate 
of transferrin-iron-binding can be followed by spectrophotometry at 470 nm, as the 
bond between a single iron atom, two tyrosine ligands, one aspartate, one 
histidine, and a carbonate anion (Bailey et al 1988) produces a red colour, with an 
absorption maximum at 470 nm. Earlier work by Van Campenhout et al (2004), has 
shown that the increase in absorbance at 450 nm over 90 minutes, when in vitro 
glycated transferrin and iron are incubated together, is lessened with increasing 
level of glycation.  
See section 2.3.11 for method. 
2.4.1.1 Glycation of samples 
 
Figure 8. Glycation of samples  
Glycation of samples used to measure the time course of iron-
binding by spectrophotometry at 470 nm, shown by lysine equivalent 
NH2 groups (n = 1) 
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2.4.1.2 Results 
 
Figure 9. The time course of transferrin-iron-binding  
The timecourse of transferrin-iron binding with in vitro glycated 
transferrin (0, 500, 750, 1000 mM glucose pre-incubation prior to 
buffer exchange into SPB) and freshly made-up transferrin in SPB, 
with the addition of 50 µM iron:nitrilotriacetic acid, and 50 µM 
sodium bicarbonate. 
 
Protein can be quantified by absorption at 280 nm, and transferrin saturation can 
be monitored by 280 nm/470 nm (Evans & Williams 1978). Fully saturated human 
serum transferrin has a value of 23.5. Transferrin saturation by 280 nm/470 nm is 
shown in Table 7. 
Table 7. Transferrin saturation by 280 nm/470 nm 
 
Glucose concentration (mM) 
Fresh 0 500 750 1000 
280 nm 1.546 1.04 1.164 1.157 1.094 
470 nm at Start 0.052 0.012 0.03 0.032 0.007 
280 nm/470 nm 29.7 86.7 38.8 36.2 156.3 
470 nm at 4 hr 0.138 0.024 0.04 0.049 0.004 
280 nm/470 nm 11.2 43.3 29.1 23.6 273.5 
Delta Start - 4 hr 0.086 0.012 0.01 0.017 0.0033 
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Figure 10. The change in absorption at 470 nm 
The change in absorption at 470 nm, between 0 and 4 hours, 
following  transferrin-iron-binding with in vitro glycated transferrin 
(0, 500, 750, 1000 mM glucose pre-incubation prior to buffer 
exchange into SPB) and transferrin freshly dissolved in SPB, with the 
addition of 50 µM iron:nitrilotriacetic acid, and 50 µM sodium 
bicarbonate. 
 
 
 
Figure 11. Glycation vs the change in absorption at 470 nm 
Lysine equivalent NH2 groups vs the change in absorption at 470 nm, 
between 0 and 4 hours, following transferrin-iron-binding with in 
vitro glycated transferrin (n = 5, r = 0.726). 
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2.4.1.3 Discussion and Conclusion 
Inhibition of iron-binding capacity is clearly seen in all the incubated samples, in 
comparison to the fresh sample. Used as a measure of iron-binding, the change in 
absorbance over the 4 hours shows a general positive correlation between degree 
of glycation and iron-binding function (r = 0.785) (Figure 11), however, as can be 
seen from the difference between freshly dissolved transferrin and transferrin pre-
incubated in SPB with no glucose (Figure 10), the process of incubation, 
independently of glucose concentration, is damaging to the protein. 
2.4.2 Total iron-binding capacity 
Incubated and fresh transferrin was tested for total iron-binding capacity (TIBC) by 
the method of Ramsay (1957), see section 2.3.8. Protein concentrations ranged 
from 103.5 to 177.0 µg/350 µl SPB, and samples were run in duplicate (Table 8).  
It was not possible to calculate transferrin saturation (total iron/TIBC x 100) by the 
method normally used in vivo (Beilby et al 1992), as total iron in this case is a 
universal 50 µM. 
Table 8. Total iron-binding capacity (TIBC) of in vitro glycated transferrin (0, 
500, 750, 1000 mM glucose pre-incubation prior to buffer exchange into SPB) 
and transferrin freshly made-up in SPB. Glycation assessed by picrylsuphonic 
acid assay of NH2 groups, measured against L-lysine standards   
 Glucose concentration (mM) 
 Fresh 0 500 750 1000 
Lysine equivalent NH2 groups (µM/mg/ml) 186.2 213.8 69.3 44.7 16.6 
Protein, mean (µg/350 µl, n = 2) 176.0 111.6 127.7 142.0 158.5 
TIBC, mean (µM/mg, n = 2) 81.43 84.44 42.25 25.24 21.53 
TIBC range (µM/mg) 13.6 68.2 62.7 9.1 12.4 
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Figure 12. Total iron-binding capacity of in vitro glycated transferrin 
Total iron-binding capacity of in vitro glycated transferrin (0, 500, 
750, 1000 mM glucose pre-incubation prior to buffer exchange into 
SPB) and transferrin freshly made-up in SPB (µM/mg, mean and 
range, n = 2). 
 
Mean TIBC is seen to decrease with degree of glycation (Figure 12). No difference 
in mean TIBC is apparent between freshly dissolved transferrin and transferrin pre-
incubated in SPB with no glucose (Figure 12). 
 
Figure 13. Glycation of in vitro glycated transferrin 
Glycation of in vitro glycated transferrin (0, 500, 750, 1000 mM 
glucose pre-incubation prior to buffer exchange into SPB) and 
transferrin freshly made-up in SPB, shown by lysine equivalent (LE) 
NH2 groups  vs total iron-binding capacity (n = 5, r = 0.992). 
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A clear decrease in total iron-binding capacity can be seen with increasing 
glycation, as measured by lysine equivalent NH2 groups.  TIBC is closely related to 
glycation (Figure 13), in agreement with Van Campenhout et al (2003).  
2.4.3 Filtration studies 
To investigate whether the loss of iron-binding ability in glycated transferrin is due 
to protein fragility and fragmentation, further batches of glycated transferrin were 
tested by filtration through Millipore Amicon Ultra 30 kDa filter units. As transferrin 
has a molecular mass of ~ 80 kDa no intact protein should pass through this size of 
filter. See section 2.3.12 for procedures. 
2.4.3.1 Glycation of samples 
Table 9. Glycation of in vitro glycated transferrin (0, 500, 750, 1000 mM 
glucose pre-incubation prior to buffer exchange into SPB) and transferrin 
freshly made-up in SPB, shown by lysine equivalent (LE) NH2 groups  
(μM/mg/ml), batches A to D 
 Glucose concentration (mM) 
LE NH2 groups (μM/mg/ml) Fresh 0 500 750 1000 
Batch A 234.15 236.13 125.54 94.85 111.52 
Batch B 323.90 284.04 203.15 191.89 181.32 
Batch C 207.19 196.38 125.70 55.44 90.45 
Batch D 251.34 248.77 147.20 75.36 92.35 
Mean 254.15 241.33 150.40 104.39 118.91 
SD 49.93 36.18 36.61 60.51 42.68 
Mean % of Fresh 100 94.96 59.18 41.07 46.79 
"% glycation" 0 5.04 40.82 58.93 53.21 
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Figure 14. Glycation of in vitro glycated transferrin 
Glycation of in vitro glycated transferrin (0, 500, 750, 1000 mM 
glucose pre-incubation prior to buffer exchange into SPB) and 
transferrin freshly made-up in SPB, shown by lysine equivalent NH2 
groups (μM/mg/ml), batches A to D (mean and SD). 
 
 
Figure 15. Glycation of in vitro glycated transferrin 
Glycation of in vitro glycated transferrin (0, 500, 750, 1000 mM 
glucose pre-incubation prior to buffer exchange into SPB) and 
transferrin freshly made-up in SPB, shown by lysine equivalent NH2 
groups (μM/mg/ml), batches A to D, individual levels. 
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Following buffer exchange, the amount of glycated sample produced in each of the 
four incubated batches varied. Runs were adjusted to have an equal protein 
concentration within batches. Mean values per batch, and within batch standard 
deviation, were as follows:  
Batch A, 274.3 μg/400 μl (SD 30.8)  
Batch B, 606.8 μg/400 μl (SD 59.5)  
Batch C, 345.7 μg/400 μl (SD 29.7) 
Batch D, 225.1 μg/400 μl (SD 8.7) 
Mean protein concentration for all 60 samples was 363.0 μg/400 μl (SD 20.8). 
2.4.3.2 Results, filtrate protein 
Protein concentrations varied between batches and a range of protein 
concentrations were used in the experiment. To aid comparison between batches, 
results for protein are reported as percentages of the pre-filtration protein 
concentration. 
Increasing mean levels of protein were seen in the filtrate with increasing glucose 
concentration, ranging from 0.17 % pre-filtration for freshly made-up transferrin, to 
3.55 % pre-filtration for 1000 mM glucose. Significant differences were seen 
between 0 and 500 mM (P = 0.043), and 0 and 1000 mM (P = 0.027) (Table 10). A 
non-significant correlation was seen between glycation as measured by Lysine 
equivalent NH2 groups and filtrate protein (r = -0.301) (Figure 17). 
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Table 10. Protein in filtrate, % of amount pre-filtration, batches A to D  
  Glucose concentration (mM) 
(n = 12) Fresh 0 500 750 1000 
 Mean 0.17 0.36 1.82 2.53 3.55 
 SD 0.44 1.26 1.98 3.56 4.49 
 P  0.626 0.043* 0.060 0.027* 
   P vs Fresh P vs 0 P vs 0 P vs 0 
SD: Standard deviation 
 
 
Figure 16. Protein in filtrate 
Protein in filtrate, % of amount pre-filtration, in vitro glycated 
transferrin (0, 500, 750, 1000 mM glucose pre-incubation prior to 
buffer exchange into SPB) and transferrin freshly made-up in SPB, 
batches A to D, mean & SD (n = 12, 0 vs 500 mM, P = 0.043; 0 vs 1000 
mM, P = 0.027). 
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Figure 17. Glycation versus filtrate protein 
Glycation versus filtrate protein, in vitro glycated transferrin (0, 500, 
750, 1000 mM glucose pre-incubation prior to buffer exchange into 
SPB) and transferrin freshly made-up in SPB, batches A to D  
(n = 20, r = - 0.301, P = > 0.05). 
 
2.4.3.3 Results, retentate protein 
Decreased mean levels of protein were seen in the retentate in the glycated 
samples, ranging from 94.09 % pre-filtration for freshly made-up transferrin, to 
77.66 % pre-filtration for 1000 mM glucose. Highly significant differences were 
seen between 0 and 750 mM (P = 0.002), and 0 and 1000 mM (P = 0.001) (Table 11, 
Figure 18). A highly significant correlation was seen between glycation as measured 
by Lysine equivalent NH2 groups and retentate protein (r = 0.610, P = 0.01) (Figure 
19). 
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Table 11. Protein in retentate, % of amount pre-filtration, Batches A to D  
  Glucose concentration (mM) 
Batch Run Fresh 0 500 750 1000 
A 1 90.08 89.13 85.01 81.28 71.17 
 2 81.17 75.09 91.41 70.26 89.99 
 3 98.20 115.60 84.11 110.24 87.79 
B 1 107.43 97.17 75.73 68.98 62.72 
 2 107.36 92.63 76.14 71.64 74.85 
 3 97.22 96.86 86.04 59.52 75.96 
C 1 94.58 125.00 75.15 63.86 74.36 
 2 90.49 91.51 67.36 77.79 73.52 
 3 86.96 93.14 106.71 60.93 80.03 
D 1 82.36 80.94 84.72 81.04 83.78 
 2 98.35 96.21 93.06 75.68 74.71 
 3 94.92 84.59 90.29 83.17 83.00 
 Mean 94.09 94.82 84.64 75.37 77.66 
 SD 8.40 13.80 10.40 13.60 7.60 
 P  0.877 0.053 0.002** 0.001** 
   P vs Fresh P vs 0 P vs 0 P vs 0 
SD: Standard deviation 
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Figure 18. Protein in retentate 
Protein in retentate, % of amount pre-filtration, in vitro glycated 
transferrin (0, 500, 750, 1000 mM glucose pre-incubation prior to 
buffer exchange into SPB) and transferrin freshly made-up in SPB, 
batches A to D, mean & SD (n = 12, 0 vs 750 mM P = 0.002; 0 vs 1000 
mM P = 0.001). 
 
 
Figure 19. Glycation versus retentate protein 
Glycation versus retentate protein, in vitro glycated transferrin (0, 
500, 750, 1000 mM glucose pre-incubation prior to buffer exchange 
into SPB) and transferrin freshly made-up in SPB, batches A to D (n = 
20, r = 0.610**, P = <  0.01). 
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Figure 20. Correlation between filtered and retained protein 
Correlation between filtered and retained protein, in vitro glycated 
transferrin (0, 500, 750, 1000 mM glucose pre-incubation prior to 
buffer exchange into SPB) and transferrin freshly made-up in SPB, 
batches A to D, mean values (n = 5, r = - 0.939). 
2.4.3.4 Results, filtrate iron 
The concentration of iron used in the experiment (50 µl of a 500 µM iron solution) 
is in excess of the iron-binding capacity of the transferrin present, calculated as 
follows: 
Transferrin 300 µg (80 kDa), 300 x 10-6 (g)/ 80 x 103 (g in 1 mol) =  
3.75 x 10-9 mols 
Iron 50 µl of a 500 µM iron solution, 50 x 10-6 x 500 x 10-6 = 25,000 x 10-12 or  
25 x 10-9 mols 
300 µg of transferrin will bind 7.5 x 10-9 mols of iron, therefore, to bind all 25 x 10-9 
mols iron in the solution, 1 mg of transferrin would be needed. 
Increased mean levels of iron were seen in the filtrate with the glycated samples, 
ranging from 37.1 μM for freshly prepared transferrin, to 46.1 μM for 500 mM 
glucose. Significant difference was only seen between 0 and 500 mM (P = 0.041) 
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(Table 12). A significant correlation was seen between glycation as measured by 
Lysine equivalent NH2 groups and filtrate iron (r = -0.459, P < 0.05) (Figure 21). 
Table 12. Iron in filtrate, batches A to D (μM) 
  Glucose concentration (mM) 
(n = 12) Fresh 0 500 750 1000 
 Mean 37.1 40.5 46.1 43.1 45.5 
 SD 6.5 5.7 6.9 7.9 7.8 
 P  0.189 0.041* 0.362 0.084 
   P vs Fresh P vs 0 P vs 0 P vs 0 
 
 
Figure 21. Glycation versus filtrate iron 
Glycation versus filtrate iron,  in vitro glycated transferrin (0, 500, 
750, 1000 mM glucose pre-incubation prior to buffer exchange into 
SPB) and transferrin freshly made-up in SPB, batches A to D (n = 20, r 
= - 0.459*, P = <  0.05). 
 
2.4.3.5 Results, iron in retentate 
Decreasing mean levels of iron were seen in the retentate with an increase in 
glucose concentration, ranging from 20.23 μM for Fresh, to 9.97 μM for 1000 mM 
glucose. A highly significant difference was seen between 0 and 500 mM (P = 
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0.0011), and very highly significant differences were seen between 0 and 750 mM 
(P = 0.0006), and 0 and 1000 mM glucose (P = 0.0002) (Table 13). A very highly 
significant correlation was seen between glycation as measured by Lysine 
equivalent NH2 groups and retentate iron (r = 0.793, P < 0.001) (Figure 23). A non-
significant correlation is seen between mean values for filtered and retained iron, 
(n = 5, r = -0.950, Figure 24). A near significant correlation is seen between filtrate 
protein and filtrate iron, batches A to D, when all samples are included individually 
(r = - 0.253, non-parametric significance at 0.255, Figure 25). 
 
Table 13. Iron in retentate, batches A to D (μM) 
  Glucose concentration (mM) 
(n = 12) Fresh 0 500 750 1000 
 Mean 20.23 17.21 10.71 10.63 9.97 
 SD 7.24 4.60 3.84 3.31 2.59 
 P  0.2359 0.0011** 0.0006*** 0.0002*** 
   P vs Fresh P vs 0 P vs 0 P vs 0 
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Figure 22. Iron in filtrate and retentate  
Measurement of iron in filtrate and retentate following glucose 
incubation, in vitro glycated transferrin (0, 500, 750, 1000 mM 
glucose pre-incubation prior to buffer exchange into SPB) and 
transferrin freshly made-up in SPB, batches A to D, mean & SD (n = 
12). Significance shown in comparison with 0 mM in each phase, see 
Table 13 for P values. 
 
 
Figure 23. Glycation versus retentate iron 
Glycation versus retentate iron,  in vitro glycated transferrin (0, 500, 
750, 1000 mM glucose pre-incubation prior to buffer exchange into 
SPB) and transferrin freshly made-up in SPB, batches A to D (n = 20, r 
= 0.793***, P = <  0.001). 
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Figure 24. Correlation between filtered and retained iron 
Correlation between filtered and retained iron, in vitro glycated 
transferrin (0, 500, 750, 1000 mM glucose pre-incubation prior to 
buffer exchange into SPB) and transferrin freshly made-up in SPB, 
batches A to D, mean values (n = 5, r = -0.950) 
 
 
Figure 25. Correlation between filtrate protein and filtrate iron 
Correlation between filtrate protein and filtrate iron, in vitro glycated 
transferrin (0, 500, 750, 1000 mM glucose pre-incubation prior to 
buffer exchange into SPB) and transferrin freshly made-up in SPB, 
batches A to D (n = 60, r = - 0.253, non-parametric significance at 
0.255) 
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Figure 26. Correlation between retentate protein and retentate iron 
Correlation between retentate protein and retentate iron, in vitro 
glycated transferrin (0, 500, 750, 1000 mM glucose pre-incubation 
prior to buffer exchange into SPB) and transferrin freshly made-up in 
SPB, batches A to D (n = 60, r = 0.480***, P <  0.001). 
2.4.3.6 Discussion 
Filtration was used to determine whether in vitro transferrin glycation and loss of 
transferrin-iron-binding was linked to protein fragmentation, as suggested by 
Fujimoto et al (1995). Glycation was established by loss of NH2 groups, and was 
found to correlate very strongly with iron loss during filtration, and protein 
fragmentation, by the methods used here. Significant differences were seen in 
results between incubation with and without glucose, but not between incubation 
without glucose and freshly made-up protein, indicating that, unlike the findings 
for absorption at 470 nm, the glucose was causing the damage to the protein, 
rather than incubation per se.  
The strengths of the relationships between filtered and retained protein (r = 0.939) 
and iron (r = 0.950), and the similarity of these correlation coefficients, 
demonstrate the parallelism in the results for these two measures, as do the 
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correlations between filtrate protein and iron (r = - 0.253, Figure 25), and retentate 
protein and iron (r = 0.480***, Figure 26). Whilst correlation does not signify cause, 
these results strongly suggest that loss of function in in vitro glycated transferrin is 
due to protein fragmentation.  
2.5 Further studies 
2.5.1 Electrophoresis 
SDS-urea gel electrophoresis was used to examine the effect of the in vitro 
glycation process on transferrin in comparison with lyophilized apo-transerrin 
freshly dissolved in SPB, and transferrin incubated for 14 days at 37°C in glucose-
free SPB. Pre-filtration apo-transferrin (pre-30 minute iron incubation), and 30 kDa 
retentate samples were used (post-30 minute iron incubation). Insufficient 
quantities of filtrate protein were available to study. 
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2.5.1.1 Result, electrophoresis 
 
 
Figure 27. SDS urea gel electrophoresis of transferrin 
SDS, 6 M urea gel electrophoresis of in vitro glycated transferrin. 
Lanes 1 to 5: human serum apo-transerrin incubated in 0, 500, 750, 
and 1000 mM glucose concentration, and freshly dissolved 
lyophilized apo-transerrin in SPB, pre-filtration, and pre-30 minute 
iron incubation. Lanes 6 to 9: human serum apo-transerrin incubated 
in 0, 500, and 1000 mM glucose concentration, and freshly dissolved 
apo-transerrin in SPB, retentate samples following 30 minute iron 
incubation and filtration through 30 kDa filters. 
 
Some disruption to the uniformity of protein size is suggested by the blurred edges 
of the glycated, and 0 M retentate samples. This is particularly evident in the 1000 
mM retentate sample. Pre-filtration glycated samples show some blurring of the 
protein band. In both pre-filtration and retentate, degree of glycation is seen to 
decrease mobility through the gel.  
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2.5.2 25 – 250 mM Glucose incubation 
Incubation and filtration were carried out at lower glucose concentrations, 
approaching high blood glucose levels in vivo, which are 10 to 33.3 mmol/l plus. 
Two batches of in vitro glycated transferrin were produced using the method 
described in section 2.3.4, using glucose concentrations of 25, 100, and 250 mM in 
SPB, and SPB with no glucose. Three ultrafiltration runs were performed from each 
batch, making six runs in total.   Due to the small sample size of six, non-parametric 
statistical analyses were carried out, using IBM SPSS version 19, for two-tailed, 
unpaired, median tests between groups (Table 14). 
2.5.2.1 Results, 25 – 250 mM glucose incubation 
Transferrin glycation following incubation in 25 to 250 mM glucose, measured by 
loss of NH2 groups, occurs in a stepwise manner in keeping with that seen following 
incubation with higher concentrations of glucose, as shown in section 2.4.3.1. No 
statistical differences were seen between groups when comparing incubated 
transferrin samples, for filtrate and retentate protein and iron (Table 14, Figure 30, 
Figure 31, Figure 32, Figure 33). Surprisingly high filtrate protein concentrations 
wee seen for freshly dissolved lyophilized transferrin, and for transferrin incubated 
in SPB without glucose (Figure 30), although values for the 25 to 250 µM samples 
increase with glycation in the expected manner (Figure 30). No difference is seen in 
median levels for retentate protein across the groups (Figure 31). Results for 
filtrate and retentate iron for freshly dissolved lyophilized transferrin, and for 
transferrin incubated in SPB without glucose, show a surprisingly high level of iron 
in the filtrate (Figure 32), with a wide range of values (Figure 33). Results for filtrate 
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and retentate iron for the 25 to 250 µM samples change with glycation following a 
trend opposite to that seen in the higher glucose incubation concentrations 
(section 2.4.3.4 and section 2.4.3.5). 
Table 14. Filtration results, transferrin glycation at 25 to 250 mM glucose 
incubation 
 
Glucose incubation (mM) 
Fresh 0 25 100 250 
P  
0 to 250 
LE NH2 groups, mean 
(µM/mg/ml) (mean, n = 2) 
262.5 245.8 200.1 186.4 140.2  
Protein pre-filtration, mean 
(µg/400 µl) (n = 6) 
471.2 452.4 459.7 444.0 423.3  
SD 247.3 221.8 225.1 208.0 186.5  
Filtrate protein (% pre-
filtration) (median, n=6) 
3.21 4.88 2.11 2.30 3.41 0.083 
Range (% pre-filtration) 
1.2 to 
7.4 
0.7 to 
6.7 
1.1 to 
3.7 
1.0 to 
3.4 
2.1 to 
5.8 
 
Retentate protein (% pre-
filtration) (median, n=6) 
80.45 81.07 81.65 81.14 84.71 1.000 
Range (% pre-filtration) 
72.1 to 
92.0 
55.1 to 
98.7 
66.8 to 
92.6 
76.3 to 
93.6 
72.9 to 
96.3 
 
Filtrate iron (µM) (median, 
n = 6) 
28.36 30.78 27.95 30.14 35.84 0.261 
Range (µM) 
26.8 to 
358 
21.6 to 
37.5 
21.8 to 
37.0 
24.4 to 
42.3 
20.7 to 
42.0 
 
Retentate iron (µM) 
(median, n = 6) 
16.91 15.14 15.60 14.08 12.47 0.083 
Range (µM) 
14.5 to 
22.0 
10.4 to 
16.6 
12.8 to 
18.8 
12.3 to 
17.4 
10.8 to 
14.5 
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Figure 28. Lysine equivalent NH2 groups, 25 to 250 mM glucose incubation 
Lysine equivalent NH2 groups following in vitro glycation of 
transferrin (0, 25, 100, and 250 mM glucose pre-incubation prior to 
buffer exchange into SPB), and transferrin freshly made-up in SPB, 
mean of 2 (µM/mg/ml). 
 
 
Figure 29. Lysine equivalent NH2 groups, 25 to 1000 mM glucose incubation  
Lysine equivalent NH2 groups following in vitro glycation of 
transferrin (0, 25, 100, 250, 500, 750, and 1000 mM glucose pre-
incubation prior to buffer exchange into SPB) and transferrin freshly 
made-up in SPB, mean and SD (µM/mg/ml) (Fresh & 0 mM, n = 18; 
25 to 250 mM, n = 2; 500 to 1000 mM, n = 12). 
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Figure 30. Filtrate protein, 25 to 250 mM glucose incubation 
Filtrate protein, % pre-filtration, following in vitro glycation of 
transferrin (0, 25, 100, and 250 mM glucose pre-incubation prior to 
buffer exchange into SPB) and transferrin freshly made-up in SPB, 
and ultrafiltration (n = 6, P = 0.083 between 0, 25, 100 and 250 mM). 
 
 
Figure 31. Retentate protein, 25 to 250 mM glucose incubation 
Retentate protein, % pre-filtration, following in vitro glycation of 
transferrin (0, 25, 100, and 250 mM glucose pre-incubation prior to 
buffer exchange into SPB) and transferrin freshly made-up in SPB, 
and ultrafiltration (n = 6, P = 1.000 between 0, 25, 100 and 250 mM). 
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Figure 32. Filtrate iron, 25 to 250 mM glucose incubation  
Filtrate iron following in vitro glycation of transferrin (0, 25, 100, and 
250 mM glucose pre-incubation prior to buffer exchange into SPB) 
and transferrin freshly made-up in SPB, and ultrafiltration (n = 6, P = 
0.261 between 0, 25, 100 and 250 mM). 
 
  
Figure 33. Retentate iron, 25 to 250 mM glucose incubation  
Retentate iron following in vitro glycation of transferrin (0, 25, 100, 
and 250 mM glucose pre-incubation prior to buffer exchange into 
SPB) and transferrin freshly made-up in SPB, and ultrafiltration (n = 6, 
P = 0.083 between 0, 25, 100 and 250 mM). 
* 
** 
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2.5.2.2 Discussion, 25 to 250 mM Glucose incubation 
When lyophilized human apo-transferrin is incubated with lower, physiological, 
glucose concentrations, glycation is seen to occur following the trend seen at 
higher glucose incubation concentrations (Figure 29). However, no significant 
differences are seen in apparent protein fragmentation or iron retention by the 
transferrin during ultrafiltration, with trends occurring in an opposite direction to 
that seen in higher glucose concentrations, therefore no effect on transferrin 
oxidative fragmentation or iron-binding ability is suggested at lower glucose 
concentrations.  
2.6 Discussion 
The aim of these experiments has been to investigate the effects of in vitro 
glycation of transferrin, and confirm or refute the role of protein fragmentation as 
a reason for loss of iron-binding capacity in this context. These results show 
support for the glycation-fragmentation theory; however a degree of oxidative 
damage may be occurring during the experiment itself cannot be ruled out. 
Some discrepancy in the data exists between the filtration results and the iron-
binding spectrophotometry findings, in the effect of the 14 day incubation in the 
absence of glucose. Most of the data suggests that these samples suffered some 
inhibition of function when compared to fresh transferrin, but in general 
maintained reasonable iron-binding capacity; however when iron-binding was 
measured by spectrophotometry at 470 nm, very little binding capacity in the 
sample incubated in the absence of glucose was found (Figure 10). This test 
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differed from the filtration studies in two ways. 1) An iron-nitrilotriacetic acid 
compound was used for iron-loading; however, this seems unlikely to account for 
the difference as the Fresh sample worked well. 2) Samples were frozen at -80°C 
for 12 days prior to testing by spectrophotometry, whereas samples for filtration 
were kept overnight on ice prior to use. This suggests that comparatively mild 
oxidative damage may occur to in the absence of glucose during the 14 day 
incubation which provokes more destructive structural damage during freezing and 
thawing.  
Oxidative damage in the absence of glucose may have occurred during incubation 
from trace amounts of iron contaminating the SPB, known to be present in other 
common laboratory reagents and buffers (Halliwell & Gutteridge 2007). If iron 
contamination from SPB is occurring, passing the samples through Chelex 100 resin 
prior to the addition of glucose might have removed it. However, this was decided 
against because Chelex had not been used by the earlier groups, and the study 
sought to explain their findings. In fact Qian et al (1998) had not used it so that 
trace levels of iron might promote protein glycation during incubation. Microbial 
contamination during the Chelex process was also considered to be a risk. 
Despite efforts to work aseptically, microbial contamination of the samples may 
have occurred. Low concentrations of sodium azide have been used to avoid this 
(e.g. Hunt et al 1993), however it was not used, as being a reducing agent sodium 
azide would disrupt the chemical balance of this experiment. 
The reactions between glucose and protein, under the umbrella term of Maillard 
reactions, and including Schiff’s base formation and Amadori rearrangements, 
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involve structural changes to protein and the development of fluorophores, similar 
to those seen in tissue in diabetes (Monnier et al 1984). However, these alone are 
not thought to be sufficient to cause structural damage such as fragmentation to 
the protein (Hunt et al 1993). The involvement of reactive oxidant species is 
required, and a number of mechanisms have been outlined which lead to the 
formation of the hydroxyl radical (OH·), capable of this degree of damage (Wolff & 
Dean 1986, Hunt et al 1993, Dean et al 1997):  
(a) Glycoxidation – the transition metal-catalysed degradation of Amadori 
products. The two hydroxyl (OH) groups in the protein enediol (two OH group 
separated by a C=C double bond) are vulnerable to oxidation by available 
copper or iron, to form a protein dicarbonyl and H2O2. Further metal catalysed 
oxidation of H2O2 produces OH· 
(b) Autoxidation – the “Wolff Pathway”, involving oxidation of free glucose in 
solution by transition metals, also producing H2O2, OH·, and reactive 
dicarbonyls, prior to attachment to protein. 
As described in section 1.3, glucose in solution exists almost entirely in the 
pyranose form, with less than 0.01% in the reactive, open-chain aldehyde form. As 
the percentage of chain-form glucose is low, reactions such as amine glycation are 
slow. However, in neutral and alkaline conditions, following Schiff base formation, 
and prior to the Amadori reaction, cleavage of 2 and 3 carbon sugar moieties can 
occur. These are thought to contain reactive carbonyl species, as they dramatically 
increase Maillard browning (Hayashi & Namiki 1986). In the presence of iron these 
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would increase the availability of carbon compounds for autoxidation via the Wolff 
Pathway, glycation, and consequently glycoxidation and dicarbonyl occurrence.  
Independently of glucose, for protein fragmentation to occur the presence of O2 is 
required. In anaerobic conditions protein-crosslinking will occur (Dean et al 1997). 
Using human serum albumin (HSA) Wolff & Dean (1986) found that only OH· and O2 
was capable of cleaving protein directly, via development of carbonyl groups, 
although other radical species were capable of enhancing susceptibility to 
enzymatic cleavage. In the presence of Fe3+ or Cu2+, and H2O2, fragmentation could 
also occur, which could be inhibited by metal chelation. 
In support of glycation fragmentation of protein, other authors have reported this 
finding. Islam et al (1995) found in vitro glycation of ceruloplasmin led to 
fragmentation, releasing its copper ion, which subsequently promoted OH· 
production via Fenton chemistry. Copper was identified following ultrafiltration 
through 5 kDa filters. The reaction could be inhibited with catalase and EDTA, 
implicating the involvement of H2O2 and copper. Earlier studies with Cu,Zn-
superoxide dismutase had demonstrated a similar pattern, whereby initial cleaving 
into two fractions could be prevented by catalase, and subsequent random smaller 
fragmentations could be prevented by EDTA and catalase. EDTA could not prevent 
the initial fragmentation, which happened following glycation at one specific 
peptide bond (Ookawara et al 1992). 
Hunt et al (1993), working with HSA, found that glycation was a prerequisite for 
oxidation and subsequent fragmentation in vitro, unglycatable protein was 
resistant to fragmentation, and copper increased oxidation and fragmentation, 
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which could be inhibited by EDTA. Based on studies in the same report, they also 
proposed that glycation of LDL enhances copper-catalysed lipid peroxidation.  
All these in vitro examples of glycation-fragmentation involve metal-catalysed 
oxidation. Apart from trace iron possibly contaminating the SPB used in the 
filtration studies reported in this thesis, iron was added 30 minutes prior to 
ultrafiltration. In retrospect this period could allow OH· development and protein 
oxidation to occur, relative to degree of glycation, perhaps producing the reported 
results. On the other hand, the results for total iron binding capacity reported here, 
and in other studies, are lessened with glycation but have a much shorter iron 
incubation time of 5 minutes.  
2.7 Conclusion 
These studies demonstrate the fragmentation of glycated transferrin by protein 
oxidation and the potential for damage by the combination of glucose, iron, and 
oxidation. However, drawing direct comparisons between in vitro and in vivo 
conditions cannot be presumed, due to the high concentrations of glucose and 
redox available iron used, and the presence in plasma of many antioxidants.
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Chapter 3. Mass spectrometry of glycated transferrin 
“Nature, in conformity with her usual benevolence, has limited the power of iron.” 
Pliny the Elder 
(23 to 79 AD) 
 
3.1 Aim 
Using two mass spectrometry systems, to indicate potential differences 
between in vitro and in vivo glycated transferrin, in position and extent of 
glucose modifications which may be relevant to the protein fragmentation 
seen in vitro or other loss of function. 
3.2 Background 
3.2.1 Total iron binding capacity in type 2 diabetes 
Impaired iron-binding by transferrin is evident in in vitro glycated protein, as shown 
in the previous chapter. In vivo, assessment of transferrin performance is 
problematic. Total iron binding capacity (TIBC) has been used by two diabetes 
studies (Van Campenhout et al 2006a, Ganesh et al 2011); however TIBC is not a 
specific measure of transferrin capacity, as described below. With the same 
subjects, Van Campenhout et al have also used iron-binding antioxidant capacity 
(IB-AC) (Van Campenhout et al 2006b), an assessment of antioxidant protection by 
plasma against lipid peroxidation, generated by iron and ascorbate, and measured 
by TBARS (Gutteridge & Quinlan 1992). The two studies found show slight non-
significant reductions in TIBC in diabetes compared with healthy controls (Table 
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15). Ganesh et al (2011) carried out their study in India, and an attenuated iron 
status can be seen in both groups compared to the European study. 
 
Table 15. Selected iron parameters in two diabetes studies 
 Van Campenhout et al 2006a Ganesh et al 2011 
 Controls 
(n = 91) 
Diabetes 
(Type 1, n = 40; 
Type 2, n = 67) 
Controls 
(n = 30) 
Diabetes 
Type 2 (n = 30) 
Age, years (range) 46 (26 - 77) 58 (19 - 84)###1 41.83 ± 6.70 43.57 ± 9.49
NS 
M/F 54/37 54/53 12/18 11/19 
HbA1c  (%) 
Type 1 diabetes 
Type 2 diabetes 
5.3 ±  0.3 7.4  ± 1.1###1 
7.7  ± 0.8 
7.2 ± 1.2# 
- - 
Fasting bd sugar (mM) 
Type 1 diabetes 
Type 2 diabetes 
4.8 ± 0.5 8.9 ± 3.7###1 
10.8 ± 4.1 
7.8 ± 3.0###2 
6.05 ± 1.18 14.09 ± 1.33###1 
Serum iron (µM) 19 ± 7 16 ± 6* 13.0 ± 4.28 14.8 ± 4.67NS 
TIBC (µM) 
Type 1 diabetes 
Type 2 diabetes 
68 ± 9 67 ± 11 
63 ± 9 
69 ± 12# 
69.37 ± 14.50 65.45 ± 15.00
NS 
Transferrin (g/l) 
Type 1 diabetes 
Type 2 diabetes 
2.65 ± 0.44 2.56 ± 0.43*** 
2.38 ± 0.44 
2.67 ± 0.38*** 
1.33 ± 0.24 1.26 ± 0.30NS 
TIBC/g transferrin 
Mean (µM/g/l) 
Type 1 diabetes 
Type 2 diabetes 
 
25.7 
 
26.2 
26.5 
25.8 
- - 
TSAT (%) 25 ± 15 27 ± 11 NS 20.87 ± 1.17 20.50 ± 0.77NS 
Tf glyc (µM fruc/g Tf) 0.79 ± 1.09 1.39 ± 1.12** - - 
Hs-CRP (mg/dl) 
median (range) 
Type 1 diabetes 
Type 2 diabetes 
0.06 
(0.02 – 1.43) 
0.34** 
(0.02 – 1.90) 
0.12 (0.02 – 1.78) 
0.41 (0.02 – 1.66)## 
- - 
Iron-binding antioxidant 
capacity (% inhibition 
relative to control with no 
plasma, ± SD) 
Type 1 diabetes 
Type 2 diabetes 
 
88.3 ± 6 
 
 
83.6 ± 7* 
 
82.9 ± 7* 
84.0 ± 5* 
  
Results expressed as mean ± SD except where stated. TIBC: Total iron binding capacity; TSAT: 
Transferrin saturation; Tf glyc: Transferrin glycation (µM fructosamine/g transferrin); Hs-CRP: High 
sensitivity C-reactive protein. 
*
denotes P <0.05 compared with control, within gender; 
**
P <0.005 comparing diabetes to controls 
within gender; 
***
P = 0.001
 
between diabetes (all types) and controls, and types 1 and 2 diabetes, 
within gender; 
#
P = 0.098 between type, within gender; 
##
P < 0.05 between types; 
###1
P < 0.0005 
between diabetes and controls, within gender; 
###2
P = < 0.0005 between types 1 and 2, within gender. 
  
139 
 
Van Campenhout et al found that TIBC differed significantly between type 1 and 
type 2  diabetes, 63 ± 9 and 69 ± 12 (µM) (mean ± SD) respectively; as did 
transferrin concentration: 2.38 ± 0.44 and 2.67 ± 0.38 (g/l); and transferrin 
glycation: 1.95 ± 1.02 and 1.06 ± 1.04 (µM fruc/g Tf), respectively. No significant 
difference was seen in serum iron. Expressing their TIBC in µM per gram transferrin 
per litre finds that mean TIBC for type 1 and type 2 diabetes are very similar (type 
1, 26.5 µM/g/l; type 2, 25.8 µM/g/l), showing that the lessened TIBC in diabetes 
type 1 can be explained by the presence of less transferrin. This is interesting 
because significantly more inflammation is seen in the type 2 group (Table 15), and 
as transferrin is a reverse acute-phase protein less transferrin might be expected. 
The authors speculate that oxidative damage might explain this loss, although they 
found no correlation between transferrin glycation and transferrin concentration in 
their study group. Oxidative damage independent of glycation is not considered. 
They also suggest transferrin loss via urine in diabetic nephropathy as a route, but 
no renal markers are reported. 
Looking at diabetes (all types) versus controls, Van Campenhout et al found mean 
TIBC/g transferrin/l to be 26.2 µM/g/l, compared to controls: 25.7 µM/g/l, with 
slightly less transferrin being present in diabetes. As Hs-CRP was highly significantly 
increased in the diabetes group, this might account for the reduced concentration 
of transferrin seen overall, except that within group results or types 1 and 2 do not 
support this, as described above. As, in vivo, TIBC assessment involves the 
precipitation of all serum iron-binding proteins, including ferritin (and albumin), 
TIBC may be confounded by inflammation, although increased ferritin in 
inflammation is presumably more likely to be in the apo form, and albumin is a 
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reverse acute-phase protein. The authors used linear regression analysis to 
determine the main parameters affecting TIBC, and found that transferrin 
concentration determined 60% of the variance, with less than 5% determined by 
serum iron, but do not mention Hs-CRP.  
Ganesh et al (2011) report a non-significant reduction in serum transferrin 
concentration in their type 2 diabetes group, however they calculate transferrin 
concentration by the simple method of multiplying TIBC by 0.7. Their results are 
low compared to normal (2.5 g/l Lentner 1984), and do not agree with their given 
method, and so cannot be relied upon. 
The significant decrease in serum iron in Van Campenhout et al’s (2006b) diabetes 
group compared with controls might also be explained by inflammation, being due 
to hepcidin up-regulation reducing dietary iron absorption and cell efflux. However 
it is interesting that the same relationship is not seen between the two Indian 
groups, who are known to have a population-level low iron status. In fact, the 
diabetes group have a higher serum iron level. Ganesh et al don’t report HbA1c, 
only fasting blood sugar: 6.05 ± 1.18 mM control, and 14.09 ± 1.33 mM for type 2 
diabetes, and so presumably a similar degree of inflammation would exist. In iron-
poor bodies less transferrin-bound plasma iron would result in less transferrin 
receptor-induced pro-hepcidin transcription. Perhaps this hepcidin regulation 
pathway may be more influential than the inflammation driven JAK/STAT pathway, 
as there would be no physiological need for inflammatory hepcidin up-regulation.  
Despite the serum iron picture, TIBC loss is more evident in the diabetes group in 
Ganesh et al’s study, though not significantly. The diabetes group have more serum 
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iron, and less TIBC, yet the TSAT for the two groups are very similar. This might be 
explained by inflammation reducing transferrin production, but as shown in Van 
Campenhout et al more hs-CRP in their type 2 group did not equate with less 
transferrin.  
In summary, Van Campenhout et al’s (2006b) results are interesting not for the lack 
of TIBC in diabetes, but the lack of transferrin per se, in diabetes compared with 
controls, and in type 1 diabetes compared with type 2. A number of other studies 
have measured serum transferrin levels and diabetes. Memisogullari & Bakan 
(2004) found, in controls (n = 21): 2.57 ± 0.30 g/l; type 2 diabetes without 
complications: 2.28 ± 0.32 g/l (n= 29, P < 0.05 compared with controls); type 2 
diabetes with complications: 2.08 ± 0.40 g/l (n = 21, P < 0.001 compared with 
controls). Telci et al (2000) also found less iron in type 2 diabetes compared with 
controls, although both levels were unusually high: 3.85 ± 0.65 g/l (n = 84) versus 
4.59 ± 0.79 g/l (n = 61, P < 0.05).  
The reason for loss of serum transferrin in diabetes may well be renal filtration loss, 
as urinary transferrin excretion has consistently been shown to be increased in 
diabetes (O’Donnell et al 1991, Konen et al 1993, Narita et al 2004 & 2006, for 
example), and in fact is recommended as a gold standard marker of diabetic renal 
damage, more sensitive than urine albumin (Matheson et al 2010). Narita et al 
(2004) found, for example, mean transferrin excretion in 61 type 2 diabetes to be 
110 ng/min (range 21 to 620), compared with 69 ng/min (20 to 230) in 17 controls. 
For the same subjects, albumin losses were: 3.9 µg/min (0.5 to 9.6); and 2.9 µg/min 
(1.1 to 8.2) respectively. As a more sensitive marker of renal damage, urine 
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transferrin can also indicate early glomerular damage before urine albumin 
(Bernard et al 1988). These results may be explained by difference in shape, as 
transferrin is elongated, 55 by 28 Å; and albumin is more spherical, 36 Å, therefore 
transferrin may pass more easily through the glomerular membrane pores (Howard 
et al 1991). This is supported by Narita et al (2004) who found good correlations 
between different urinary proteins with a radius of less than 55 Å, in diabetes 
patients with normal urine albumin, and no increase in the larger α2-macroglobulin 
(molecular radius 88 Å). The glomerular filter is thought to consist of two 
populations of pores, the majority of which have a radius of 29 to 31 Å, with a small 
number of 80 to 90 Å radii pores. Additional sporadic defects or “shunts” are 
suggested to occur in the glomerular capillary wall which can allow very large 
proteins or red blood cells through (Bakoush et al 2002). 
Van Campenhout et al (2006b) assessed plasma iron-binding antioxidant capacity, 
finding a significant reduction in diabetes compared with controls, but not within 
diabetes types (Table 15). Regression analysis found that lessened transferrin, 
ceruloplasmin, and albumin did not fully account for this, and that their influence 
was lower in diabetes than in controls, explaining 4.2 and 6.3% of variance in type 1 
and type 2 respectively, and 13.9% in controls. IB-AC improved with transferrin 
concentration in controls (r = 0.3, n = 100), but not with diabetes (type 1: r = 0.13, n 
= 40; type 2: r = -0.07, n = 67). Transferrin glycation did not account for this, and 
the authors suggest the presence of another, unidentified, factor associated with 
diabetes which either impaired iron binding or promoted iron-catalysed lipid 
peroxidation.  
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To summarise from the small number of studies which have included TIBC in 
diabetes, reduction of TIBC in diabetes appears to be linked to reduced levels of 
transferrin rather than loss of function. Although transferrin is a reverse acute-
phase protein, this does not seem to be due to inflammation, but is linked to 
protein losses via renal damage. This being the case other proteins of a similar size 
or smaller may also be expected to be reduced, as has been reported by Narita et al 
(2004). The link with diabetes therefore is AGE-related basement membrane 
damage as described in Chapter 1, and so, as Narita et al (2006) found urinary 
transferrin, IgG, and ceruloplasmin to be equally able to predict microalbuminuria, 
we might assume transferrin losses in diabetes to be no different from losses of 
any other similar size protein.   
Whether or not protein glycation and subsequent oxidative cleavage plays any part 
in increased renal protein loss is unknown, however as Van Campenhout et al 
(2006b) found no link between glycation and loss of plasma IB-AC in vivo, perhaps 
any indirect functional effects of transferrin glycation, such as from a 
(mechanistically undefined) risk for increased NTBI, may not be important in the 
plasma phase.  
3.2.2 Glycated proteins in vivo 
Efforts to identify and quantify glycated proteins in vivo, in people with diabetes, 
have been on-going for a number of decades, with methods based on affinity gel 
chromatography to separate glycated sites. Most early work centred on 
haemoglobin and the use of HbA1c, however albumin has also long been recognised 
as a useful marker of blood glucose due to it representing 60% of total plasma 
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proteins, and having a shorter half-life, ranging from 12 to 19 days for glycated 
albumin (Yatscoff et al 1984, Roohk et al 2008), compared with 120 days for 
haemoglobin.  Estimates for clinical levels of glycated albumin range from 0.6% to 
8.6% for healthy people, and 1.4% to 16.59% in diabetes (Roohk et al 2008). Garlick 
& Mazur (1983) determined the major site of albumin glycation as being lysine-525.    
Glycated transferrin in vivo has been observed and comparatively quantified, by 
Van Campenhout et al (2006a), Austen et al (1987, Table 16), and Jaleel et al 
(2005). Austen et al started with whole plasma, separated glycated from non-
glycated protein using Glycogel B affinity columns, and then identified protein 
bands after electrophoresis. They found most glycation on gamma-globulins, 
albumin, beta-globulins, and complement C3. Transferrin was comparatively much 
less glycated (5.2% compared with 19.8% IgG).  Jaleel et al used electrophoresis to 
separate proteins, and Western blotting to identify those proteins that reacted 
with Amadori antibody, followed by mass spectrometry to identify the protein, in 
eight type 2 diabetes patients. They identified 11 plasma proteins that showed a 
significant difference in glycation compared with controls, including albumin, fibrin, 
Ig heavy chain constant, transferrin, and Ig light chain. Intensive 10 day insulin 
treatment was able to significantly reduce this glycation. Band intensity for 
transferrin was ~40 arbitary units (AU) in controls, compared with ~75 AU in 
diabetes, falling to ~53 AU after insulin. Other proteins identified as glycated and 
improved by insulin included hemopexin and vitamin D binding protein. 
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Table 16. Characteristics of glycated proteins identified by Austen et al (1987)   
 Glycation (%) Half-life (days) Lysine mole (%) 
Immunoglobulin G 19.8 24 7 
Albumin 16 15 - 19 9.5 
Complement C3 11.1 2 - 5 7.1 
Fibrinogen 5.9 2.5 6.7 
Transferrin  5.2 7 8.7 
Haptoglobin 2.2 2 10.5 
Alpha-1-antitrypsin 1.4 4 8.9 
 
Study of in vivo glycation of other proteins has reported the following observations: 
Affinity chromatography was used by Danze et al (1987) to observe a good 
correlation between glycated haemoglobin and glycated albumin, with a smaller 
correlation between glycated haemoglobin and glycated immunoglobulin G (IgG). 
The main site of IgG glycation was found to be the Fab fragment. 
Calvo et al (1988) reported a 400% increase in glycated high density lipoprotein 
(HDL) in diabetes patients, and a positive correlation with blood glucose level. 
Whilst all the HDL apolipoproteins were glycated, Apo A-1 represented 80% of the 
total. They later showed, in rats, that glycated Apo A-1 had a diminished 
association with HDL, and that, in vitro, glycated Apo A-1 had a reduced capacity to 
activate lecithin:cholesterol acyltransferase, necessary for reverse cholesterol 
transportation to the liver (Calvo et al 1993). In further work on Apo A-1, Lapolla et 
al (2008) compared 10 people with diabetes, 10 with nephropathy but not 
diabetes, receiving peritoneal dialysis, and 10 healthy controls. Looking exclusively 
in the 30 kDa region following electrophoresis, they found glycated apoliprotein A-
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1 to be as prevalent as unglycated Apo A-1 in the diabetes and nephropathy 
patients, and that the protein was over-expressed in comparison to controls. The 
glycated peptide sequences indicated that the preferential site for glycation was 
the ε-amino group of lysine, and single and double glycations were seen repeatedly 
to three particular peptides. In the same 30 kDa region, retinol binding protein was 
also highlighted as increasingly glucose-modified in these subjects. 
More recently the use of mass spectrometry has added depth to this literature, and 
in particular ion-trap Orbitrap devices (Thermo Fischer) have provided a more 
detailed analysis of the specific amino acids involved. Working with reconstituted 
whole human plasma, Priego-Capote et al (2010) used 24 hour, 37°C incubation 
with 30 mM isotopically labelled glucose, boronate affinity chromatography, and 
Orbitrap mass spectrometry to identify glycated proteins and lysine sites, and 
estimate glycation quantity. They looked at lysine glycation only, and found 35 
different proteins to be glycated, with 113 sites in total, 35 of which were on 
albumin. Eleven lysine glycation sites were found on transferrin, seven on Apo A-1, 
and six on haptoglobin β-chain. Transferrin sites where Lys 252, 278, 315, 359, 384, 
508, 515, 553, 564, 588, and 676 (the numbering includes the 19 residue signal 
peptide). 
An extensive study of glycated peptides in diabetes and control plasma and 
erythrocytes was carried out by Zhang et al (2011), using plasma samples from 238 
individuals with normal glucose tolerance, 97 individuals with impaired glucose 
tolerance, and 25 individuals with type 2 diabetes, with electron transfer 
dissociation, on an LQT-XL Orbitrap mass spectrometer. Again, lysine glycations 
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only were counted. Pooled whole diabetes plasma identified 799 glycated proteins, 
and a further 380 following immunodepletion of the top 12 most abundant 
proteins. 952 erythrocyte membrane proteins were glycated, and 853 from the 
cytosol. Ten glycated plasma and erythrocyte membrane proteins were found to be 
consistently up-regulated in diabetes, including clusterin, hemopexin, and spectrin 
alpha and beta chain.  
3.2.3 Glycation sites on proteins 
The occurrence of glycated proteins in vivo is primarily linked to half-life, as shown 
by Table 16.  Glycation has been proposed to be a flag for protein identification by 
AGE receptors for proteolysis, however as mentioned earlier, glycated albumin 
half-life is unchanged (Johnson 1991). 
The siting of Schiff and Amadori adducts within protein structures has been the 
subject of a great deal of study. In general terms, reaction sites need to be solvent-
accessible, and not buried within the protein. Positively charged amino acids lysine 
and arginine are the least hydrophobic, and charged groups are almost never 
buried (Lesk 2003), therefore they will be more exposed. Schiff’s bases commonly 
occur on the ε-amino group of lysine residues, and [within the guanidinium group 
of] arginine (Ahmed & Thornalley 2003), or on N-terminal α-amino groups of other 
amino acids. Reaction is dependent on their nucleophilicity (Watkins et al 1985), 
and arginine and lysine are both basic in nature at pH 7.4. Stable, post-Amadori, 
AGE products have also been found on histidine side-chains (which has a positively 
charged group within its side-chain) of sarco(endo)plasmic reticulum Ca2+-ATPase 
(Bidasee et al 2004). Glycated haemoglobin HbA1c is the product of a reaction on 
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the β-chain N-terminal valine (Acharyna & Sussman 1983). Valine residues were 
found to be more at risk of modification, and the presence of an adjacent acidic 
amino acid in the primary or tertiary structure is thought to be influential, (Watkins 
et al 1985, Johansen et al 2006).  
A number of larger scale data analyses have described the environment needed for 
glycation to occur. Johansen et al (2006) found that for lysine glycation at neutral 
pH, acidic residue glutamic acid, and lysine, commonly occur C-terminally of the 
glycated lysine, whereas basic lysine, and neutral valine and leucine residues occur 
more frequently N-terminally. The influential region lay within 11 amino acids 
either side of the glycation. In disagreement with Acharyna & Sussman (1983), 
Johansen et al found no evidence for histidine involvement in promotion of lysine 
glycation, in the primary structure, however catalysis through three dimensional 
proximity could not be ruled out. 
In the most comprehensive investigation to date Zhang et al (2011), catalogued the 
amino acid at every position 30 residues either side of the glycated lysine, along the 
primary sequence of peptides from 3742 human plasma and erythrocyte proteins. 
They found that position + 1 (C-terminally) alanine and valine were always in the 
top 4 occurring, for all sample types (Plasma/RBC/in vivo/in vitro). In vivo, 
hydrophobic, short chain or uncharged side chain amino acids such as alanine, 
valine, leucine, and serine occurred most frequently, with leucine, serine, and 
glutamic acid occurring most frequently in vitro.  In agreement with Johansen et al 
(2006), histidine was not in evidence significantly in the primary sequence proximal 
to glycation. Also identified were lysine residues that became glycated in vitro, that 
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did not occur in vivo, for example the peptide corresponding to Lys500 in HSA, 
perhaps due to the protein unfolding during incubation. Zhang et al (2011) 
identified leucine, glutamic acid, and serine, as occurring most frequently N-
terminally of glycation, from in vitro glycated human plasma proteins. 
Both of these interesting studies are limited by consideration only of lysine 
glycation, and proximities within the primary sequence only, and there may be 
much more to learn by considering other glycated residues, and the three 
dimensional environment surrounding them. Also, it might be useful to take into 
account the rate of occurrence of a particular amino acid within that protein, as 
those that appear more frequently glycated may occur more frequently anyway, 
for example, human serum transferrin has 58 lysine compared to 26 arginine 
residues.  
Gallet et al (2000) predicted which amino acid sequences within a protein were 
likely to be receptor-binding domains. Their predictions are based on plotting the 
mean alpha-helical hydrophobic moment against the mean hydrophobicity within a 
5-residue window, for each amino acid along the protein chain (Eisenberg et al 
1984). Likely interaction sites are highlighted by the plot, and are of relevance to 
glycation as it is the protein surface-seeking regions that are predicted. The 80,000 
proteins in the SwissProt database were analysed, finding the most frequently 
occurring receptor-binding regions to be arginine (19.6%), lysine (12.5%), glutamic 
acid (8.9%), serine (7.0%), and aspartic acid (6.9%). When compared with gross rate 
of occurrence in the database, arginine was found to occur 3.8 times more 
frequently in a binding domain than would be suggested by random distribution. 
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Results for all residues, reported as times more frequently occurring than random 
distribution would suggest, were: arginine (3.8), lysine (2.1), glutamine (1.5), 
glutamic acid (1.4), aspartic acid (1.3), asparagine (1.3), histidine (1.2), serine (1.0), 
threonine (0.9), tyrosine (0.9), proline (0.8), cysteine (0.8), glycine (0.6), methionine 
(0.6), alanine (0.5), tryptophan (0.5), leucine (0.4), valine (0.3), phenylalanine (0.3), 
isoleucine (0.2). Based on this study, the investigation of glycation on arginine 
could be expected to provide a rich source of data. 
3.2.4 Summary of Background and Aims 
In summary, glycated transferrin in vitro is clearly damaged by glucose incubation 
in a concentration-dependent manner, and the lack of iron-binding capacity in 
diabetes may be explainable by protein losses via the kidney, due to AGE-related 
tissue damage. It is not known whether the glycation state, or oxidation, of the 
transferrin plays any role in this. Mass spectrometry and other methods have been 
able to describe much about protein glycation generally, but very little has been 
done specifically on human serum transferrin. In an attempt to compare, for the 
first time, in vitro with in vivo glycated transferrin, outsourced mass spectrometry 
was undertaken. Work was very generously carried-out by the laboratories of 
Waters UK (Manchester), and The University of Bristol Proteomics Facility. 
Although only single samples in each of three cases are analysed (one healthy 
control, one type 2 diabetes, one in vitro glycated transferrin sample), it is hoped 
that they might give an indication of where glycation is occurring, how the siting of 
glycation adducts may differ between in vitro and in vivo glycation, whether these 
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differences could account for the damage seen in vitro, and whether or not further 
studies would be justified.  
3.3 Experimental methods (in brief) 
3.3.1 In vivo samples 
Following consent, and local and regional ethical approvals, blood samples were 
given by one healthy adult male, and one adult male with type 2 diabetes (HbA1c 
6.2%). Whole undepleted serum was lyophilized and briefly stored at -80°C prior to 
dilution to 1 µg/µl. 100 µl of each sample was reduced with dithiothreitol, alkylated 
with iodoacetamide, and digested with trypsin. Single 2 μl injections of 1.56 μg 
protein were used, in a Waters NanoAQCUITY UPLC plus SYNAPT G2 mass 
spectrometer. Peptide identification was by BiopharmaLynx software, with a 
minimum fragment ion match per peptide of 3, minimum fragment ion match per 
protein of 7; minimum peptide match per protein of 1. Work was carried out by Dr 
Joanne Connolly, and Dr Gushinder Atwal at Waters UK, Manchester, in July 2010. 
3.3.2 In vitro sample 
Human apo-transferrin (Sigma Aldrich, 98% purity) was incubated in 100 mM 
glucose solution in sodium phosphate buffer, pH 7.4,   at 37˚ C, for 15 days. 
Following buffer exchange, protein was assessed for glycation by picrylsulphonic 
acid assay of remaining NH2 groups, measured against standard solutions of L-
lysine. Fresh, 0 mM, and 100 mM incubations had consecutively 336, 305, and 191 
µM/mg/ml lysine equivalence.  The lyophilized sample digest was treated as above. 
A single injection of 1 μg protein in 2 μl of solution was used, on a Thermo Scientific 
LTQ Orbitrap Velos mass spectrometer.  Modified amino acid and peptide 
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identification was by Proteome Discoverer software. Glycation on Cys, Lys, Asn, 
Arg, Thr, Trp, Tyr, and the N-terminus were allowed as variable modifications. 
Separate searches were done for oxidation on Met, Cys, Asp, Phe, Lys, His, Trp, Asn, 
Arg, Tyr, & C-terminal Gly. High and medium confidence scores were counted. 
Work was carried out by Dr Kate Heesom, at The University of Bristol Proteomics 
Facility, in July 2011. 
3.4 Results 
3.4.1 Results in vivo 
The Waters mass spectrometer identifies glycated peptides only, not individual 
residues. In the healthy control 249 transferrin peptides in total were identified 
(Table 18), giving 96% protein coverage, average length 11.2 amino acids (SD 4.6). 
Of these, 87 peptides (34.9%) had a single glycation, average length 10.6 (SD 3.8), 
32 (36.8%) from the N-lobe, 55 (63.4%) from the C-lobe (Table 17). 
Table 17. Rate of glycation per lobe, all samples 
 In vivo In vitro (100 mM Glucose) 
 Control Diabetes Total Top 4# Less top 4 
Peptide count 249 261 1136 - - 
Glycated peptide count 
(% of total for type) 
87 
(34.9) 
103 
(39.5) 
240 
(21.1) 
92 
(8.10) 
148 
(13.03) 
N-Lobe glycation count  
(% of glycated total) 
(Less top 4, % glyc total) 
32 
(36.8) 
- 
32 
(31.1) 
- 
144 
(60) 
- 
92 
(38.3) 
- 
52 
(21.7)  
(35.2) 
C-Lobe glycation count  
(% of glycated total) 
(Less top 4, % glyc total) 
55 
(63.4) 
- 
71 
(68.9) 
- 
96 
(40) 
- 
- 
96 
(40)  
(64.8) 
# N-lobe peptides associated with Met309, Lys312, Tyr314, and Tyr317  
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Table 18. In vivo peptide detail, Waters 
  
Glycated peptide count, by Waters mass spectrometry, Control Glycated peptide count, by Waters mass spectrometry, Type 2 diabetes
N-lobe plus half linker peptide C-lobe plus half linker peptide N-lobe C-lobe
Peptide Start End Count Start End Count Peptide Start End Count Start End Count
TVRWCAVSEHEATK 5 18 2 KDK 329 346.3 1 VPDK 1 4 1 EAPTDECKPVK 333 343 1
WCAVSEHEATK 8 18 1 WCALSHHERLK 344 354 2 TVRWCAVSEHEATK 5 18 1 WCALSHHERLK 344 354 1
CQSFRDHMK 19 27 5 LKCDEWSVNSVGK 353 365 2 CQSFRDHMK 19 27 2 LKCDEWSVNSVGK 353 365 2
DHMKSVIPSDGPSVACVK 24 41 1 CDEWSVNSVGK 355 365 1 SVIPSDGPSVACVK 28 41 3 CDEWSVNSVGKIECVSAETTEDCIAK 355 380 1
SVIPSDGPSVACVK 28 41 1 IECVSAETTEDCIAK 366 380 1 SVIPSDGPSVACVKK 28 42 1 IECVSAETTEDCIAK 366 380 2
PSDGPSVACVKK 31 42 1 CGLVPVLAENYNK 402 414 1 KASYLDCIR 42 50 3 IMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNK 381 414 1
KASYLDCIR 42 50 3 SDNCEDTPEAGYFAVAVVK 415 433 2 EDPQTFYYAVAVVK 89 102 3 IMNGEADAMSLDGGFVYIAGK 381 401 1
KDSGFQMNQLR 103 113 2 SASDLTWDNLK 435 445 2 SAGWNIPIGLLYCDLPEPRKPLEK 125 148 1 CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK 402 433 1
DSGFQMNQLRGK 104 115 1 SASDLTWDNLKGK 435 447 1 DGAGDVAFVKHSTIFENLANK 197 217 1 CGLVPVLAENYNK 402 414 1
CLK 194 196 1 KSCHTAVGR 448 456 2 DGAGDVAFVK 197 206 1 SDNCEDTPEAGYFAVAVVKK 415 434 3
CLKDGAGDVAFVK 194 206 2 KDSSLCK 490 496 2 HSTIFENLANKADR 207 220 1 SDNCEDTPEAGYFAVAVVK 415 433 2
DGAGDVAFVK 197 206 1 LCMGSGLNLCEPNNK 497 511 1 KPVDEYKDCHLAQVPSHTVVAR 233 254 1 SASDLTWDNLK 435 445 2
HSTIFENLANK 207 217 1 EGYYGYTGAFRCLVEK 512 527 2 KPVDEYK 233 239 3 SASDLTWDNLKGK 435 447 1
KPVDEYKDCHLAQVPS 233 248 1 CLVEKGDVAFVK 523 534 4 DCHLAQVPSHTVVARSMGGK 240 259 2 KSCHTAVGR 448 456 1
KPVDEYK 233 239 1 GDVAFVK 528 534 1 EDLIWELLNQAQEHFGK 260 276 1 SCHTAVGRTAGWNIPMGLLYNK 449 470 1
EFQLFSSPHGKDLLFK 281 296 2 GDVAFVKHQTVPQNTGGK 528 545 1 DKSK 277 280 1 TAGWNIPMGLLYNKINHCR 457 475 2
DLLFK 292 296 1 HQTVPQNTGGK 535 545 1 EFQLFSSPHGK 281 291 1 FDEFFSEGCAPGSKK 476 490 2
DLLFKDSAHGFLK 292 304 1 NLNEKDYELLCLDGTR 553 568 4 EFQLFSSPHGKDLLFK 281 296 1 LCMGSGLNLCEPNNKEGYYGYTGAFR 497 522 2
DSAHGFLK 297 304 2 NLNEK 553 557 1 DLLFK 292 296 1 LCMGSGLNLCEPNNK 497 511 1
SAHGFLK 298 304 1 KPVEEYANCHLAR 569 581 2 NLREGTCPEAPTDECKPVK 325 343 2 EGYYGYTGAFRCLVEK 512 527 1
DLLFK 322.4 341.2 1 APNHAVVTRK 582 591 3 EGTCPEAPTDECKPVK 328 343 1 CLVEK 523 527 2
NLNEK 323.3 341.9 1 KDK 591 593 1 CLVEKGDVAFVK 523 534 1
CLK 328.5 346 1 DKEACVHK 592 599 5 HQTVPQNTGGKN 535 546 1
EACVHK 594 599 1 NPDPWAKNLNEK 546 557 3
SETKDLLFR 624 632 1 NPDPWAK 546 552 1
DLLFRDDTVCLAK 628 640 2 NLNEKDYELLCLDGTR 553 568 5
DDTVCLAK 633 640 2 NLNEK 553 557 1
LHDRNTYEK 641 649 1 DYELLCLDGTRKPVEEYANCHLAR 558 581 1
YLGEEYVKAVGNLR 650 663 1 KPVEEYANCHLAR 569 581 1
KCSTSSLLEACTFR 664 677 2 KPVEEYANCHLARAPNHAVVTR 569 590 4
34 53 KPVEEYAN 569 576 1
KPVEEY 569 574 1
KPVEEYANCHLARAPNH 569 585 1
APNHAVVTRK 582 591 1
KDK 591 593 1
DKEACVHK 592 599 3
KEACVHK 593 599 1
EACVHKILR 594 602 2
SETKDLLFR 624 632 1
SETK 624 627 1
DDTVCLAKLHDR 633 644 3
LHDRNTYEK 641 649 1
NTYEK 645 649 3
NTYEKYLGEEYVK 645 657 1
AVGNLRK 658 664 1
32 71
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Table 19. Regulated proteins, Waters 
 
 
Unique and regulated proteins by Waters mass spectrometry, Control and Type 2 diabetes
Control unique Type 2 diabetes unique
Accession Description Unique Accession Description Unique
P01623 Ig kappa chain V III region WOL OS Homo sapiens PE 1 SV 1 Control P04206 Ig kappa chain V III region GOL OS Homo sapiens PE 1 SV 1 Diabetes
P01717 Ig lambda chain V IV region Hil OS Homo sapiens PE 1 SV 1 Control
P04208 Ig lambda chain V I region WAH OS Homo sapiens PE 1 SV 1 Control
Down-regulated Diabetes to Control Up-regulated Diabetes to Control
Accession Description D:C_Ratio Accession Description D:C_ratio
P01861 Ig gamma 4 chain C region OS Homo sapiens GN IGHG4 PE 1 SV 1 0.14 P01777 Ig heavy chain V III region TEI OS Homo sapiens PE 1 SV 1 3.00
P01860 Ig gamma 3 chain C region OS Homo sapiens GN IGHG3 PE 1 SV 2 0.18 P02749 Beta 2 glycoprotein 1 OS Homo sapiens GN APOH PE 1 SV 3 2.97
P02763 Alpha 1 acid glycoprotein 1 OS Homo sapiens GN ORM1 PE 1 SV 1 0.38 P00738 Haptoglobin OS Homo sapiens GN HP PE 1 SV 1 2.46
P01766 Ig heavy chain V III region BRO OS Homo sapiens PE 1 SV 1 0.43 P00739 Haptoglobin related protein OS Homo sapiens GN HPR PE 1 SV 2 2.08
P01764 Ig heavy chain V III region VH26 OS Homo sapiens PE 1 SV 1 0.44 P20742 Pregnancy zone protein OS Homo sapiens GN PZP PE 1 SV 4 1.51
P01621 Ig kappa chain V III region NG9 Fragment OS Homo sapiens PE 1 SV 1 0.45 P0C0L4 Complement C4 A OS Homo sapiens GN C4A PE 1 SV 1 1.46
P01876 Ig alpha 1 chain C region OS Homo sapiens GN IGHA1 PE 1 SV 2 0.47 P27169 Serum paraoxonase arylesterase 1 OS Homo sapiens GN PON1 PE 1 SV 2 1.31
P01591 Immunoglobulin J chain OS Homo sapiens GN IGJ PE 1 SV 4 0.48 P00751 Complement factor B OS Homo sapiens GN CFB PE 1 SV 2 1.30
P01617 Ig kappa chain V II region TEW OS Homo sapiens PE 1 SV 1 0.49 P00734 Prothrombin OS Homo sapiens GN F2 PE 1 SV 2 1.25
P01620 Ig kappa chain V III region SIE OS Homo sapiens PE 1 SV 1 0.50 P01023 Alpha 2 macroglobulin OS Homo sapiens GN A2M PE 1 SV 2 1.23
P06396 Gelsolin OS Homo sapiens GN GSN PE 1 SV 1 0.53 P68871 Hemoglobin subunit beta OS Homo sapiens GN HBB PE 1 SV 2 1.22
P01857 Ig gamma 1 chain C region OS Homo sapiens GN IGHG1 PE 1 SV 1 0.53
P0C0L5 Complement C4 B OS Homo sapiens GN C4B PE 1 SV 1 0.53
P04220 Ig mu heavy chain disease protein OS Homo sapiens PE 1 SV 1 0.54
P01842 Ig lambda chain C regions OS Homo sapiens GN IGLC1 PE 1 SV 1 0.54
P01834 Ig kappa chain C region OS Homo sapiens GN IGKC PE 1 SV 1 0.55
P02649 Apolipoprotein E OS Homo sapiens GN APOE PE 1 SV 1 0.59
P01877 Ig alpha 2 chain C region OS Homo sapiens GN IGHA2 PE 1 SV 3 0.64
P02655 Apolipoprotein C II OS Homo sapiens GN APOC2 PE 1 SV 1 0.69
P01871 Ig mu chain C region OS Homo sapiens GN IGHM PE 1 SV 3 0.72
P05090 Apolipoprotein D OS Homo sapiens GN APOD PE 1 SV 1 0.73
P01019 Angiotensinogen OS Homo sapiens GN AGT PE 1 SV 1 0.74
O43866 CD5 antigen like OS Homo sapiens GN CD5L PE 1 SV 1 0.76
P02656 Apolipoprotein C III OS Homo sapiens GN APOC3 PE 1 SV 1 0.76
P02747 Complement C1q subcomponent subunit C OS Homo sapiens GN C1QC PE 1 SV 3 0.78
Q96PD5 N acetylmuramoyl L alanine amidase OS Homo sapiens GN PGLYRP2 PE 1 SV 1 0.79
P04217 Alpha 1B glycoprotein OS Homo sapiens GN A1BG PE 1 SV 3 0.79
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In the type 2 diabetes sample 261 peptides were identified, with 100% protein 
coverage, average length 12.7 amino acids (SD 6.3). 103 (39.5%) of these were 
glycated, average length 12.9 (SD 6.3), 32 (31.1%) from the N-lobe, 71 (68.9%) from 
the C-lobe. Areas of highest modification were peptides Cys19 to Lys27, Ser415 to 
Lys433, Cys523 to Lys527, and Asn546 to Lys599 (Table 18).  No double glycations 
were reported in either case. 
The total number of proteins confidently identified in the control and diabetes 
samples were 143 and 124, respectively. 117 proteins were identified in at least 2 
out of 3 repeated sample injections, 3 of these were unique to the control, 1 
protein was unique to the diabetes subject. All 4 unique proteins were regions of 
immunoglobulin light chain kappa and lambda. Expression differed in 38 proteins, 
11 of these were up-regulated in diabetes versus control, 27 were down-regulated 
in diabetes versus control. 75 proteins were unregulated (Table 19).    
3.4.2 Results in vitro 
In the in vitro glycated sample, 1136 transferrin peptides were identified (Table 20), 
average length 15.8 amino acids, of which 240 (21.1%) had a single glycation, 60% 
from the N-lobe, and 40% from the C-lobe (Table 17). 38.3% of the glucose 
modifications were to four amino acids (Met309, Lys312, Tyr314, and Tyr317, 
referred to as “the top 4”), sited close to the C-terminal end of the N-lobe in an 
area free of glycation in the human serum samples. No doubly glycated peptides 
were reported. 823 oxidized residues were found, 49.3% of which were methionine 
(Table 23). The most frequently occurring oxidized residue was Met389 (99), 
followed by Met382 (94), which between then made-up 23.5% of the oxidations 
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(Table 21). Forty seven peptides had both glycation and oxidation simultaneously, 
66% of these from two α-helices near the C-terminal end of the N-lobe, Met309 to 
Arg324. Other peptides with simultaneous glycation and oxidation are: Ile366 to 
Lys401, Lys103 to Arg113, Leu497 to Arg522 (Table 20).  
Twenty amino acids were prone to both glycation and oxidation non-
simultaneously, of particular note are Met313, Tyr314, Tyr317, and Asn383 (Table 
22). Two of the top 4 glycated residues were also subject to non-simultaneous 
oxidation (Tyr314 and Tyr317), with adjacent Met313 also being prone to 
oxidation. 
Table 20. In vitro modified peptides, Orbitrap 
 
All modified peptides, by Orbitrap
Start End Glycated peptide Count Start End Oxidized peptide Count
24 41 dHMKSVIPSDGPSVAcVK 17 8 18 WcAVSEhEATK 13
42 50 KASyLDcIR 3 51 88 AIAANEADAVTLDAGLVYDAYLAPNNLkPVVAEFYGSK 6
51 88 AIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFyGSK 7 89 102 EDpQTFYYAVAVVK 5
103 113 kDSGFQmNQLR 6 103 113 KDSGFQmNQLR 5
197 217 DGAGDVAFVkHSTIFENLANK 1 104 113 DSGFQmNQLR 47
207 217 HStIFENLANK 3 125 143 SAGWnIPIGLLYcDLPEPR 14
221 232 dQYELLcLDNTR 2 197 206 DGAGDVAfVK 1
233 254 kPVDEYKDcHLAQVPSHTVVAR 7 200 206 GDVAfVK 2
240 254 dcHLAQVPSHTVVAR 1 207 217 HSTIfENLANK 6
255 276 sMGGKEDLIWELLNQAQEHFGK 2 221 232 dQYELLcLDNTR 1
279 291 sKEFQLFSSPHGK 2 233 254 KPVDEYkDcHLAQVPSHTVVAR 2
309 324 MDAKMyLGYEYVTAIR 91 240 254 DchLAQVPSHTVVAR 2
313 324 mYLGYEYVTAIR 2 255 276 SMGGkEDLIWELLNQAQEHFGK 18
355 380 cDEwSVNSVGKIEcVSAETTEDcIAK 8 281 291 EfQLFSSPHGK 2
366 380 iEcVSAETTEDcIAK 2 313 324 mYLGYEYVTAIR 16
366 401 IEcVSAETtEDcIAKImNGEADAMSLDGGFVYIAGK 10 344 352 WcALShhER 7
381 401 iMNGEADAMSLDGGFVYIAGK 3 353 365 LKcDEwSVNSVGK 6
434 445 kSASDLTWDNLK 6 355 365 cDEwSVNSVGK 1
435 445 sASDLTWDNLK 1 366 380 IEcVSAETTEDcIAK 1
457 470 tAGWNIPMGLLYNK 7 381 401 IMNGEADAMSLdGGFVYIAGK 126
476 489 fDEFFSEGcAPGSK 1 415 433 SDNcEDTpEAGYFAVAVVK 8
491 511 dSSLcKLcMGSGLNLcEPNNK 15 434 445 KSASDLTWDnLK 7
497 511 lcMGSGLNLcEPNNK 1 435 445 SASDLTWDNLk 16
497 522 lcMGSGLNLcEPNNKEGYYGYTGAFR 6 435 447 SASDLTWDNLkGK 8
512 522 eGYYGYTGAFR 2 457 470 TAGWNIPmGLLYNK 35
535 545 hQTVPQNTGGK 2 476 489 FdEFFSEGcAPGSK 26
553 568 nLNEKDYELLcLDGTR 18 497 511 LcmGSGLNLcEPNNK 9
569 581 kPVEEYANcHLAR 1 497 522 LcMGSGLNLcEPNNKEGYYGYTGAFR 7
664 677 kcSTSSLLEAcTFR 12 512 522 EGYYGYTGAFr 5
665 677 cSTSSLLEAcTFR 1 535 545 hQTVPQNTGGK 1
546 552 NPDpWAK 3
553 568 NLNEKDyELLcLDGTR 1
558 568 DYELLcLdGTR 1
569 581 KPVEEYANchLAR 6
582 590 APNhAVVTR 7
240 421
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Table 21. In vitro modified amino acids by highest frequency, Orbitrap  
 
 
Table 22. Non-simultaneous  modification of in vitro glycated transferrin  
 
Glyc & Oxi modified AA
Frequency per 1136 peptides
# Glyc Oxi
Asn 75 1 1
Asn 76 1 1
Lys 78 1 1
Tyr 85 2 1
Lys 88 2 2
His 207 2 2
Asp 221 2 1
Cys 240 1 2
Lys 259 1 8
Met 313 1 21
Tyr 314 26 7
Tyr 317 17 2
Trp 358 2 7
Asn 383 5 31
Trp 460 1 7
Phe 476 1 6
Asn 504 2 2
His 535 2 1
Tyr 559 1 1
Lys 569 1 1
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Table 23. In vitro glycated and oxidized amino acids 
 
Table 24. Amino acid glycation by frequency per native frequency in native 
transferrin 
 
Modified AA by type
Glyc AA % Oxi AA %
Lys 36.3 Met 49.3
Tyr 19.6 Asn 11.3
Asn 12.1 Asp 10.4
Met 10.8 Phe 7.8
Asp 7.9 Trp 6.7
Thr 4.2 Tyr 4.3
Cys 1.7 Pro 4.1
His 1.7 Lys 3.5
Ile 1.7 His 1.6
Trp 1.3 Cys 0.5
Glu 0.8 Arg 0.4
Leu 0.8
Ser 0.8
Phe 0.4
Amino Glyc Native Glyc Native Ratio
acid count count % % G/N
Met 26 9 10.8 1.3 8.2
Tyr 47 26 19.6 3.8 5.1
Lys 87 58 36.3 8.5 4.2
Asn 29 34 12.1 5.0 2.4
Asp 19 45 7.9 6.6 1.2
Trp 3 8 1.3 1.2 1.1
Thr 10 30 4.2 4.4 0.9
Ile 4 16 1.7 2.4 0.7
His 4 19 1.7 2.8 0.6
Cys 4 38 1.7 5.6 0.3
Ser 2 41 0.8 6.0 0.1
Glu 2 42 0.8 6.2 0.1
Phe 1 28 0.4 4.1 0.1
Leu 2 59 0.8 8.7 0.1
Ala _ 57 _ 8.4 _
Gly _ 50 _ 7.4 _
Val _ 44 _ 6.5 _
Pro _ 32 _ 4.7 _
Arg _ 26 _ 3.8 _
Gln _ 17 _ 2.5 _
240 679 100.0 100.0
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Table 25. In vitro glycated amino acid type less top 4, frequency per 
frequency in native transferrin 
 
Amino Glyc Native Glyc Native Ratio
acid count count % % G/N
Lys 63 58 42.6 8.5 5.0
Asn 29 34 19.6 5.0 3.9
Asp 19 45 12.8 6.6 1.9
Trp 3 8 2.0 1.2 1.7
Thr 10 30 6.8 4.4 1.5
Ile 4 16 2.7 2.4 1.1
His 4 19 2.7 2.8 1.0
Tyr 4 26 2.7 3.8 0.7
Met 1 9 0.7 1.3 0.5
Cys 4 38 2.7 5.6 0.5
Ser 2 41 1.4 6.0 0.2
Glu 2 42 1.4 6.2 0.2
Phe 1 28 0.7 4.1 0.2
Leu 2 59 1.4 8.7 0.2
Ala _ 57 _ 8.4 _
Gly _ 50 _ 7.4 _
Val _ 44 _ 6.5 _
Pro _ 32 _ 4.7 _
Arg _ 26 _ 3.8 _
Gln _ 17 _ 2.5 _
148 679 100.0 100.0
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Table 26. Frequency of amino acid type occurring -1 position N-terminally, and +1 position C-terminally to glycated residue  
 
  
Less 1
N-terminally Cys Asp Glu Phe His Ile Lys Leu MetAsn Ser Thr Trp Tyr Tot %
Lys 2 2 1 2 2 3 1 1 1 2 17 30.4
Arg 2 1 3 1 1 1 9 16.1
Gly 2 1 1 4 7.1
Ser 2 1 1 4 7.1
Glu 1 1 1 3 5.4
Leu 1 2 3 5.4
Met 1 1 1 3 5.4
Asn 1 2 3 5.4
Ala 2 2 3.6
Pro 2 2 3.6
Val 1 1 2 3.6
Cys 1 1 1.8
Asp 1 1 1.8
Phe 1 1 1.8
Thr 1 1 1.8
Tyr
Ile
Gln
His
Total 2 4 1 1 2 2 18 1 2 9 3 4 2 5 56 100
Glycated residue Plus 1
C-terminally Cys Asp Glu Phe His Ile Lys Leu Met Asn Ser Thr Trp Tyr Tot %
Glu 1 4 1 1 2 9 16.1
Ser 1 1 1 2 1 1 7 12.5
Leu 1 3 2 6 10.7
Asp 1 1 2 1 5 8.9
Ala 1 1 1 3 5.4
Cys 1 1 1 3 5.4
Gly 1 1 1 3 5.4
Ile 2 1 3 5.4
Met 1 1 1 3 5.4
Asn 2 1 3 5.4
Pro 3 3 5.4
His 1 1 2 3.6
Lys 1 1 2 3.6
Gln 1 1 2 3.6
Thr 1 1 1.8
Tyr 1 1 1.8
Val
Phe
Arg
Total 2 4 1 1 2 2 18 1 2 9 3 4 2 5 56 100
Glycated residue
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Figure 34. Human serum transferrin glycation by mass spectrometry 
a) Human serum transferrin glycated peptides, by Waters NanoACQUITY mass spectrometry 
b) In vitro glycated human serum transferrin, glycated amino acids, by Thermo Orbitrap Velos mass spectrometry. 
a) 
b) 
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Figure 35. Human serum transferrin, amino acid glycation (a), and oxidation (b), following in vitro glycation, by Orbitrap mass 
spectrometry 
a) 
b) 
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Table 27. Human serum transferrin sequence, primary and secondary structures, with in vitro glycated amino acids, by Orbitrap MS 
   
Human serum transferrin, primary and secondary structures Key: α-helices; β-strand; Turn; In vitro  glycation; N: N-linked glycosylation; O: O-linked glycosylation (by similarity);
Ms: Methylation (by similarity); P: Phosphorylation; IB: Iron binding; IBs: Iron binding (by similarity); AB: Anion binding; ABs: Anion binding (by similarity); DB: Disulfide bond;
DT: Dilysine trigger; Td: Triad; Hg: Hinge; ILC: Inter-lobe contact; RB: Receptor binding (proposed1)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
V P D K T V R W C A V S E H E A T K C Q S F R D H M K S V I P S D G P S V A C V K K A S Y L D C I R
N- L o b e DB DB Ms O DB DB
51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
A I A A N E A D A V T L D A G L V Y D A Y L A P N N L K P V V A E F Y G S K E D P Q T F Y Y A V A V
IB RB RB RB RB Hg IB
101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
V K K D S G F Q M N Q L R G K K S C H T G L G R S A G W N I P I G L L Y C D L P E P R K P L E K A V
DB AB AB AB AB DB RB RB RB RB
151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200
A N F F S G S C A P C A D G T D F P Q L C Q L C P G C G C S T L N Q Y F G Y S G A F K C L K D G A G
DB DB DB DB DB DB IB DB
201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250
D V A F V K H S T I F E N L A N K A D R D Q Y E L L C L D N T R K P V D E Y K D C H L A Q V P S H T
DT DB ILC DB Hg Hg IB
251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
V V A R S M G G K E D L I W E L L N Q A Q E H F G K D K S K E F Q L F S S P H G K D L L F K D S A H
DT
301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350
G F L K V P P R M D A K M Y L G Y E Y V T A I R N L R E G T C P E A P T D E C K P V K W C A L S H H
ILC DB L i n k e r DB C- L o b e DB AB AB
RB
351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400
E R L K C D E W S V N S V G K I E C V S A E T T E D C I A K I M N G E A D A M S L D G G F V Y I A G
DB DB ILC DB IBs
RB RB RB RB RB RB RB RB RB RB RB RB RB
401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450
K C G L V P V L A E N Y N K S D N C E D T P E A G Y F A I A V V K K S A S D L T W D N L K G K K S C
DB N DB IBs DB
451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500
H T A V G R T A G W N I P M G L L Y N K I N H C R F D E F F S E G C A P G S K K D S S L C K L C M G
ABs ABs AB ABs ABs DB DB DB DB
501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550
S G L N L C E P N N K E G Y Y G Y T G A F R C L V E K G D V A F V K H Q T V P Q N T G G K N P D P W
DB P DB Td
IBs
551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600
A K N L N E K D Y E L L C L D G T R K P V E E Y A N C H L A R A P N H A V V T R K D K E A C V H K I
DB DB Hg Hg Hg IBs DB
601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650
L R Q Q Q H L F G S N V T D C S G N F C L F R S E T K D L L F R D D T V C L A K L H D R N T Y E K Y
N DB DB Td Td DB
651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 N-lobe: 1 - 331;   Sub-domain N1: 1 - 92, 247 - 331;   N2: 93 - 246
L G E E Y V K A V G N L R K C S T S S L L E A C T F R R P C-lobe: 339 - 679;   Sub-domain C1: 339 - 425, 573 - 679;   C2: 426 - 572
DB DB ILC (Sequence & detail: UniprotKB/Swiss-Prot version 160; 1Cheng et al 2004, Wally et al 2006)
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3.5 Discussion 
The aim of this study was to indicate potential differences between in vitro and in 
vivo glycated transferrin, in position and extent of glucose modifications which may 
be relevant to the protein fragmentation seen in vitro or other loss of function. Due 
to the small number of samples, their assessment on different equipment, and the 
lack of a control sample for the in vitro sample, suggestions only can be inferred 
from these results.  
The complete human serotransferrin amino acid sequence was first described by 
MacGillivray et al (1982), and the sequence used here is that of UniProtKB/Swiss-
Prot version 160, a free access, reviewed, compilation of sequence identification 
data. The human serotransferrin page was last modified in November 2010. The 
first 19 UniProt amino acids comprise the signal peptide and, in agreement with the 
majority of authors, have been subtracted from the UniProtKB sequence to give the 
residue numbers reported here. The three dimensional structure of human serum 
transferrin is shown in Figure 36, the secondary structure is shown in Figure 37, and 
the position of amino acids found to be glycated following in vitro glycation, is 
shown in Table 27, superimposed onto primary and secondary structures, with 
functional sites indicated.  
3.5.1 Glycation and glycosylation 
Human serum transferrin is made up of a 679 amino acid sequence, arranged into 
two structurally similar lobes (designated N and C), with a short linker peptide 
between them. Within each lobe the protein is sub-divided into two domains, 
between which lies a binding site for one iron atom (Figure 36).   
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Figure 36. The crystal structure of human apo-transferin  
Showing subdomain N1 in blue, N2 in red, C1 in green, and C2 in 
yellow. The linker peptide is shown in grey. This figure was originally 
published in the Journal of Biological Chemistry. Wally, J. Halbrooks, 
P. Vonrhein, C. et al. The crystal structure of iron-free human serum 
transferrin provides insight into inter-lobe communication and 
receptor binding. Journal of Biological Chemistry. 2006; Vol. 281: 
24934 – 24944 © the American Society for Biochemistry and 
Molecular Biology. Reproduced and adapted with permission from 
the publishers. 
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Figure 37. Topology map of the secondary structure of apo-human transferrin 
Showing subdomains, coloured N1 – red, N2 – blue, C1 – green, and 
C2 – yellow. This figure was originally published in the Journal of 
Biological Chemistry. Wally, J. Halbrooks, P. Vonrhein, C. et al. The 
crystal structure of iron-free human serum transferrin provides 
insight into inter-lobe communication and receptor binding. Journal 
of Biological Chemistry. 2006; Vol. 281: 24934 – 24944 © the 
American Society for Biochemistry and Molecular Biology. 
Reproduced and adapted with permission from the publishers. 
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The Waters’ in vivo data showed a clear preference for glycation of the C-lobe over 
the N-lobe (Table 17), which is also seen in the positioning of the two N-linked 
carbohydrate glycosylation moieties in human serum transferrin, which both occur 
within the C-lobe, at Asn413 and Asn611. Around 50% of all proteins in nature are 
believed to be glycoproteins (Apweiler et al 1999), and have either one or more 
serine or threonine linked O-glycans, and/or one or more asparagine linked N-
glycans. Glycosylation takes place enzymatically, in the Golgi apparatus for O-linked 
glycans, and in the endoplasmic reticulum for N-linked glycans. O-linked glycans are 
thought to play a role in antibody recognition, structural rigidity, and as ligands for 
carbohydrate bonding proteins such as selectins and adhesins (Hounsell et al 1996). 
N-glycans help to facilitate protein production operations such as folding, sorting 
and transport, and tagging for enzyme recognition (Helenius & Aebi 2001). N-
glycans occur as part of the amino acid sequence N-X-S/T, where X is any residue 
apart from proline (Apweiler et al 1999). It is interesting that this sequence has 
been conserved twice within the C-lobe of transferrin, and that the C-lobe is also 
preferred for non-enzymatic glycation. As, in extracellular proteins, only about two 
thirds of potential N-glycosylation sites are utilised as such (Apweiler et al 1999), 
other influences must be involved, which may be relevant to non-enzymatic 
glycation.  
Efforts to determine the factors influencing residue preference within and adjacent 
to the N-X-S/T sequon, for N-glycans in archaeal protein, have found that simple 
properties, such as size or charge, did not appear to be explanatory (Igura & Kohda 
2010). However, N-glycosylation did occur more frequently within an extended 
protein conformation, where fully extended β-strands have successive residue side-
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chains projecting straight up, and then straight down from the protein back bone in 
a horizontal plane. This has also been noted in eukaryotic proteins, and in 60% of 
the 350 glycoprotein chains characterised within the Structural Assessment of 
Glycosylation Sites (SAGS) database (Petrescu et al 2006). Igura & Kohda (2010) 
suggest that the extended conformation allows a more efficient scanning by the 
glycan-catalysing enzyme oligosaccharyltransferase, coupled with the transient 
interaction of the required sequon with the active site of the enzyme, favouring 
glycan synthesis.  
Work on N-glycan positioning of 21 sites on one particular eubacterial protein (C. 
jejuni, Kowarik et al 2006) has also identified the requirement for aspartic acid or 
glutamic acid to be present at the -2 position N-terminally, of the glycosylated 
asparagine. Igura & Kohda (2010) propose that this suggests a turn in the 
secondary protein structure that brings the hydroxyl group of serine or threonine 
closer to the asparagine carboxamide group, to increase the nucleophilicity of the 
asparagine. This occurs post-translationally to the folded protein, and does not 
involve enzyme scanning, and is not influenced by an extended protein 
conformation.  
To draw relevance to non-enzymatic glycation positioning on transferrin, the 
requirement for the presence of glutamic acid or aspartic acid is familiar, occurring 
at 25% of the +1 position residues in the Orbitrap data (Table 26); although the 
position differs, and the reaction is enzymatic. As the pro-glycosylation effect of an 
extended, beta, conformation is effected within the endoplasmic reticulum, it is 
unlikely to have any influence on non-enzymatic glycation, and indeed there were 
169 
 
fewer glycations on beta strands (14) than on helices (17), with 8 on turns (Table 
27.). 
3.5.2 Glycation frequency by residue  
The Orbitrap data shows that the most frequently glycated residues in vitro are 
lysine (36.3% of glycated total), tyrosine (19.6%), asparagine (12.1%), and 
methionine (10.8%) (Table 23). When the top 4 residues Met309, Lys312, Tyr314, 
and Tyr317 are excluded the most frequently glycated residues are lysine (42.6%), 
asparagine (19.6%), aspartic acid (12.8%), and threonine (6.8%) (Table 25). Amino 
acid glycation frequency per frequency of amino acid occurrence in the native 
protein finds methionine, tyrosine, lysine, and asparagine the highest, in 
descending order (Table 24). Excluding the top 4 finds lysine, asparagine, aspartic 
acid, and tryptophan have the highest ratio (Table 25). Chetyrkin et al (2007) also 
found tryptophan to be vulnerable to glycation and oxidation within in vitro 
glycated lysozyme, and Halliwell & Gutteridge (2007) have highlighted the aromatic 
ring of tryptophan as particularly susceptible to oxidation by a range of free 
radicals. 
Compared to the top residues predicted by hydrophobicity (arginine, lysine, 
glutamine, and aspartic acid, Gallet et al 2000), it is surprising that no arginine 
residues were found to be glycated, although they were included in the search 
during mass spectrometry. Arginine is often cited as being a key glycation residue 
(Ahmed & Thornalley 2003, Sharma & Santhoshkumar 2009 for example). This 
might be explained by the observation that arginine occurs less frequently in 
transferrin compared with lysine, representing 3.8% of residues (the same as 
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tyrosine), whereas lysine is the second most common (after leucine), representing 
8.5% of residues (Table 24). However, tyrosine was frequently glycated despite its 
low occurrence rate, therefore other factors must influence this. Tyrosine, in 
common with tryptophan, has an aromatic ring, and is also vulnerable to oxidation 
(Halliwell & Gutteridge 2007) therefore may have a similar susceptibility to 
glycation.  
In some agreement with Priego-Capote (2010), of the 11 transferrin lysine glycation 
sites they identified (corresponding to Lys 233, 259, 296, 340, 365, 489, 496, 534, 
545, 569, and 657), the Orbitrap analysis found lysine glycations at: 233, 259, 365, 
496, and 569, all of which corresponded to glycated peptides in the Waters 
analysis. Priego-Capote et al only performed a light incubation (30 mM glucose for 
24 hours at 37°C), however a heavier degree of lysine glycation is seen compared to 
the 100mM, 14 day incubation used for the Orbitrap study. Priego-Capote et al 
used 50 µl reconstituted plasma added to 500 µl phosphate buffer, with 30 mM 
glucose. A very similar protein concentration was used, as total plasma protein is 
60-80 g/l, therefore 3.5 mg/50 µl, diluted 3.5 mg/550 µl, = ~ 1.93 mg/ml, compared 
with 2mg/ml buffer transferrin concentration used prior to Orbitrap analysis. This is 
suggestive of either: a pro-glycation influence by other plasma components, 
glycation reversal during the longer incubation, or increase or loss of glycation 
during processing prior to MS, in one or other (or both) of the samples. The 
Orbitrap findings may show lysine residues more vulnerable to glycation than 
others, and at higher glucose concentration (or lower protein concentration) the 
rest of the lysines identified by Priego-Capote et al may subsequently become 
glycated.  
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3.5.3 The influence of neighbouring residues 
In consideration of the nature of the neighbouring amino acids, the Orbitrap data 
found, in descending order, glutamic acid, serine, aspartic acid, and leucine to be 
the top 4 residues occurring +1 position C-terminally of all glycated residue types 
(Table 26). For glycated lysine only, glutamic acid was the most common, followed 
by proline, then serine, aspartic acid and isoleucine equally. This is not in 
agreement with Zhang et al (2011), who found that the most likely residues to 
occur +1 position C-terminally of the glycated lysine, in vitro, are leucine, serine, 
and glutamic acid. It is in some agreement with Johansen et al (2006), who 
identified the occurrence of glutamic acid and lysine to be common here. Analysis 
of the Waters’ in vivo data found that the amino acid most likely to occur +1 
position C-terminally of the trypsin-cleaved lysine following protein digest was 
aspartic acid, representing 17.8% of residues, followed by serine, lysine, and 
cysteine. The carboxylic acid group in acidic side-chains is thought to participate in 
the reaction (Watkins et al 1985). Presumably the combination of a negative charge 
and a functional hydroxyl group may be destabilising for the area, but the glycation 
occurs on the neighbouring lysine side-chain amine, which has a lower bond energy 
of ≤ 338.9 kJ/mol-1 (Luo & Kerr 2005), and a positive charge. Serine also has a 
hydroxyl group, but has a neutral charge, and leucine has two methyl groups, which 
are relatively unreactive.  
The Orbitrap data found one position N-terminally of the glycated residue in vitro, 
lysine, to be most frequent (30.4%), followed by arginine, glycine, and serine (Table 
26), whereas Zhang et al (2011) identified leucine, glutamic acid, and serine here. 
Again, the Orbitrap data agrees more with Johansen et al (2006), who found lysine, 
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valine, and leucine most frequent. There can be seen from the Orbitrap data a 
general tendency for glycation to favour sites that have a negatively charged 
residue C-terminally, and a positively charged residue N-terminally, however, other 
factors are also involved and the influences on glycation are evidently complex.  
3.5.4 Comparison between in vivo and in vitro glycated transferrin 
As different protocols and devices were used for the mass spectrometry, only 
general comparisons can be made between in vivo and in vitro results. The most 
striking difference between the two is the heavy glycation in vitro of Met309, 
Lys312, Tyr314, and Tyr317, near to the C-terminal end of the N-lobe, a region 
which has no glycation in vivo (Figure 34). The other, less notable, difference is 
Cys665 at the carboxyl end of the C-lobe where there appears to be a higher rate of 
glycation in vitro. In general, a broad agreement is seen. Surprisingly, less glycation 
has occurred overall in vitro with 100 mM glucose incubation, suggesting that apart 
from the glycation position differing, 14 day incubation with approximately 200 
mM glucose may provide a degree of glycation similar to that seen in vivo. 
Alternatively, glucose concentration of 100 mM in vitro may lead to formation of 
glycation aducts larger than those measured by MS, and the glycated residues 
measured may represent only a portion of the total. 
Residues Met309, Lys312, Tyr314, and Tyr317 are sited on an α-helix, close to the 
inter-lobe contact Arg308, which links to Asp376 via a salt-bridge (Table 27, Figure 
38). The other inter-lobe contact is between Asp240 and Arg678, and Asp240 was 
found to have a low level of glycation in vitro, and peptide glycation of both cases 
in vivo. As salt-bridges occur as hydrogen bonds between the positively charged 
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primary amine on the side-chain of lysine or arginine, and the negatively charged 
carboxylate on the side-chains of glutamic acid or aspartic acid (Dougherty 2006), 
glycation to this particular aspartic acid may follow the breaking of this bond, which 
has a weaker bond strength than the adjacent carbonyl double-bond in the side-
chain.
  
Figure 38. The interface between the two lobes of apo-transferrin 
Showing Arg308 in the NI-subdomain to Asp376 in the C1-
subdomain, and Asp240 in the N2-subdomain to Arg678 in the C1-
subdomain. This figure was originally published in the Journal of 
Biological Chemistry. Wally, J. Halbrooks, P. Vonrhein, C. et al. The 
crystal structure of iron-free human serum transferrin provides 
insight into inter-lobe communication and receptor binding. Journal 
of Biological Chemistry. 2006; Vol. 281: 24934 – 24944 © the 
American Society for Biochemistry and Molecular Biology. 
Reproduced and adapted with permission from the publishers. 
 
To identify reasons why the top 4 (Met309 to Tyr317) residues are heavily glycated 
in vitro, but not at all in vivo, one difference between the samples is that the in 
vitro protein is entirely in the apo-form, and therefore open in structure, allowing 
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solvent accessibility to parts of the protein that might otherwise be protected. The 
difference is not clear-cut however, as transferrin in vivo exists in four forms, in the 
following approximate proportions: apotransferrin (44.5%); monoferric transferrin 
(44.5%); holotransferrin (11.1%) (in Van Campenhout et al 2004). The N-lobe is 
preferred for iron-binding by human serotransferrin in vivo, in blood taken from 
the arm (Williams & Moreton 1980). Given the strength of glycation of the top 4 in 
vitro, and the concentration of apotransferrin occurring in vivo, it would seem 
unlikely that none of the in vivo peptides would be glycated at these sites, 
suggesting that structural changes due to iron loading is not the cause. Moreover, 
these residues lie within the central region of transferrin (Figure 36), not between 
the two sub-domains which close around and sequester the iron atom, and 
therefore the iron status of the protein should not affect solvent accessibility of the 
Met309 to Tyr317 region. 
3.5.5 Glycation of functional sites – iron binding 
The N- and C-lobes of transferrin open and close via a hinge connecting sub-
domains 1 and 2, which closes with a twisting action around the iron atom, and 
which is co-ordinated by an aspartic acid, two tyrosine residues, and a histidine. 
The iron is bound by two oxygen atoms from a carbonate anion, which is stabilised 
by an arginine and a threonine (Lambert et al 2005). Wally et al (2006) 
demonstrated that that in the apo-form the two lobes are equally open, and 
therefore differences in glycation position between the open and closed forms 
might be expected to occur within this iron-binding pocket. In fact, none of the 
eight iron-binding residues are glycated, despite tyrosine and aspartic acid being 
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prone to glycation in this experiment. In the C-lobe, one anion-binding residue is 
glycated (Thr457), as is Trp460, which lies adjacent to another proposed anion-
binding ligand in that group. Plotting the 3-dimensional structure may identify 
other glycated proteins sited within these clefts. No other glycations are seen 
proximal to binding residues. In the human serum samples glycated peptides are 
seen in the Thr457 region in both subjects, and in the Trp460 region in the diabetes 
sample, and as no other glycation was seen in vitro for 20 residues N-terminally, or 
15 residues C-terminally, it may be suggested that glycation to these important 
residues might be occurring in vivo. If that were the case, glycation of Thr457 would 
prevent carbonate anion-binding, and the provision of the two oxygen atoms 
required for iron-binding within the C-lobe. Failure of iron-binding within the C-
lobe may have a greater physiological effect than failure within the N-lobe, as a 
number of studies have indicated that C-lobe interaction with cell membrane 
transferrin receptors is stronger than that of the N-lobe, and that, in the mono-
ferric state, N-lobe iron-loaded transferrin may not bind to the transferrin receptor 
as effectively (Young et al 1984; Zak et al 1994, and Mason et al 1997, in Crichton 
2009). Cheng et al (2004) describe C-lobe-receptor binding within the C1 domain 
only, leaving C2 free to open and release the iron atom once internalised into the 
cell. In contrast, the N-lobe binds to the transferrin receptor at two sites, requiring 
the N1 and N2 domains, which is suggested to constrict lobe opening and iron 
release. 
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3.5.6 Receptor binding 
The human transferrin receptor is an 80 kDa transmembrane bilobed glycoprotein, 
capable of binding two mono- or diferric-transferrins. The complex is endocytosed, 
and the iron is released from the transferrin at acidic intracellular pH 5-6, probably 
by protonation of the carbonate anion and opening of the interlobe cleft. The apo-
transferrin remains attached to the receptor and is returned to the cell surface, 
where the extracellular pH of 7.4 causes the transferrin to disassociate from the 
receptor, and return to circulation. This is estimated to be repeated more than 100 
times within the life of the transferrin (in Crichton 2009). 
Consideration of glycation within the transferrin-receptor binding regions finds that 
two of the residues proposed as such are glycated, Lys365, and Ile366, in the C-lobe 
(Wally et al 2006). This peptide region is also glycated in both the in vivo samples, 
although alternative candidates for glycation are present. It would be interesting to 
repeat the Orbitrap procedure with human samples to establish the presence of 
glycation on proposed receptor binding residues as this would have implications for 
iron delivery to cells, if Lys365 and Ile366 are proven to be essential for protein 
docking. To speculate further, iron-loaded transferrin unable to discharge its load 
(and not lost via the kidney) would ultimately be taken up by hepatocytes, or 
macrophages, potentially leading to iron deposition in the liver, or within 
atherosclerotic plaques. However, Dineen et al (1994) found no difference in liver 
iron in post-mortem examination of 15 non-insulin-dependent diabetes sufferers, 
compared with 17 age-matched controls.  
Two cysteines involved in disulphide bonds were glycated, Cys355 and Cys665.  
Glycation on these cysteine side-chains may involve breaking the disulphide bonds 
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within the protein. Both of these are within the C-lobe, Cys355 is bound to Cys368, 
and Cys665 to Cys474. Cys368 is also a proposed receptor binding residue (Wally et 
al 2006), but in any case, loss of either bridge would be a significant structural 
impairment. Both Cys355 and Cys368 lie within glycated peptide regions in both in 
vivo samples.  
3.5.7 In vitro oxidation 
Oxidation is a common artefact of mass spectrometry, particularly to methionine, 
histidine, and tryptophan, and not surprisingly 49.3% of the 823 oxidized residues 
were methionine (Table 23).  Met389 and Met382 alone made-up 23.5% of the 
oxidations, and were part of a heavily oxidized region between Met382 and Asp392 
which included glycation at Asn383 (Figure 33). Two of the top 4 glycated residues 
were also subject to non-simultaneous oxidation (Tyr314 and Tyr317), with 
adjacent Met313 also prone to oxidation. It is a limitation of this study that without 
an unglycated control sample the degree of oxidation due to glycation cannot be 
determined, however, methionine oxidation in vivo is repairable by disulphide and 
methionine sulphoxide (MeSOX) reductases. Methionine and cysteine are 
particularly vulnerable to oxidation to the sulphur atom in vivo, however they are 
also the only proteins for which oxidation modifications can be repaired (Berlett & 
Stadtman 1997). Methionine has been suggested to operate as an ROS scavenging 
system, to protect irreparable proteins, based on the little apparent effect of 
oxidation on biological function (Levine et al 1996). Therefore, in vivo, unless the 
MeSOX antioxidant system fails or is overwhelmed, methionine (and cysteine) 
oxidation cannot be expected to contribute to protein damage by oxidation, 
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irrespective of whether or not the oxidation seen in vitro is a consequence of MS. 
The inclusion of a control sample might have determined whether these high levels 
of methionine and cysteine oxidation are linked to glycation. 
3.5.8 Comparison between Control and Diabetes – in vivo 
The Waters MS analysis identified 87 glycations in the Control sample, with an 
average peptide length, for all peptides, of 11.2 amino acids, and 10.6 for glycated 
peptides. The average length of all peptides for the diabetes sample was 12.7 
amino acids, average length for glycated peptides only was 12.9 (data not shown). 
The diabetes sample peptides may be longer on average than the Controls’, 
because glycated lysine is known to be resistant to trypsin cleavage, and therefore 
fewer cleavage sites are available. 
Many glycated peptides were common to both cases, particularly at the N-terminal 
end of the N-lobe, and within the C-lobe, corresponding to Asp24 and Lys27, and 
Asn553 and 555 in the in vitro sample. Consequently, these are regions that may be 
commonly glycated in vivo (Figure 33). 
It is difficult to quantitively compare the degree of glycation found in the two 
human samples with that reported in vivo in the literature, due to the differences 
in methodologies and units of measurement used. Van Campenhout et al (2006) 
reported µM fructosamine per gram transferrin (Table 15). Austen et al (1987) 
reported percent glycated (whole) protein (Table 16), finding 5.2% glycated (and 
therefore presumably 94.8% unglycated) in diabetes. Measuring glycated peptides 
as a result of MS does not account for how many glycated peptides there may be 
per protein, never-the-less, the rate of 39.5% of all peptides being glycated for the 
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Waters diabetes sample, and 34.9% for the control (Table 17), seems to be very 
high, and accords with the surprising finding of less glycation being present in the in 
vitro sample. The presence of two N-glycans does not explain this, as these 
modifications are larger than a glycation (in the oligosaccharide structure the first 
N-acetylglucosamine moiety alone has a molecular weight of 221.21 g/mol, larger 
than glucose, 180.16 g/mol), and would be identified by MS. In addition, no 
modification is reported in one of the glycan regions, Asn611. No obvious 
explanation for the high degree of glycation in vivo is apparent, and without being 
fully involved in the experimental procedure it is difficult to speculate on the cause. 
Analysis of a number of human samples through an Orbitrap device would provide 
useful and detailed information about this. 
3.6 Conclusion 
Due to the small number of samples, their assessment on different equipment, and 
the lack of a control sample for the in vitro sample, suggestions only can be 
inferred from these results.  
Using Orbitrap MS, a surprisingly large range of amino acids were found to be 
vulnerable to glycation in vitro, that has not been seen by other groups who have 
only searched for lysine glycation. Orbitrap MS should be used to determine 
whether a similar range is occurring in vivo, and if any of the functional sites found 
to be glycated in this single experiment in vitro also occur in vivo. 
In vitro transferrin glycation experiments such as this one, and those by other 
groups, may not produce results that are relevant in vivo, as 38.3% of all glycations 
found in vitro here were to four residues, all unglycated in vivo, which were also 
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associated with amino acid oxidations. Consequently they provide a likely region 
for protein fragmentation in vitro not seen in vivo, and suggest an explanation for 
the loss of in vitro transferrin function seen by this and other groups, which would 
have no equivalent in vivo. The loss of TIBC in vivo reported by Van Campenhout et 
al (2006a) can be explained by renal transferrin loss. Close to half of the oxidation 
sites observed were to methionine, and therefore potentially MS artefacts, or if 
not, likely to be repaired by MeSOX in vivo. If the later, they also represent 
modifications seen in vitro only, and will contribute to the protein oxidation and 
fragmentation found in this study and the studies of others. 
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Chapter 4. Non-transferrin-bound iron in type 2 diabetes 
“For the life of the flesh is in the blood.” 
Leviticus 17:11 
 
4.1 Aim 
To evaluate non-transferrin-bound iron in people with type 2 diabetes and 
controls, and to assess its association with haemoglobin glycation, lipid 
peroxidation, antioxidant status, and other iron parameters. To compare NTBI in 
people with and without diabetes, and with and without cardiovascular and renal 
disease. 
4.2 Background 
The potential for iron to be involved in advanced glycation end product 
development, and the known effects of glycation on some iron binding proteins in 
vitro, have led to the investigation of reactive plasma iron in people with type 2 
diabetes by several groups. Very little work has been done specifically on the links 
between NTBI, diabetes, and CVD, or renal disease, but much of the work done on 
iron and CVD, and iron and chronic kidney disease (CKD) has relevance. The effects 
of IV iron supplementation in CKD provide an additional view from an extreme 
vantage point. 
As discussed in Chapters 1 and 2, glycation of iron proteins in vitro alters their 
ability to interact with iron.  For transferrin, in vivo, the effects of glycation may be 
far less catastrophic (Chapter 3), and perhaps this is also the case for other glycated 
proteins in vivo. Haemoglobin glycation in vitro weakens the haem-globin structure 
(Sen et al 2005), and plasma and sub-endothelial free glycated haemoglobin may 
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represent a form of NTBI in diabetes. NTBI may correlate with HbA1c, as was found 
to be the case by Shetty et al (2008) (r = 0.436, P < 0.01), demonstrating this 
association, however Lee et al (2006) found an inverse correlation between the two 
(r = -0.28, P = 0.06). 
4.2.1 Cardiovascular disease and non-transferrin-bound iron 
Speculation has long been made that iron may be linked to cardiovascular risk in 
the general population, perhaps contributing to the reduced risk seen in females 
prior to menopause (Sullivan 1992). Extension of the theory to explain the 
increased risk in diabetes has quickly been proposed, in the half-light of the serum 
ferritin-iron status data (reviewed in Chapter 1).  
A review of the literature regarding iron status and cardiovascular risk, finds little 
agreement between studies. A table of relevant studies has been compiled (Table 
28), outlining the nature of the study, assessment method for iron status, outcome 
measures, and findings.   
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Table 28. Compilation of the literature regarding iron status and CVD risk - key points 
Author, year, and study Iron measures Outcome measures Results and Conclusion  
Salonen et al 1992 
n=1,931 M, 42 to 60 yrs, 
3 yr f-up 
sFt, Hb. No control for 
inflammation 
Acute myocardial 
infarct 
sFt > 200 µ/l gave a 2.2 fold risk of acute MI. Hb had no 
significant effect on risk when ferritin was controlled for 
 
 
Sempos et al 1992 
(NHANES II) n=1,604 M & 
F, < 16 yr f-up 
sFt. No control for 
inflammation 
Mortality from all 
causes, CVD, CHD, and 
MI 
Significant increased risk for African-American men sFt < 50 
µg/l. No other associations found 
 
 
Ascherio et al 1994 
(HPFS) 
n=44,933 M, 40 to 75 yrs, 
4 yr f-up 
Dietary iron intake 
(total and haem) 
 
Coronary events No significant association total, non-haem, or haem iron 
and CHD. Risk for MI increased non-significantly in quintile 
5 compared to 1. Highly significant risk for MI in quintile 5 if 
not taking vitamin E or multi-vitamin supplement 
 
 
 
Corti et al 1997  
Review of 11 studies 
 
Range of serum 
measures and dietary 
iron intake 
Association between 
iron status or intake, 
and CVD 
Higher iron states do not appear to be strongly associated 
with increased risk of CVD. The evidence is inconsistent; 
larger studies find an inverse relationship, with lower iron 
levels linked to adverse CVD outcomes. 
 
 
 
Danesh & Appleby 1999 
Meta-analysis of 12 
studies, n=7,800 CHD 
cases 
sFt (n=5), TSAT (n=5), 
TIBC (n=3), serum iron 
(n=3), dietary iron 
intake (n=3) 
 
CHD No good evidence was found for existence of strong 
associations between iron status and CHD 
 
 
Sarnak et al 2002 
n=14,410 M & F, 6.1 yr f-
up 
 
Hb: anaemia Y/N CVD event Anaemia was significantly associated with risk for CVD 
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Menke et al 2009 
n=2,662 M & F, (n=219 
with PAD) 
sFt, TSAT, CRP OR for peripheral 
arterial disease (PAD) 
Non-significant positive trends were seen between ferritin, 
and TSAT, and PAD. OR were calculated against tertile 1 
however, therefore possible negative influences of lowest 
tertiles may confound these results 
 
Zacharski et al 2007 
(FeAST) 
n=1,277 M & F with PAD, 
6 yr f-up. Phlebotomy 
(n=636), control (n=641) 
sFt: controls 122.5 ± 
87.2 µg/l ± SD; 
intervention 58.3 ± 31.3 
µg/l ± SD. 
 
All-cause mortality; 
death plus non-fatal 
MI and stroke 
No significant decrease seen with decreased sFt 
 
Ahluwalia et al 2010 
n=124 age sex matched 
pairs, +/-two or more 
carotid atherosclerotic 
plaques 
sFt, serum iron, sTfR, 
TSAT, Hb. AGP, hsCRP 
OR for two or more 
plaques 
When inflammation was controlled for by CRP, ferritin had 
a small non-significant influence on OR for plaques. When 
controlled by AGP, ferritin had a significant influence on OR 
for plaques (p = 0.03). There were no significant influences 
shown by the other iron parameters 
 
 
 
 
Menke et al 2011 
(NHANES III) 
n=12,258 M & F, 18yr f-
up 
sFt, TSAT, CRP All cause, CVD, or 
cancer mortality 
sFt and TSAT were not associated with risk for all-cause 
mortality 
 
 
Casiglia et al 2011 
(abstract) 
n=906 F, 10 yr f-up 
Dietary iron intake Cardio- and 
cerebrovascular 
events 
Low iron intake independently predicted cerebrovascular 
and coronary morbidity and mortality. Haem iron intake 
was not a predictor 
 
 
Morkdal et al 2011 
(abstract) 
n=28,154 M, 32,644 F, 
without MI or stroke. 
11.4 yr f-up 
TSAT, TIBC, serum iron RR for ischaemic heart 
disease mortality 
RR was higher in quartile 1 for TSAT, and serum iron, 
compared to quartile 4 for M&F, and for TIBC in F. In M, 
TIBC quartile 1 was slightly protective compared to quartile 
4. Low iron status may be a late sign of IHD pathology 
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Relevant study 
DePalma et al 2010, 
(FeAST) 
(sFt: 25 and 60 µg/l, 
n=51), control (n=49) 
sFt, statins, IL-6, hsCRP Mortality Positive correlations are found between sFt and IL-6 (r = 
0.185; P = 0.002), and hsCRP (r = .118; P = 0 .04). Statin use 
reduced ferritin levels independently of phlebotomy, 
indicating an effect of these agents on iron metabolism 
 
Key:    : support for high iron status and increased CVD risk;        : No support for high iron status and increased CVD risk;    : support for low iron 
status and increased CVD risk; AGP: α-1 acid glycoprotein; CRP/hsCRP: (high sensitivity) C-reactive protein; F: females; FeAST: Iron and 
Atherosclerosis Study; Hb: haemoglobin; HPFS: Health Professionals Follow-up Study; M: Males; NHANES II: National Health and Nutrition 
Examination Survey; OR: odds ratio; PAD: peripheral arterial disease; RR: relative risk; sFt: serum ferritin; TIBC: total iron binding capacity; 
TSAT: transferrin saturation. 
 
Table 29. Results of a meta-analysis of upper and lower threshold haemoglobin concentrations (with 95% CIs), and excess population 
risk of mortality attributable to low or high haemoglobin levels, in two patient groups (Shah et al 2011). 
Haemoglobin thresholds Stable angina  Post myocardial infarction  
 Women Men Women Men 
Lower threshold 
Haemoglobin level (g/dl) (95% CI) 11.9 (11.5–13.5) 13.1 (13.0–13.4) 12.8 (12.1–13.5) 13.5 (13.2–13.9) 
Relative risk of death below 
threshold (95% CI) 1.92 (1.44–2.38) 2.03 (1.72–2.40) 1.77 (1.51–2.10) 2.00 (1.76–2.29) 
Upper threshold 
Haemoglobin level (g/dl) (95% CI) 16.3 (14.0–17.5) 17.2 (13.6–18.0) 15.1 (13.9–16.6) 16.4 (15.1–17.8) 
Relative risk of death above 
threshold (95% CI) 2.65 (1.06–10.8) 1.11 (1.00–3.86) 1.81 (1.13–3.53) 1.14 (1.01–1.51) 
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From Table 28, it can be seen that the only significant association between serum 
ferritin and CVD risk is evident when inflammation is not controlled for (Salonen et 
al 1992). Serum ferritin has also been found to not be associated with risk when 
inflammation is not controlled for (Sempos et al 1992). A review (Corti et al 1997), 
and a meta-analysis (Danesh & Appleby 1999), found no consistent evidence for an 
association between iron status and CVD or CHD. Non-significant positive 
associations are reported when CRP is used to control for inflammation (Menke et 
al 2009, Ahluwalia et al 2010), but in a larger study no associations are found 
(Menke et al 2011). Compared with IL-6, CRP does not correlate as closely with sFT 
(DePalma et al 2010), and therefore the use of CRP to control for inflammation may 
be inadequate, and the results of studies controlled thus may still include 
inflammation as a factor in the level of risk seen. No benefit is seen with 
phlebotomy to lower serum ferritin (Zacharski et al 2007). Three studies find an 
association between CVD risk and low iron status (Sarnak et al 2002, Casiglia et al 
2011, Morkdal et al 2011). No association between higher Hb and CVD risk was 
found to be evident by Salonen et al (1992), Sarnak et al (2002), or Ahluwalia et al 
(2010).  
Shah et al (2011) (Table 29) conducted a meta-analysis of retrospective cohort 
studies totalling 20,131 people following diagnosis of stable angina with no 
previous CHD, and 14,171 people following myocardial infarction survival of seven 
days, for 3.2 years. They found additional mortality risks below and above a range 
of haemoglobin threshold levels, suggesting a U-shaped relationship between 
haemoglobin and CHD risk. 
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In conclusion, the literature does not clearly support a link between high iron status 
as measured by a range of iron indices and CVD risk. The evidence is stronger for 
low iron status and risk for CVD. From the conclusions of the meta-analysis by Shah 
et al (Table 29), there is an association between low Hb concentration and 
increased mortality, with evidence that high Hb is also associated with poor 
prognosis, although in the case of females with stable angina, the 95% confidence 
interval for relative risk is wide, suggesting some uncertainty in the result. No 
probability values are reported with the relative risk values. 
4.2.2 Non-transferrin-bound iron and cardiovascular disease risk 
Considering NTBI and CVD risk, Rajapurkar et al (2011) found a strong detrimental 
association between catalytic iron and prevalent CVD, in a cross-sectional study of 
496 middle-aged people of mixed health. When fully adjusted for confounding 
variables, the highest third by NTBI had an odds ratio of 3.8 (95% CI, 1.4 to 10.1) for 
CVD. NTBI was measured by the bleomycin assay (Gutteridge & Xiao-Chang 1981), 
finding a mean level for the lowest tertile of 0.04 µM, and 3.15 µM for the highest 
tertile. Disagreeing with this, Van der A et al (2006) found no increased risk of CHD 
or MI in their highest tertile of NTBI compared with the lowest, in 1132 women 
over a 4.3 year study. NTBI was measured at baseline using the method of Breuer & 
Cabantchik (2001), finding a range from -2.06 to 3.51 µM, where negative values 
are explained as describing the free iron scavenging effect of transferrin. 
Of the evidence for iron status in diabetes and link to CVD, Lee et al (2006) 
instigated their NTBI in type 2 diabetes study as a result of finding that diabetes 
patients who used supplemental vitamin C had increased CVD mortality. They 
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hypothesised that NTBI was causing this, and that increased oxidative stress was 
resulting from chemical reduction of ferric NTBI by ascorbic acid. Their results, and 
others, are given in Table 30. Sulieman et al (2004) (Appendix 1.ii) measured NTBI 
(method of Esposito et al 2003) in patients within 24 hours of acute MI, 329 with 
diabetes, 322 without. Mean NTBI in controls was 0.14 ± 0.23 (µM ± SD), compared 
with diabetes, 0.43 ± 0.7 (µM ± SD). The 30 day mortality rate was 2.5-fold higher in 
diabetes, and NTBI was associated with increased mortality at 30 days in the 
diabetes group only. Diabetes patients without NTBI had the same mortality risk as 
non-diabetes.  
Haptoglobin genotype is not reported in Sulieman et al’s study, but would be a very 
interesting addition to these findings, along with HbA1c, as the haptoglobin 2-2 
genotype might account for some or part of the increased mortality in diabetes. 
Glycated plasma haemoglobin may be detrimental via LDL oxidation, possibly from 
iron-linked redox toxicity from structural damage to haemoglobin (see Chapter 1). 
Such damage might account for the NTBI being measured in diabetes. 
4.2.3 Renal disease and non-transferrin-bound iron 
Physiological iron status in advanced renal disease is characterised by anaemia, as 
measured by transferrin saturation (particularly if receiving erythropoiesis 
stimulating agents), and the appearance of raised iron stores indicated by ferritin 
level (Wish 2006). This may be due to inflammation, which is common in CKD 
(Oberg et al 2004), as hepcidin (which prevents iron release from cells, including 
across the gut), and ferritin, are acute-phase proteins. Haemodialysis also leads to 
blood losses from frequent sampling, and residue remaining in dialyzer, 
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compounded by decreased oral iron intake (Wish 2006). Treatment with oral 
supplemental iron can lead to NTBI (Hutchinson et al 2004) (Appendix 1.ii), as can 
intravenous (IV) iron (Kooistra et al 2002, Slotki et al 2005). IV iron in haemodialysis 
patients leads to oxidative stress (Lim et al 1999), which is improved by 
supplemental vitamin E (Roob et al 2000). Lim et al do not say if IV iron is given 
concomitantly to haemodialysis treatment in their study, but simultaneous 
haemodialysis and IV iron (as commonly performed) might be more toxic than the 
two received separately. Kooistra et al found NTBI levels of 0.74 ± 0.69 to 3.79 ± 
1.41 µM in ten haemodialysis patients undergoing 100 mg iron infusion over 60 
minutes. NTBI levels were raised prior to IV infusion, compared to normal, but no 
controls were included in the study. Prakash et al (2005) found no increased NTBI 
in CKD patients compared with controls, but NTBI was significantly increased in 
haemodialysis patients not on intravenous iron therapy compared to CKD and 
controls. Patients receiving intravenous iron were not included in the study. No 
associated lipid peroxidation, or protein thiol formation, was found by FOX2 or 
5’5’dithio-bis(2-nitrobenzoic acid) (DTNB) assays, indicating that the NTBI was not 
redox active. Microhaemolysis was suggested to be a cause of NTBI in 
haemodialysis, by mechanical damage to red blood cell releasing haem, therefore it 
is surprising that no associated lipid peroxidation was seen.   
Miyata et al (1997) have shown that enhanced AGE formation in haemodialysis 
patients is not accounted for by elevated glucose levels, but is accelerated by 
increased oxidative stress, as measured by oxidised ascorbate.  This was a linear 
relationship, not seen in healthy controls, leading Miyata et al to suggest the 
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presence of an unknown catalyst in its development. This could be suggested to 
involve iron, either as concomitant IV iron or haem from red blood cell 
degradation.  
In uraemia, serum AGE build-up is observed irrespective of diabetes being present, 
or haemodialysis. Thornalley et al (2000) investigated serum albumin glycation in 
13 renal-function impaired uremic patients, finding renal impairment associated 
with a low but significant increase in albumin mass, perhaps caused by AGE 
formation, increased oxidation, or fatty acid binding. As glycated and oxidized 
albumin binds an increased amount of iron (Silva & Hider 2009, see Chapter 1), 
NTBI as an albumin-bound species would be a likely scenario in uraemia. 
Evidence for iron status and links to CKD include serum ferritin studies. Prakash et 
al (2005) did not find ferritin to be associated with NTBI in haemodialysis, however, 
Kalantar-Zadeh et al (2001) did find high serum ferritin to be a reliable predictor of 
morbidity in haemodialysis patients, though having previously demonstrated that it 
is likely to reflect inflammation rather than iron overload (Kalantar-Zadeh et al 
1999), perhaps the link with morbidity is not surprising.  
Replacing red meat with chicken as dietary protein for four weeks can reduce urine 
albumin excretion by 46% in diabetes patients with microalbuminurea (Gross et al 
2002), hinting at haem iron as a possible link. The authors do not include measures 
of ferritin, haemoglobin, or serum iron, and so it is not known what effect the diets 
are actually having on iron status. In rats with proteinuria and glomerular sclerosis, 
investigation of the effect of a low iron diet compared with normal (Remuzzi et al 
1991), found that reduction of haematocrit following iron restriction had a reno-
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protective effect, significantly lowering urine protein excretion compared with 
controls. The effect may have been due to lessening of local oxygen radical 
production, or an increase in blood viscosity and shear stress on glomerular 
capillary walls. The authors propose that anaemia may be protective in renal 
disease progression, and that normalising haematocrit may in fact contribute to its 
progression. 
Within the kidney, the presence of redox active iron is proposed to be a factor in 
the progression of kidney disease (Alfrey et al 1989, Howard et al 1991, 
Swaminathan et al 2007). Howard et al (1991) found that in patients with diabetes, 
with varying amounts of proteinuria, transferrin and albumin were leaked through 
the kidney equally. Urinary iron excretion increased early in the course of renal 
disease (pre-proteinuria) and became more marked as disease progressed. Iron 
was present in the urine in excess of transferrin at all stages, leading the authors to 
suggest that either a) the transferrin was being reabsorbed in the proximal tubule, 
or b) the iron was occurring by means other than transferrin filtration. In either 
case, the iron could be redox active and result in tubule-interstitial injury. Human 
biopsy studies in patients with proteinuria found that protein excretion correlated 
with iron accumulation in proximal tubular lysosomes, though not with glomerular 
filtration rate (Nankivell et al 1992).  
A mechanism for the involvement of NTBI in progression of renal disease has been 
proposed by Smith & Thevenod (2009). This model describes iron excretion, via 
glomerular filtration of transferrin, and re-absorption; with evidence from mouse 
and rat studies showing that in response to a reduction in dietary iron, divalent 
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metal transporter-1 (DMT-1) in the proximal tubular membrane increases, and 
decreases following dietary iron increase. Iron levels reflected these changes, and 
studies of iron in urine taken from the proximal tubule, and in excreted urine, had 
demonstrated that 99.3% of glomerular filtered iron was reabsorbed. These 
examples describe transferrin-iron filtration and reabsorption to varying degrees in 
the proximal tubule, where it may or may not subsequently cause oxidative 
damage. Diabetic nephropathy however is characterised by extracellular matrix 
thickening to tubule and to glomerular basement membranes, and so it might 
appear that diabetic glomerular damage comes about via AGE development 
(Kanwar et al 2008), without involvement of iron, whereas proximal tubule damage 
perhaps involve AGE and iron in tandem. 
Whilst the dietary intake data is suggestive of a reduction in iron status having a 
protective effect on protein loss in glomerular filtration, the mechanisms involved 
are not known. It is not known for example whether the detrimental effect is due 
to less post-prandial transferrin-iron present in the blood stream, or less stored 
iron leading over a longer period to less red blood cell haemoglobin, perhaps 
leading to less plasma haemoglobin. How any form of iron or NTBI species alters 
glomerular filtration is unknown, despite knowing it can be reabsorbed afterwards. 
4.2.4 Non-transferrin-bound iron methodologies 
No one standard method is used to measure NTBI, and a comparison study of the 
commonest of the methods used (Jacobs et al 2005) found significant variations in 
results within samples. The two methods most commonly used by researchers are 
the fluorescence-based assay described by Breuer & Cabantchik (2001), and high 
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performance liquid chromatography (HPLC) assay with nitrilotriacetic acid (NTA) by 
Singh et al (1990), with modification by Gosriwatana et al (1999). There are a 
number of problems with measuring NTBI – losing the low molecular weight iron 
ligands to vacant transferrin iron binding sites, and displacing and chelating iron 
from loaded transferrin sites. Methods that involve plasma or serum incubation 
with added ligands risk either of these.  
Early methods used antibiotic bleomycin to bind iron, and the subsequent DNA 
damage by this complex measured by reaction with thiobarbituric acid (Gutteridge 
& Xiao-Chang 1981). Jacobs et al found that the bleomycin method showed 
remarkably lower values of mean NTBI than other assays, with poor correlation 
between values, in their comparison. An alternative biological method, 
recommended by Halliwell & Gutteridge (2007), but rarely used in practice, 
involves use of the enzyme aconitase, following mobilisation by apoconalbumin, 
which was found to provide NTBI levels close to those found by the earlier 
bleomycin assay. Most recently, research has concentrated on development of 
fluorescent iron-chelating probes which can scavenge iron from iron-citrate 
complexes, and have a very slow exchange with apo-transferrin (Ma & Hider 2009). 
These are useful for monitoring iron-citrate in β-thalassemia patients (Hider et al 
2010). Gel filtration followed by inductively coupled mass spectrometry (ICP-MS) 
has usefully described glycated and oxidized albumin bound iron in vitro (Silva & 
Hider 2009), however this method is not suitable for serum as gel filtration cannot 
resolve albumin from transferrin-bound iron (Hider et al 2010). 
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Because NTBI is heterogeneous, different iron species may occur in different 
diseases, and in different tissues (Evans et al 2008), and NTBI present in diabetes 
may not be fully measured by some assays. In particular, increased iron on glycated 
and oxidized albumin is not picked up by NTA, and therefore assays employing NTA 
will under-report NTBI in diabetes (Silva & Hider 2009). Consequently, comparison 
between the results reported for diabetes is difficult, and the findings of the groups 
below are diverse. NTA-based assays may not give an accurate picture of NTBI in 
diabetes. Despite this, Lee et al (2006), and Leoncini et al (2008), find some 
agreement in levels for established diabetes, Lee et al with NTA, and Leoncini et al 
without. This suggests that deferrioxamine (DFO), used by Leoncini et al, may not 
displace glycated albumin-iron either. The DFO-iron complex has an association 
constant of pKa of 31 (Davis & Porter 2002), while the NTA-ferric iron association 
constant is 15.9 at 0.1 M KCL (Motekaitis & Martell 1993). The association constant 
for transferrin-iron binding is between 19 and 20 (Harris 1986). 
4.2.5 Methods and findings for non-transferrin-bound iron in diabetes  
Four studies of type 2 diabetes have included NTBI measures, using different 
methodologies (Table 30).   
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Table 30. Non-transferrin-bound iron reported in diabetes by other groups 
Authors (NTBI method) Controls Diabetes  Diabetes  
Van Campenhout et al (2006b)* 
(Breuer & Cabantchik 2001) 
 Type 2 diabetes Type 1 diabetes 
n = 100 n = 67 n = 39 
Age (years) 43.5  62.5  44  
HbA1c (%) 5.35  7.3  7.8  
Iron (μM) 18  15.5  16  
TSat (%) 27  24  26  
Hb (g/dl) No report No report No report 
NTBI (μM mean) 1.44  0.68  0.91  
Lee et al (2006)  
(Gosriwatana et al 1999) 
 Newly diagnosed  
type 2 
Type 2, 4-15 years  
post diagnosis 
n = 47 n = 49 n = 48 
Age (years ± SD) 58.3 ± 9.7 59.8 ± 9.7 58.9 ± 9.2 
HbA1c (% ± SD) No report No report 8.1 ± 1.7 
Iron (μM ± SD) 17.1 ± 7.5 21.5 ± 9.7 18.1 ± 6.0 
TSat (% ± SD) 32.0 ± 15.4 29.4 ± 11.7 33.0 ± 11.2 
Hb (g/dl ± SD) 13.1 ± 1.2 13.2 ± 1.6 14.2 ± 1.5a 
NTBI (μM mean ± SD) 0.04 ± 0.13 0.24 ± 0.29b 0.62 ± 0.43b 
Leoncini et al (2008) 
(Ferrali et al 1989) 
 Type 2 diabetes Type 1 diabetes 
n = 39 n = 51 n = 25  
Age (years ± SEM) 46.2 ± 0.8 68.8 ± 1.5 50.6 ± 3.1 
HbA1c (% ± SEM) 5.0 ± 0.2 7.5 ± 0.2
c 7.6 ± 0.2c 
Iron (μM ± SEM) No report No report No report 
TSat (% ± SEM) 26.6 ± 0.7 26.5 ± 1.6 26.1 ± 1.7 
Hb (g/dl ± SEM) No report No report No report 
NTBI (μM mean ± SEM) 0.10 ± 0.03 (n = 24) 0.53 ± 0.09d (n = 24) 
Shetty et al (2008) 
(Nilsson et al 2002) 
 Good control BG Poor control BG  
n = 40 n = 53 n = 50 
Age (years ± SD) 55 ± 8 50 ± 5 55 ± 10 
HbA1c (% ± SD) 6 ± 1 7 ± 1 11 ± 2
e 
Iron (μM ± SD) No report No report No report 
TSat (% ± SD) No report No report No report 
Hb (g/dl ± SD) No report No report No report 
NTBI (μM mean ± SD) 0.5 ± 0.2 0.8 ± 0.5 34.2 ± 27.5e 
Key: BG Blood glucose; * Data shown are approx. means of Male and Female results; a p 
< 0.01 known diabetes vs newly diagnosed and control; b p < 0.01 between groups; c p 
< 0.001 vs controls; d p < 0.001 vs controls; e p < 0.01 vs controls and good BG.
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Van Campenhout et al (2006) used the NTBI method developed by Breuer & 
Cabantchik (2001). This uses fluorescein-apo-transferrin (Fl-aTf) to chelate 
unbound iron, with readings taken as a ratio of two reagents of varying 
fluorescence. The serum apotransferrin sites are first blocked with gallium 
(Ga(Cl)3), then reaction-available iron is mobilised with oxalate. Serum and 
reagents are mixed in multiwell plates, with fluorescence determined after 1 hour 
in a microplate reader. Drawbacks are that not all the apotransferrin sites were 
filled, leading to some false positives, and that efforts to overcome this led to 
underestimation of NTBI, and failure to detect it at low levels. The Fl-aTf assay by 
Breuer & Cabanchik was included in Jacobs et al’s (2005) study of different 
methodologies, and was performed in three different laboratories using identical 
blockers and scavengers, but differing equipment, reagent preparation, and 
procedures. Jacobs et al found that of all the methods tested, the Fl-aTf assay, 
whilst variations in results were seen, had the optimal profile for reproducibility. 
Van Campenhout et al (2006) found significantly less NTBI in male controls than 
males with type 2 diabetes (1.08 ± 2.15 vs 1.37 ± 1.65 μM, mean ± SD, 
respectively). Significant differences were seen within each group between males 
and females. More NTBI was seen in female compared with male controls, and in 
males compared with females in both diabetes groups. Mean NTBI level for females 
with type 2 diabetes was -0.02 ± 1.87 μM. A high NTBI level was seen in female 
controls which did not appear to be due to undiagnosed haemochromatosis as all 
other iron measures were normal, and which are unexplained. The large spread of 
values was seen, and negative values were reported, which may have been due to 
movement of iron onto vacant transferrin sites. All groups had a sizeable 
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proportion (> 50%) positive for NTBI, with transferrin saturation < 40%. In 
explanation for their findings, Van Campenhout et al suggest that their assay may 
not be detecting the various different isoforms of NTBI equally, possibly 
overlooking differences due to diabetes and gender.  
Lee et al (2006) used the HPLC assay of Gosriwatana et al (1999), based on the 
method of Singh et al (1990). NTA is added to plasma to mobilise and chelate NTBI 
non-specifically bound to serum proteins, citrate, and low molecular weight 
ligands. This then undergoes ultrafiltration, and the iron content of the filtrate 
determined by HPLC, with 1,2-dimethyl-3-hydroxy-4(1H)-pyridinone (deferiprone, 
DHP, CP20, L1), the chromophore of which was read at 450 nm. A drawback of the 
method of Singh et al is that unsaturated transferrin might compete with low 
molecular weight iron complexes including the Fe-NTA ligand, leading to artificially 
low NTBI readings. Singh et al‘s method was modified by Gosriwatana et al with the 
addition of sodium-tris-carbonatecobalt (lll), to block free transferrin binding sites. 
Variations on this method use additional chelators such as 3-hydroxyl-1-propyl-2-
methyl-pyridin-4-one hydrochloride (CP22) (Kime et al 1996, Buonocore et al 2003), 
and final NTBI detection by colorimetry or inductively coupled plasma mass 
spectrometry (ICP-MS), although these appear to be rarely used. Gosriwatana et 
al’s method, with both colorimetry and ICP-MS detection, was included by Jacobs 
et al and found to have an elevated within-sample variation, suggesting it to be less 
favourable than the Fl-aTf assay, although full comparisons were difficult to make 
due to the negative values found by some of the methods. Lee et al (2006) filtered 
through Millipore Microcon YM-30, 30 KDa filters.  
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Lee et al (2006) found NTBI levels  in controls and established type 2 diabetes to be 
0.04 ± 0.13 and 0.62 ± 0.43 (μM, mean ± SD, respectively), and differed significantly 
between the controls and both newly diagnosed and established diabetes. NTBI 
was present in 91.7% of patients at 4 to 15 years post-diagnosis, 59.2% of newly 
diagnosed patients, and 10.6% of controls.  
Leoncini et al (2008) used the method of Ferrali et al (1989), whereby plasma 
samples were reacted with desferrioxamine (DFO), which chelates any available 
iron forms, producing ferrioxamine. This is ultrafiltrated through 30 kDa filters, and 
excess DFO removed by silica column chromatography. The remaining DFO-iron 
complex is determined by HPLC detection at 229 nm. Leoncini et al found NTBI 
levels of 0.10 ± 0.03 and 0.53 ± 0.09 (μM, mean ± SEM), in control and diabetes 
respectively, with significant difference seen between groups. 
Shetty et al (2008) used Nillson et al’s 2002 bathophenantroline disulphonate (BPS) 
assay. BPS is added to plasma samples and left to stand for 15 minutes. The BPS 
binds to ferrous iron with a binding constant of pKa 22 (Perrin, in Nillson et al) to 
produce a measurable colour, and to ferric iron which is measurable after 
reduction, typically via ascorbate. In Nillson et al’s method, samples are then 
filtered through a “MultiScreen filtration system” with a pore size of 0.45 μm, 
through which all individual plasma proteins could be expected to pass. Shetty et al 
do not specify a pore size, and did not respond to a request for clarification of this 
point. The sample is read by spectrophotometry at 535 nm, and results found by 
subtracting the value of an equivalent sample without BPS. Shetty et al found 
extremely high levels of NTBI in diabetes patients with poor glucose control, 34.2 ± 
27.5 μM, mean ± SD. Healthy controls had 0.5 ± 0.2 μM, and diabetes patients with 
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controlled blood glucose to have 0.8 ± 0.5μM (mean ± SD). Similarly high levels 
were found by this group in haemodialysis patients, 10 out of 22 of whom had 
diabetes (the controls had ~3 μM) (Prakash et al 2005). These levels seem 
unfeasibly high, and perhaps the method may include measurement of glycated 
albumin-iron, However, as there is no agreement on the number of iron atoms that 
will bind to albumin, and it is not known how many more might bind to glycated 
albumin (see Chapter 1), it is not possible to say whether these figures are a likely 
representation of those which might be seen in diabetes. As Shetty et al’s reported 
levels for the newly diagnosed, and control groups, are not unfeasibly high by other 
reports, it is possible that they might be correct. However, the association constant 
for BPS is 22, less than the DFO-iron constant of 31, which could not chelate 
glycated albumin-iron in Leoncini et al’s study, and therefore BPS would not be 
expected to do so either. Another reason for Shetty et al’s high NTBI levels may be 
due to the chelation of iron from transferrin or plasma haemoglobin by BPS, 
although Nillson et al report in their original description of the assay that this did 
not occur even after a three-hour incubation. 
4.2.6 Summary 
Some agreement is seen for levels of NTBI in diabetes, and one study has found a 
link between NTBI, diabetes, and cardiovascular mortality. In renal disease, NTBI is 
seen following IV supplementation, and in haemodialysis, but NTBI has not yet 
been measured in CKD patients prior to dialysis. It is not known what form NTBI 
takes in diabetes, other than that glycated albumin-bound iron is thought to occur 
and not be picked-up by methods that use NTA to mobilise NTBI prior to 
measurement. Plasma and sub-endothelial extracellular glycated haemoglobin may 
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represent a form of NTBI in diabetes. HbA1c is used here as a marker for total 
protein glycation, and correlation of NTBI with HbA1c is used to investigate the 
presence of association between NTBI and protein glycation. Two studies disagree 
completely on this association, therefore a third investigation is justified. 
Correlation of NTBI with HbA1c will not demonstrate that extracellular glycated 
haemoglobin is a source of NTBI, as glycated haemoglobin correlates well with 
other glycated proteins such as albumin. However, additional correlation, if any, 
between NTBI and extracellular haemoglobin might suggest this to be the case. If 
an increased presence of NTBI is found in those with vascular and renal 
complications, and a source can be suggested, this would be a useful contribution 
for directing future interventional work. 
Our laboratory has developed a method for measuring NTBI based on published 
techniques, and it has been employed to measure NTBI in a cross-section of people 
with and without type 2 diabetes. Both groups have a range of cardiovascular and 
renal function profiles. This will provide valuable additional information on NTBI, 
iron and antioxidant status, and lipid peroxidation, along with other clinical 
biochemistry and anthropometry parameters. The measurement of NTBI in CKD 
patients prior to dialysis is reported for the first time.   
4.3 Hypotheses 
H1   NTBI will correlate with HbA1c in type 2 diabetes and controls. 
H2   NTBI will correlate with extracellular (plasma) haemoglobin in type 2 diabetes 
and controls. 
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H3 NTBI will correlate with lipid peroxidation, measured by plasma 
malondialdehyde, in type 2 diabetes and controls. 
H4   NTBI will correlate with reduced plasma ascorbate, in type 2 diabetes and 
controls. 
H5   In people with type 2 diabetes levels of NTBI will differ in those with pre-
established cardiovascular disease (a history of myocardial infarct, bypass surgery, 
stent, angina, stroke, transient ischaemic attack), compared to controls with 
cardiovascular disease. 
H6   In people with type 2 diabetes levels of NTBI will differ in those with chronic 
kidney disease (CKD) (established by assessment of albuminuria, glomerular 
filtration rate, plasma creatinine, and blood pressure) compared to controls with 
CKD. 
4.4 Materials and Methods 
See Appendix 3.i for laboratory protocols, solutions, and equipment. 
4.4.1 Measurement of non-transferrin-bound iron 
The NTBI method used is a development of the methods of Singh et al (1990), Kime 
et al (1996) as described above, and Paffetti et al (2006). Kime et al use NTA 
mobilisation of loosely-bound iron (100 µl plasma plus 10 µl 0.8 mM NTA pH 7.0, 
for 20 minutes at room temperature (RT), samples are then diluted in an equal 
volume of 5 mM 3-morpholinopropanesulfonic acid (MOPS) buffer, left to stand for 
10 minutes at RT, then 130 µl sample is placed in a 100 kDa Whatman 
ultracentrifuge filter and centrifuged at 12,000 x g for 30 minutes and 4°C. The 
filtrate is placed in a 20 kDa Whatman ultracentrifuge filter and centrifuged at 
202 
 
12,000 x g for 30 minutes and 4°C, filtrates held on ice until HPLC. Iron is detected 
following reaction with CP22 dissolved within the mobile phase (3 mM CP22 made 
up in 5 mM MOPS pH 7.0, 800 ml of this added to 200 ml acetonitrile, filtered and 
degassed. Kime et al found iron contamination in their blanks (mean 1.75 µM), 
which was traced to the Whatman filters, and consequently sample values were 
calculated following subtraction of the mean value for contiguous blanks. They 
report assay sensitivity down to 0.02 µM, recovery following spiked plasma of 
between 92.0 and 99.2%, intra-batch coefficient of variation of 5.13%, and inter-
batch coefficient of variation of 9.97% (but do not give a concentration of iron used 
for these). 
Paffetti et al (2006) use 50 µl of plasma, to which is added 5 ml of 0.8 M NTA, 
incubated for 30 minutes at RT, then diluted with an equal volume of 5 mM PIPES 
buffer, then left to stand for 20 minutes at RT. The samples are then filtered using 
100 kDa Whatman Vecta-Spin ultracentrifuge filters, at 13,660 x g, 4°C, for 40 
minutes. The filtrate is then filtered again through 20 kDa filters under the same 
conditions. The injected sample reacts with CP20 (Deferiprone, DHP) within the 
mobile phase (3.5 mM DHP in 5 mM PIPES buffer pH7.0, plus 4% acetonitrile).  
Using two filtration steps makes these assays lengthy and expensive, and increases 
the possibility of contamination. Experimentation by our laboratory with different 
filters has led to development of a reliable method using a single filtration step. 150 
µl of plasma is added to 15 µl of 0.8 M NTA, incubated for 20 minutes at RT, then 
diluted with 150 µl PBS. Samples are then filtered through 30 kDa Millipore Amicon 
Ultra filters, at 13,000 x g, 4°C, for 30 minutes. The filtrates are held on ice. Prior to 
HPLC injection, 150 µl of filtrate received 15 µl 50 mM DHP and incubated for 5 
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minutes. The mobile phase consists of 3.5 mM DHP in 5 mM PIPES buffer pH7.0, 
plus 5% acetonitrile.  
4.4.2 Non-transferrin-bound iron assay performance – coefficient of variation 
The results of the measurement of standards over a 24 month period have been 
collated to find mean and SD values (Table 31, Figure 39). The standard size most 
frequently used for finding plasma NTBI are 1, 5, and 10 µM (Figure 40). 
Table 31. NTBI assay compilation of standards 
Absorbance at 450 nm (AU) 
Fe3+ µM Mean SD n 
0.5 0.006 
 
1 
1 0.019 0.008 26 
2 0.035 0.008 9 
5 0.078 0.022 32 
10 0.155 0.051 26 
20 0.315 0.127 2 
30 0.576 0.082 5 
 
 
 
Figure 39. NTBI assay compilation of standards  
(Mean and SD). For sample size see Table 31. 
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Intra-day precision test of four 1 µM ferric iron standards found a coefficient of 
variation of 21.9% (mean 0.023, SD 0.005 AU), tested on a single day. Inter-day 
CV% over 24 months was found to be 43.2% (Table 32). This is high, however it is 
the result of standards made freshly on the day, and therefore contains pipetting 
errors. The coefficient of variation given by other groups, for example Paffetti et al 
(2006), used stored aliquots of a single spiked pooled plasma batch for assay intra- 
and inter-batch precision. 
The system was found to give linear measurements of iron standards down to 500 
nM.  
Table 32. NTBI assay coefficient of variation 
Absorbance at 450 nm (AU) 
Ferric iron standard Mean SD CV 
1 µM (n=26) 0.019 0.008 0.432 
5 µM (n=32) 0.078 0.024 0.309 
10 µM (n=26) 0.155 0.051 0.332 
 
 
Figure 40. NTBI assay standards over 24 months 
(Mean and SD, Table 32. 
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4.4.3 Study subjects and design 
Subjects were a sub-group of recruits to the SUMMIT (Surrogate Markers for 
Micro- and Macro-vascular Hard Endpoints for Innovative Diabetes Tools) Study, 
taking place at The Diabetes and Vascular Medicine Research Centre, University of 
Exeter. SUMMIT is a pan-European research consortium funded by the Innovative 
Medicines Initiative (IMI), involving 24 universities, research centres, and 
pharmaceutical companies, over a five year period. The Exeter cohort comprises 
450 participants, made up of type 2 diabetes patients with manifest CVD, type 2 
diabetes patients without CVD, and non-diabetic controls. Samples from 
participants eligible for the NTBI study were included from their baseline visit to 
the SUMMIT study at Exeter. Sample collection began in April 2011, and ran until 
the end of the NTBI study period, in April 2012.  
4.4.4 Assignment of work 
The candidate is responsible for the following work: development of ideas and 
hypotheses in this thesis, assay of NTBI, total iron, total iron binding capacity, 
unsaturated iron binding capacity, transferrin saturation, malondialdehyde, 
reduced and oxidized ascorbate, extracellular (plasma) haemoglobin; compilation 
and statistical analysis of data. All other work contributing specifically to the 
results, including participant recruitment and contact, anthropometry, all other 
clinical biochemistry and measures of physiology, were carried out by the SUMMIT 
study research team in Exeter and the laboratories at the Royal Devon and Exeter 
Hospital, Wonford. 
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4.4.5 Ethical considerations 
Ethical permission was granted by the South West regional ethics committee, study 
number: 10/H0206/67, and the local ethical committees of The Royal Devon and 
Exeter NHS Foundation Trust, University of Exeter, and Plymouth University. 
4.4.6 Statistical considerations 
Statistical analyses were carried out by IBM SPSS software, version 19. Parametric 
and non-parametric methods were employed as required, and are specified within 
the results. All tests of central tendency used independent samples testing. All tests 
were 2-tailed, with significance level set at 0.05.  
4.4.7 Sample size  
For median testing of NTBI between groups (type 2 diabetes versus controls), the 
numbers used by the four previous NTBI in diabetes investigations have been 
repeated. As Lee et al (2006), using a similar HPLC assay to our own, found highly 
significant differences between the groups, these numbers can be expected to be 
sufficiently powerful for our own analysis. 
4.4.8 Inclusion and Exclusion criteria 
Inclusion criteria were: older than 18 years; type 2 diabetes patients with manifest 
CVD or CKD, type 2 diabetes patients without CVD or CKD, non-diabetic controls 
with and without CVD and CKD, hypertension, dyslipidaemia, angina, proteinuria, 
rheumatoid and osteoarthritis.  Subjects receiving medications including insulin 
were included and the drugs and dosages recorded. Subjects receiving oral 
supplemental iron were included as blood samples were taken in the fasted state, 
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prior to supplement intake. Iron supplementation was recorded. Pre-menopausal 
females were included and their status noted. 
Subjects were excluded on grounds of any malabsorption disease, peritoneal 
dialysis or haemodialysis, cancer, any known communicable disease. 
4.5 Results 
The characteristics of the two sample groups, probability values for differences in 
central tendency, and correlations, are given in Table 33 and Table 34. Significant 
differences are seen in BMI and body fat % (higher in diabetes), and 
malondialdehyde (MDA) (lower in diabetes) (Table 33). A highly significant 
difference is seen for white blood cell count (higher in diabetes, Table 34), and very 
highly significant differences are seen in HbA1c (higher in diabetes), and total 
cholesterol and LDL (lower in diabetes) (Table 33).   
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Table 33. Group characteristics – anthropometry, lipids, and antioxidant 
status 
Group characteristics – anthropometry, lipids, and antioxidant status 
  
  Female (n) Male (n) Total (n) 
Gender Control 7 17 24 
 Diabetes 18 36 54 
  
 
 
Mean 
 
SD 
T-test between 
groups,  P 
Age  
(years) 
Control 66.5 9.3  
Diabetes 69.3 11.6 0.309 
BMI  
(kg/m2) 
Control 25.6 9.3  
Diabetes 30.5 6.1 0.028* 
Waist-hip ratio Control 0.89 0.21  
Diabetes 1.01 0.35 0.155 
Body fat  
(%) 
Control 28.0 8.0  
Diabetes 33.6 9.2 0.016* 
HbA1c  
(mmol/mol) 
Control 40.0 4.4  
Diabetes 55.6 10.8 <0.001*** 
Systolic blood pressure 
(mmHg) 
Control 134.8 17.8  
Diabetes 129.1 24.1 0.337 
Diastolic blood pressure 
(mmHg) 
Control 75.8 7.0  
Diabetes 73.2 14.1 0.299 
Total cholesterol 
(mM) 
Control 5.3 1.0  
Diabetes 4.1 1.0 <0.001*** 
Triglycerides 
(mM) 
Control 1.5 0.9  
Diabetes 1.5 0.9 0.722 
HDL 
(mM) 
Control 1.6 0.5  
Diabetes 1.2 0.3 0.313 
LDL 
(mM) 
Control 3.1 0.9  
Diabetes 2.0 1.0 <0.001*** 
Total/HDL ratio Control 3.7 1.1  
Diabetes 3.9 3.0 0.676 
Ascorbate1 Control 33.41 2.94 to 67.62  
(Reduced) (µM)      Diabetes 21.53 0.00 to 59.96 0.285 
Ascorbate  Control 3.47 2.48  
(Oxidized) (µM) Diabetes 4.08 5.05 0.490 
Urate  
(µM) 
Control 
Diabetes 
349.7 
337.8 
90.0 
78.8 
 
0.573 
Malondialdehyde  Control 2.48 0.82  
(µM) Diabetes 2.00 1.18 0.041* 
 Key: *P < 0.05; **P < 0.01; *** P < 0.001; 1 non-normal distribution, median & range 
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Table 34. Group characteristics – iron, and blood cell indices 
Group characteristics – iron, and blood cell indices 
  
  No NTBI (n) NTBI (n) Total (n) 
Non-transferrin-bound iron  Control 5 (20.8%) 19 (79.2%) 24 
present  Diabetes 20 (37.0%) 34 (63.0%) 54 
 Total 25 53 78 
  
Median 
Range 
Minimum 
Range 
Maximum 
Non-transferrin-bound iron 
(µM) (non-normal distribution) 
Control 0.34 0.00 1.08 
Diabetes 0.21 0.00 1.34 
 Independent samples median test                           P = 0.326  
  
 
 
Mean 
 
SD 
T-test between 
groups,  P 
Total iron  
(µM) 
Control 19.0 6.56  
Diabetes 17.9 7.56 0.557 
Total iron binding capacity 
(µM/ml) 
Control 50.9 13.9  
Diabetes 53.9 12.1 0.377 
Transferrin saturation  
(%) 
Control 39.9 16.7  
Diabetes 35.2 17.0 0.262 
Unsaturated iron binding 
capacity (µM/ml) 
Control 32.0 15.8  
Diabetes 36.0 15.2 0.304 
Plasma haemoglobin
1
 
(g/l)      
Control 0.26 0.05 to 4.00  
Diabetes 0.38 0.00 to 1.90 0.092 
Whole blood haemoglobin 
(g/dl) 
Control 13.7 0.98  
Diabetes 13.3 1.33 0.104 
Red blood cell count 
(x 1012/l) 
Control 4.50 0.35  
Diabetes 4.46 0.32 0.574 
Haematocrit  
(%) 
Control 0.40 0.02  
Diabetes 0.39 0.03 0.157 
Mean corpuscular volume  
(x 1014 l/cell) 
Control 87.9 3.29  
Diabetes 86.7 5.41 0.236 
Mean corp.  haemoglobin 
(x 1011 g/cell) 
Control 30.5 1.30  
Diabetes 29.8 2.35 0.098 
Red blood cell distribution 
width (%) 
Control 13.2 0.61  
Diabetes 13.5 1.11 0.152 
White blood cell count Control 5.62 1.27  
(x 109/l) Diabetes 6.57 1.39 0.007** 
Platelets Control 223.5 40.6  
(x 109/l) Diabetes 236.5 56.2 0.322 
Key: *P ≤ 0.05; **P ≤ 0.01; *** P ≤ 0.001; 1 non-normal distribution, median & range 
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4.5.1 Non-transferrin-bound iron 
Within all cases, 25 of the 78 participants had no detectable NTBI. Frequency 
distributions for all cases are shown in Table 34, and Figure 41. The data has a non-
normal, right-skewed distribution and therefore non-parametric methods are used 
for testing central tendency and associations with other variables.  
 
Figure 41. Non-transferrin-bound iron distribution of values 
All cases (n = 78). 
 
NTBI is seen to correlate positively with LDL (P = 0.005) (Figure 42), 
malondialdehyde (P < 0.001) (Figure 53), total plasma iron (P < 0.001) (Figure 43), 
transferrin saturation (P < 0.001) (Figure 44), haemoglobin (P = 0.001) (Figure 45), 
haematocrit (P = 0.002) (Figure 46), mean corpuscular haemoglobin (P = 0.004) 
(Figure 47), and red cell distribution width (P = 0.044) (Figure 48). 
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Figure 42. Correlation between low density lipoprotein and NTBI 
All cases (n = 78, r = 0.324, P = 0.005). 
 
 
Figure 43. Correlation between total iron and NTBI 
All cases (n = 78, r = 0.460, P = 0.000). 
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Figure 44. Correlation between transferrin saturation and NTBI  
All cases (n = 78, r = 0.407, P = 0.000). 
 
  
Figure 45. Correlation between haemoglobin and NTBI 
All cases (n = 75, r = 0.386, P = 0.001). 
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Figure 46. Correlation between haematocrit and NTBI 
All cases (n = 75, r = 0.355, P = 0.002). 
 
 
Figure 47. Correlation between mean corpuscular haemoglobin and NTBI 
All cases (n = 75, r = 0.326, P = 0.004). 
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Figure 48. Correlation between red cell distribution width and NTBI 
All cases (n = 75, r = -0.233, P = 0.044). 
 
4.5.2 Hypothesis testing 
4.5.2.1 H1 NTBI will correlate with HbA1c in type 2 diabetes and controls. 
The null hypothesis is retained. No correlation is seen between NTBI and HbA1c (r = 
-0.167; P = 0.155) (Figure 49), with results suggestive of a slight negative trend. 
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Figure 49. The relationship between HbA1c and Non-transferrin-bound iron 
All cases (n = 78, r = -0.167; P = 0.155). 
 
No significant difference is seen in in median NTBI in the control group 
compared to type2 diabetes (P = 0.326), (Figure 50). 
 
Figure 50. Non-transferin-bound iron in Controls and Type 2 Diabetes 
Controls (n = 24), Type 2 Diabetes (n = 54, P = 0.326 for difference 
between medians). 
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4.5.2.2 H2 NTBI will correlate with free plasma haemoglobin in type 2 diabetes and 
controls. 
The null hypothesis is retained. No correlation is seen between NTBI and 
extracellular haemoglobin (r = -0.056; P = 0.640), (Figure 51).   
 
 
Figure 51. Extracellular haemoglobin vs Non-transferrin-bound iron 
All cases (n = 73, r = -0.056; P = 0.640). 
 
No significant difference is seen between medians for Controls or Type 2 diabetes 
(P = 0.092) (Figure 52). 
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Figure 52. Extracellular plasma haemoglobin in Controls and Type2 Diabetes 
Controls (n = 23), Type 2 Diabetes (n = 50, P = 0.092 for difference 
between medians). 
 
4.5.2.3 H3 NTBI will correlate with lipid peroxidation, measured by plasma 
malondialdehyde, in type 2 diabetes and controls. 
The null hypothesis is rejected. With all cases pooled, NTBI positively correlates 
very highly significantly with MDA (0.440, P < 0.001) (Figure 53). Within controls, 
NTBI correlates very highly significantly with MDA (r = 0.707, P < 0.001) (Figure 54). 
Within type 2 diabetes, a significant correlation is seen (r = 0.311, P < 0.022) (Figure 
55). 
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Figure 53. The relationship between Non-transferrin-bound iron and 
Malondialdehyde 
All cases (n = 78, r = 0.440, P < 0.001). 
 
 
Figure 54. The relationship between Non-transferrin-bound iron and 
Malondialdehyde, Controls  
Controls (n = 24, r = 0.707, P < 0.001). 
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Figure 55. The relationship between Non-transferrin-bound iron and 
Malondialdehyde, Type 2 diabetes  
Type 2 Diabetes, (n = 54, r = 0.311, P < 0.022). 
 
Significantly less malondialdehyde is seen in the type 2 diabetes group compared 
with controls (P = 0.041) (Figure 56). 
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Figure 56. Malondialdehyde in Controls and Type 2 Diabetes 
Controls (n = 24), Type 2 diabetes (n = 54) (mean and SD, P = 0.041 
for difference between means). 
 
4.5.2.4 H4 NTBI will correlate with chemically reduced plasma ascorbate, in type 2 
diabetes and controls. 
The null hypothesis is retained. No significant trend is seen between NTBI and 
reduced ascorbate, by non-parametric correlation, all cases (n = 78, r = 0.168, P = 
0.149) (Figure 57).  
* P = 0.041 
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Figure 57. Correlation between NTBI and reduced ascorbate 
All cases (n = 75, r = 0.168, P = 0.149). 
 
No significant difference is seen between groups for median values (P = 0.285) 
(Figure 58). 
 
Figure 58. Chemically reduced ascorbate in Controls and Type 2 Diabetes 
Controls (n = 24) and Type 2 diabetes (n = 51, P = 0.285 for difference 
between medians). 
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4.5.2.5 H5 In people with type 2 diabetes levels of NTBI will differ in those with pre-
established cardiovascular disease (a history of myocardial infarct, bypass surgery, 
stent, angina, stroke, transient ischaemic attack), compared to controls with 
cardiovascular disease. 
The null hypothesis is retained. No significant difference is found between medians 
for NTBI across groups, by independent samples median test (P = 0.379) (Table 35, 
Figure 59). 
Table 35. NTBI in type 2 diabetes and Controls with co-morbidities 
NTBI in type 2 diabetes and Controls with co-morbidities 
 N NTBI  
Median (µM) 
Range P 
Control 
Diabetes 
24 
54 
0.34 
0.21 
0.00 to 1.08 
0.00 to 1.34 
 
0.326 
Control + Cardiovascular disease 
Diabetes + Cardiovascular disease 
8 
15 
0.46 
0.29 
0.00 to 1.08 
0.00 to 1.34 
 
0.426 
Control + Chronic kidney disease 
Diabetes + Chronic kidney disease 
18 
38 
0.20 
0.21 
0.00 to 1.03 
0.00 to 1.02 
 
0.272 
 
Table 36. Group characteristics and NTBI – cardiovascular disease 
Group characteristics – Cardiovascular disease 
Cardiovascular disease (History 
myocardial infarct, bypass surgery, 
stent, angina, stroke, transient 
ischaemic attack) 
 No CVD (n) CVD (n) Total (n) 
Control 15 (65.2%) 8 (34.8%) 23 
Diabetes 38 (71.7%) 15 (28.3%) 53 
Total 53 23 76 
NTBI (µM, median & range) 
No CVD CVD P 
0.19 (0.00 to 1.02) 0.31 (0.00 to 1.34)      0.212 
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Figure 59. Non-transferrin-bound iron in Controls and Type 2 Diabetes, 
without and with CVD 
Controls without and with CVD (n = 15; n = 8), Type 2 diabetes 
without and with CVD (n = 38; n = 15).  
 
When all cases are pooled no significant difference is found in NTBI between those 
without and with pre-established vascular disease (P = 0.212 for independent 
samples median test) (Table 36). A trend towards more NTBI is seen in the CVD 
group (median 0.19 for subjects without CVD, compared to 0.31 µM in CVD, P = 
0.212 (Figure 60). Comparing this result with others, Rajapurkar et al (2011) 
detected less NTBI generally, though found a significant median increase in CVD 
compared to no CVD in a cohort with mixed morbidities (0.10 µM compared to 0.21 
µM in CVD) using the bleomycin detectable iron assay.  
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Figure 60. Non-transferrin-bound iron in all cases, without and with CVD 
All cases, without CVD (n = 53), with CVD (n = 23, P = 0.212 for 
difference between medians).  
 
4.5.2.6 H6 In people with type 2 diabetes levels of NTBI will differ in those with 
chronic kidney disease (CKD) (established by assessment of albuminuria, glomerular 
filtration rate, plasma creatinine, and blood pressure) compared to controls with 
CKD. 
The null hypothesis is retained. No significant difference was seen for medians of 
NTBI across groups, by independent median test (P = 0.283) (Table 37, Figure 61). 
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Figure 61. Non-transferrin-bound iron in Controls and Type 2 Diabetes, 
without and with CKD 
Controls, without and with CKD (n = 6 and n = 18), Type 2 diabetes 
without and with CKD (n = 11 and n = 38). 
 
When controls and type2 diabetes cases are pooled, no significant difference is 
seen in median NTBI across stages of CKD (P = 0.406) (Figure 62), or between those 
without or those with CKD (P = 1.00) (Figure 63). 
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Figure 62. Non-transferrin-bound iron in CKD 
All cases. No CKD (n = 17), CKD stage I (n = 25), CKD stage II (n = 28), 
CKD stage III (n = 3). 
 
 
Figure 63. Non-transferrin-bound iron in participants without or with CKD 
All cases, without CKD (n = 17), with CKD (n = 56) (P = 1.00 for 
difference in medians). 
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Table 37. Group characteristics – renal profile, urea and electrolytes 
Group characteristics – renal profile, urea and electrolytes 
 Random albuminuria  
  No (n) Yes (n) Total (n) 
Random albuminuria Control 22 (91.7%) 2 (8.3%) 24 
(> 20 mg/l) Diabetes 48 (88.9%) 6 (11.1%) 54 
No/Yes Total 70 8 78 
CKD (see Appendix 1.i for 
classification criteria. No 
cases of stages IV or V 
were found) 
Chronic kidney disease stage (n) 
 No CKD CKD I CKD II CKD III 
Control 6 5 10 3 
Diabetes 11 20 18 0 
NTBI (µM, median) 
(Range) 
 0.36 
(0.0 to 1.34) 
0.07 
(0.0 to 0.96) 
0.27 
(0.0 to 1.02) 
1.02 
(0.06 to 1.03) 
 Median test across groups, P = 0.283 
 
Non-normal distribution 
  
Median  
 
Range 
Median test 
between groups, P 
Random urine creatinine 
(mmol/l) 
Control 5.70 3.0 to 14.5  
Diabetes 5.6 0.0 to 20.8 0.984 
Random urine albumin 
(mg/l) 
Control 0.00 0.0 to 76.2  
Diabetes 2.10 0.0 to 213.7 0.240 
Albumin/creatinine ratio Control 0.00 0.0 to 7.4  
Diabetes 0.25 0.0 to 32.9 0.384 
Albumin excretion rate 
(µg/min) 
Control 0.00 0.0 to 57.0  
Diabetes 1.70 0.0 to 591.7 0.500 
 
Normal distribution 
  
Mean 
 
SD 
T-test between 
groups,  P 
Plasma creatinine 
(µM) 
Control 84.6 18.3  
Diabetes 78.4 16.0 0.139 
Urea 
(mM) 
Control 5.69 2.09  
Diabetes 5.57 1.83 0.815 
Sodium 
(mM) 
Control 140.8 2.17  
Diabetes 141.2 2.82 0.521 
Potassium 
(mM) 
Control 4.37 0.34  
Diabetes 4.35 0.28 0.768 
 
The investigation of NTBI in pre-dialysis renal disease, with and without diabetes, 
and all cases pooled, shows no median difference between No CKD, and CKD 
(Figure 61, Figure 63). When CKD is divided by stage (Figure 62) a trend towards 
increasing NTBI with renal deterioration is seen, although the small group sample 
size in stage 3 (n = 3) makes this finding insecure. Further work would be useful to 
increase this sample size, and include cases from CKD stages 4 and 5 (prior to 
dialysis) to give a fuller picture over the range of disease. No relationships are seen 
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when linear renal indices were correlation tested against NTBI or haemoglobin 
(Table 38). Overall, insufficient evidence is found here to support a link between 
NTBI and pre-dialysis renal disease. 
Table 38. Association between NTBI and case characteristics, by non-
parametric correlation (Spearman’s rho) 
Association between NTBI and case characteristics, by Spearman’s rho 
(all cases included unless specified) 
 r P 
Age (years) 0.034 0.769 
BMI (kg/m2) 0.042 0.725 
HbA1c (mmol/mol) 
Control 
Diabetes 
-0.167 
0.130 
-0.120 
0.155 
0.544 
0.408 
Systolic BP (mm Hg) 0.142 0.239 
Diastolic BP (mm Hg) 0.096 0.425 
Total cholesterol (mM) 
Control 
Diabetes 
0.169 
0.165 
0.072 
0.147 
0.440 
0.618 
LDL (mM) 
Control 
Diabetes 
0.324** 
0.481* 
0.187 
0.005 
0.017 
0.189 
Total/HDL ratio 0.290* 0.012 
Urate (µM) 0.200 0.095 
Ascorbate (Reduced) (µM) 
Control 
Diabetes 
0.168 
0.274 
0.025 
0.149 
0.195 
0.863 
Ascorbate (Oxidized) (µM) 
Control 
Diabetes 
0.202 
0.281 
0.191 
0.082 
0.183 
0.179 
Malondialdehyde (µM) 
Control 
Diabetes 
0.440*** 
0.707*** 
0.311* 
0.000 
0.000 
0.022 
Plasma haemoglobin 
Control 
Diabetes 
-0.056 
-0.224 
-0.111 
0.640 
0.304 
0.443 
Total iron (µM) 
Control 
Diabetes 
0.460*** 
0.451* 
0.437*** 
0.000 
0.027 
0.001 
Transferrin saturation (%) 
Control 
Diabetes 
0.407*** 
0.307 
0.414** 
0.000 
0.144 
0.002 
Total iron binding capacity (µM/ml) -0.020 0.863 
Unsaturated iron binding capacity (µM/ml) -0.256* 0.023 
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Whole blood haemoglobin (g/dl)       
Control 
Diabetes 
0.386*** 
0.376 
0.395** 
0.001 
0.077 
0.004 
Red blood cell count (x 1012/l) 0.183 0.116 
Haematocrit (%) 0.355** 0.002 
Mean corpuscular volume (x 1014 l/cell) 0.219 0.059 
Mean corpuscular haemoglobin (x 1011 g/cell) 0.326** 0.004 
Red blood cell distribution width (%) -0.233* 0.044 
White blood cell count (x 109/l) -0.106 0.364 
Platelets (x 109/l) -0.010 0.930 
Random urine creatinine (mmol/l) 0.125 0.287 
Random urine albumin (mg/l) 0.079 0.500 
Albumin/creatinine ratio 0.063 0.589 
Albumin excretion rate (µg/min) 0.079 0.499 
Key: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 
Table 39. Additional correlation testing by Pearson correlation and 
Spearman’s rho 
 
Additional correlation testing by Pearson correlation unless specified (np) 
 r P 
LDL vs Haemoglobin 
All cases 
Controls 
Diabetes 
0.335** 
-0.104 
0.446*** 
0.004 
0.635 
0.001 
LDL vs Malondialdehyde 
All cases 
Controls 
Diabetes 
0.362*** 
0.334 
0.311* 
0.001 
0.111 
0.026 
LDL vs HbA1c (mmol/mol) 
 
All cases 
Controls 
Diabetes 
-0.176 
-0.100 
0.161 
0.135 
0.643 
0.269 
Haemoglobin vs Plasma haemoglobin 
All cases 
Controls 
Diabetes 
0.044 
0.253 
-0.165 
0.718 
0.255 
0.262 
Haemoglobin vs MDA 
Controls 
Diabetes 
0.084 
0.207 
0.703 
0.141 
MDA vs haematocrit All cases 0.172 0.139 
Redu ascorbate vs oxi ascorb (µM) (np) All cases 0.467*** 0.000 
LDL vs Reduced ascorbate (np) All cases 0.102 0.395 
MDA vs Reduced ascorbate (np) All cases 0.1783 0.116 
Extracellular haemoglobin vs MDA All cases -0.110 0.355 
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Key: *P ≤ 0.05; **P ≤ 0.01; *** P ≤ 0.001; np: non-parametric correlation 
 
Extracellular haemoglobin vs LDL All cases -0.117 0.337 
Haemoglobin vs LDL 
HbA1c Tertile 1 
(n = 24) 
-0.058 
 
0.789 
 
Haemoglobin vs LDL 
HbA1c Tertile 2  
(n = 24) 
0.495* 
 
0.014 
 
Haemoglobin vs LDL 
HbA1c Tertile 3 
(n = 24) 
0.538** 
 
0.007 
 
Haematocrit vs LDL 
HbA1c Tertile 1 
(n = 24) 
-0.144 0. 503 
Haematocrit vs LDL 
HbA1c Tertile 2 
(n = 24) 
0.424* 0.039 
Haematocrit vs LDL 
HbA1c Tertile 3 
(n = 24) 
0.543** 0.006 
HbA1c vs NTBI (np) 
HbA1c Tertile 1 
(n = 25) 
0.018 0.933 
HbA1c vs NTBI (np) 
HbA1c Tertile 2  
(n = 24) 
-0.274 0.195 
HbA1c vs NTBI (np) 
HbA1c Tertile 3 
(n = 25) 
-0.036 0.866 
LDL vs NTBI (np) 
No statins (n = 27) 
Statins (n = 46) 
0.545** 
0.134 
0.003 
0.373 
Haemoglobin vs NTBI (np) 
No statins (n = 27) 
Statins (n = 46) 
0.373 
0.408** 
0.056 
0.005 
Haemoglobin vs LDL 
No statins (n = 27) 
Statins (n = 46) 
0.472* 
0.389** 
0.015 
0.008 
LDL vs MDA 
No statins (n = 27) 
Statins (n = 46) 
0.514** 
0.130 
0.006 
0.388 
HbA1c vs NTBI (np) 
No statins (n = 27) 
Statins (n = 46) 
-0.131 
-0.245 
0.523 
0.101 
HbA1c vs NTBI (np) Controls 
 
No statins (n = 14) 
Statins (n = 9) 
0.263 
-0.312 
0.263 
0.413 
HbA1c vs NTBI (np) Diabetes 
 
No statins (n = 12) 
Statins (n = 37) 
-0.093 
-0.168 
0.775 
0.320 
NTBI vs MDA (np) No statins (n = 27) 
Statins (n = 46) 
697*** 
0.301* 
0.000 
0.040 
Haemoglobin vs MDA No statins (n = 27) 
Statins (n = 46) 
0.290 
0.240 
0.142 
0.107 
NTBI vs Haemoglobin (np) No statins (n = 27) 
Statins (n = 46) 
0.373 
0.408** 
0.056 
0.005 
HbA1c vs Reduced ascorbate (np) All cases -0.374*** 0.001 
HbA1c vs Reduced ascorbate (np) Controls (n = 24) -0.041 0.850 
HbA1c vs Reduced ascorbate (np) Diabetes (n = 47) -0.303* 0.038 
HbA1c vs Reduced ascorbate (np) No statins -0.405* 0.045 
HbA1c vs Reduced ascorbate (np) Statins -0.314* 0.038 
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4.5.3 The effect of nitrilotriacetic acid on haemoglobin 
The SUMMIT NTBI measurements were found to correlate with whole blood 
haemoglobin, and small quantities of extracellular, plasma, haemoglobin were 
consistently seen. In order to assess the ability of nitrilotriacetic acid (NTA) to bind 
iron associated with haemoglobin, potentially forming a species measured as NTBI, 
a series of tests were undertaken.  
To assess the total amount of iron in haemoglobin, bovine haemoglobin (2.5 
mg/ml, n = 2) was first measured for total iron by the method of Bothwell (1971), 
and protein concentration by the method of Bradford (1976), finding a mean value 
of 24.2 µM/mg. Following protein precipitation, the residual plug had a strong 
brown colour, indicating that iron may have remained on the protein. It is not clear 
if this measure was successful, and therefore recovered iron per cent of total has 
not been calculated for the results below. 
4.5.3.1 The effect of nitrilotriacetic acid on haemoglobin, Experiment 1.  
To assess the effect of 0.8 M NTA on bovine haemoglobin, concentrations (2 mg 
and 5 mg) of lyophilised bovine haemoglobin (Sigma lot # 010K7618, no purity 
given) were dissolved in PBS (1 ml). Aliquots of these (150 µl) were made, and 
taken through the usual NTBI assay (n = 2), receiving 15 µl of 0.8 M NTA, or PBS for 
controls.  
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Experiment 1. Results 
 Apparent iron (µM, mean of 2) 
 No NTA With NTA 
2 mg/ml 14.6 24.5 
5 mg/ml 25.3 59.3 
Table 40. Apparent iron following 0.8 M NTA and NTBI assay 
 
Using 0.8 M NTA with two concentrations of lyophilized haemoglobin, finds that in 
both cases NTA is associated with increased iron being measured when 
haemoglobin is separated from the solution (Table 40). The greater concentration 
of haemoglobin results in increased iron (Figure 64). 
 
Figure 64. Apparent iron following NTBI assay with and without 0.8 M NTA 
 
NTA leads to more iron being measurable from haemoglobin during the NTBI assay 
procedure. This may be due to NTA binding loosely-bound haemoglobin-iron; or 
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binding free iron in solution, perhaps present as a consequence of being prepared 
from lyophilised protein.  
4.5.3.2 The effect of nitrilotriacetic acid on haemoglobin, Experiment 2. 
To assess the amount of iron removed from haemoglobin by varying 
concentrations of NTA, single aliquots (500 µl) of bovine haemoglobin (2 mg/ml) 
received varying concentrations of NTA (0.05 M to 0.8 M, 50 µl), followed by 20 
minute incubation and the remainder of the usual NTBI procedure. 
Experiment 2. Results 
Added  NTA (M) Apparent iron (µM) 
0.05 10.9 
0.1 10.2 
0.2 12.0 
0.4 13.7 
0.8 14.1 
Table 41. Apparent iron (µM) following varying concentration of NTA, and 
NTBI assay 
 
Using single aliquots of a constant concentration of dissolved lyophilized 
haemoglobin, and increasing concentrations of NTA (Table 41), a trend in increased 
iron is seen, in a dose-dependent manner (Figure 65). 
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Figure 65. Apparent iron following varying concentrations of NTA 
Following assay for non-transferrin-bound iron. 
 
During the NTBI procedure, incubation with NTA results in increases in measurable 
iron in a generally dose-dependent manner. 
4.5.3.3 The effect of nitrilotriacetic acid on haemoglobin, Experiment 3. 
To assess the effect of incubation time of bovine haemoglobin (2.5 mg/ml) with 0.8 
M NTA, the usual NTBI procedure was performed with and without the 20-minute 
incubation at room temperature (n = 2).  
Experiment 3. Results 
 
Apparent iron (µM, mean of 2) 
No incubation 12.7 
20 minute incubation  15.6 
Table 42. Apparent iron (µM) following addition of 0.8 M NTA, without and 
with the 20-minute incubation at room temperature. 
 
Repeating the NTBI assay on further equal aliquots of dissolved lyophilized 
haemoglobin, but omitting the usual 20-minute incubation at room temperature 
(Table 42) finds an increase in iron following incubation (Figure 66). 
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Figure 66. Apparent iron following normal NTBI procedure with and without 
20 minute incubation  
Following 0.8 M NTA administration. 
 
4.5.3.4 The effect of nitrilotriacetic acid on haemoglobin – conclusion 
The studies here give a strong indication that NTA is able to sequester iron 
associated with lyophilised haemoglobin dissolved in PBS, in a dose-, and time-
dependent manner. It is not known if this is due to the nature of haemoglobin in 
this form, or if the same effect is seen with NTA and extracellular haemoglobin in 
plasma samples.  
4.6 Discussion 
The aim of this study has been to evaluate the presence of non-transferrin-bound 
iron in people with type 2 diabetes and controls, and to assess its association with 
haemoglobin glycation, lipid peroxidation, antioxidant status, and other iron 
parameters. Further to these, the comparison of NTBI in people with and without 
diabetes, and with and without cardiovascular and renal disease has also been 
undertaken. It can be seen from these results that no positive association is found 
between NTBI and HbA1c (r = -0.167; P = 0.155) and there is no significant 
difference between controls and type 2 diabetes groups for NTBI (P = 0.326), as 
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measured by this assay. The occurrence of NTBI in direct association with protein 
glycation is not supported here. 
The range of levels of NTBI over all cases bears some similarity to that of Lee et al 
(2006), and Leoncini et al (2008), however the increase in diabetes reported by 
both groups is not seen, suggesting that the source of NTBI measured by this assay 
may be different. No correlation is seen between NTBI and extracellular 
haemoglobin (r = -0.056; P = 0.640) despite the strong positive association between 
NTBI and whole blood haemoglobin (r = 0.386, P = 0.001), suggesting no 
contribution from this potential source. Neither is an association found between 
extracellular and whole blood haemoglobin (r = 0.044, P = 0.718), although it is not 
clear from the literature whether or not these may be expected to correlate. For 
the diabetes group here, the correlation hints at being inverse (r = -0.165, P = 
0.262) although the trend is weak, and the probability is poor. A very highly 
significant correlation is seen between NTBI and MDA (r = 0.440, P < 0.001), which 
might be expected given the potential for iron-induced lipid peroxidation.  
Across the iron indices results a non-significant trend is seen for a lower iron status 
in the type 2 diabetes group. These include total iron, transferrin saturation, 
haemoglobin, red blood cell count, haematocrit, and the NTBI result (Table 34). 
Readings for ferritin and CRP would be interesting to have in addition, never-the-
less the results from this relatively small study indicate a trend towards lower levels 
of iron by various markers. The highly significantly raised white blood cell count 
suggests this is probably due to inflammation. Other groups do not agree on iron 
status in diabetes (Table 30). Lee et al (2006) found non-significantly higher level of 
total iron and transferrin saturation, and highly significantly more haemoglobin 
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(and ferritin); Van Campenhout et al (2006) found non-significantly less total iron 
and transferrin saturation. No clear picture is evident, suggesting perhaps little 
importance in the overall scheme, although it would be interesting to have 
haemoglobin values from Van Campenhout et al (2006), Leoncini et al (2008), and 
Shetty et al (2008).  
NTBI significantly positively correlates with total iron (r = 0.460, P = < 0.001), and 
transferrin saturation (r = 0.407, P = < 0.001) in this study (Table 38), in agreement 
with Lee et al (2006). No such correlations are found by Van Campenhout et al 
(2006), or reported by the others. As NTBI is normally found to correlate with 
transferrin saturation (Jacobs et al 2005) this may be due to shortcomings in Van 
Campenhout et al’s NTBI assay. Interestingly, the positive correlation reported here 
between NTBI and haemoglobin, strengthening with diabetes (Table 38), is in 
agreement with Lee et al (2006) (r = -0.11, P = 0.07; r = 0.22, P = 0.14; r = 0.37, P = < 
0.01; for Controls, Newly diagnosed, and Known diabetes in Lee et al’s study). This 
agreement in correlation is in spite of a disagreement in mean level between 
controls and diabetes, and although it is difficult to draw firm conclusions it 
appears that the strengthening correlation between NTBI and haemoglobin in 
diabetes is independent of haemoglobin level. 
To suggest a source of the NTBI measured here, a scenario is proposed whereby 
MDA (a dicarbonyl compound) is partially the result of erythrocyte lipid membrane 
peroxidation, leading to cell haemolysis and increased plasma MDA, with further 
cell membrane and endothelial damage from extracellular haemoglobin, and haem. 
A number of observations underlie this theory. Firstly, the unexpected correlations 
of NTBI with haematocrit (r = 0.355, P = 0.002) and haemoglobin (r = 0.386, P = 
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0.001), and the perplexing correlations between NTBI and LDL (r = 0.324, P = 
0.005), and haemoglobin and LDL (r = 0.335, P = 0.004). Secondly, it is shown here 
that NTA, at the concentration used in the NTBI assay, can bind iron associated 
with haemoglobin. Thirdly, there is a growing body of evidence linking altered   
cholesterol content and composition profile of erythrocyte membranes in 
atherosclerosis, which is predictive of acute coronary events (Tziakas et al 2007, 
Shearer et al 2009). 
The data showing the ability of NTA to scavenge iron from lyophilised haemoglobin 
in solution shows a dose, and time-dependent effect. Whether the same occurs 
with haemoglobin in plasma samples is not known, however Kolb et al (2009) found 
that NTA concentrations of 10 to 100 mM could influence NTBI measurements in 
serum following 20 minute incubation and ultrafiltration, in a dose-dependent 
manner. Kolb et al do not speculate on the source of iron being sequestered by 
NTA in their unspiked samples, but extracellular haemoglobin might be a donor, 
based on the results of the small in vitro study here.   
In acute coronary syndrome, the most vulnerable plaques have a significantly 
higher level of unesterified cholesterol than is seen earlier in the time-course of 
CVD, when macrophage in atherosclerotic lesions have more accumulated 
esterified cholesterol (Tabas 2000). The source of unesterified cholesterol in later-
stage plaques is likely to be erythrocyte membranes, which have more unesterified 
cholesterol than any other cell (Arbustini 2007), and occur alongside increased iron 
accumulation in the necrotic core of advanced coronary atheroma (Kolodgie et al 
2003).  The cholesterol content of erythrocyte membranes is acquired via rate-
limited exchange between lipoproteins and erythrocytes (Gottlieb 1980), thought 
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to be independent of circulating cholesterol level, although the mechanism 
involved is not known (Tziakas et al 2007). Both the total lipid content, and the 
fatty acid profile of erythrocyte membranes are predictive of acute coronary 
syndrome (Tziakas et al 2007, Shearer et al 2009), with protective fatty acids being 
essential n-3 docosapentaenoic acid, and n-6 linoleic acid. Treatment with statins in 
acute coronary syndrome leads to a significant reduction in erythrocyte cholesterol 
(Tziakas et al 2009). Zhang et al (2011) have shown that erythrocyte membrane 
cholesterol is significantly higher in acute coronary syndrome than stable angina 
pectoris, correlating positively with plasma lipoprotein(a), and negatively with 
apolipoprotein A-1 (the major apolipoprotein in HDL). 
Given the scenario outlined above, with erythrocyte membrane damage and 
release of haemoglobin, extracellular haemoglobin might be expected to correlate 
with NTBI if NTBI is a product of this source, but this is not seen. Extracellular 
haemoglobin level may be thought of as a consequence of rate of haemolysis, and 
rate of haptoglobin clearance, however the saturating effect of haptoglobin (400 
molar excess, Asleh & Levy 2005) should ensure none is normally present. If NTBI is 
occurring from this source then either haptoglobin capacity must be overwhelmed, 
the haptoglobin-haemoglobin bond altered, or NTA is able to scavenge iron from 
haptoglobin-bound haemoglobin. As haptoglobin-haemoglobin binding is normally 
irreversible, with an association constant greater than 10-15 mol/l (Handin et al 
2003) the last option seems unlikely. Levels of haemoglobin between 0.07 to 0.15 
g/dl can normally be bound by haptoglobin (Langlois & Delanghe 1996), and 
haemoglobin levels  in episodes of severe haemolytic disease can exceed 1.0 g/dl 
(Rother et al 2005). Plasma haemoglobin reported here ranges from 0.0 to 0.4 g/dl, 
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therefore the haptoglobin capacity may be exhausted. Considering an alteration in 
binding functionality, it is interesting to note that Jia et al (2007) have described 
haemoglobin oxidation by H2O2 affecting two particularly vulnerable cysteine 
residues in the β-globin chain, causing irreversible change to cysteic acid. Loss of 
haem pocket structure occurs, with cross-linking between α-globin chains, which is 
associated with reduced haptoglobin binding.  
A further source of NTBI could be haem, from haemoglobin degradation, perhaps 
by the effect of glycation weakening the haem-globin linkage (Sen et al 2005), as 
described in Chapter 1. This would also explain the lack of correlation between 
NTBI and plasma haemoglobin, as Drabkin’s reagent in the haemoglobin assay 
specifically measures haemoglobin following its oxidation to ferric 
methaemoglobin. Plasma haem is highly pro-oxidant if not complexed by 
haemopexin or albumin, and as smaller than haemoglobin will be more invasive of 
the sub-endothelium. Haem is hydrophobic, and can be rapidly taken up by cell 
membranes and LDL (Balla et al 2003). Both haemoglobin and haem are known to 
be potent extracellular oxidants, producing nitric oxide depletion, vascular 
dysfunction including hypertension, and renal damage from glomerular filtration 
(Kato 2009). Extracellular haemoglobin and haem perform all the roles that NTBI is 
implicated for in CVD, and are plausible NTBI sources in diabetes. 
A significant decrease in MDA is seen in the diabetes group compared with controls 
(P = 0.041), and a very highly significant decrease in LDL (P < 0.001). This probably 
reflects the more aggressive use of statins for cholesterol lowering, used by 71.7% 
of the diabetes group compared with 39.1% of controls (Table 43). Significant 
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differences in LDL are seen across groups for controls and diabetes, and without 
and with statins (Figure 67).  
Table 43. Group characteristics and NTBI – use of statins 
Group characteristics – use of statins  
Use of statins   No Statins (n) Statins (n) Total (n) 
Control 14 (60.9%) 9 (39.1%) 23 
Diabetes 15 (28.3%) 38 (71.7%) 53 
Total 29 47 76 
NTBI (µM, median & range) 
No statins Statins P 
0.32 (0.00 to 1.02) 0.22 (0.00 to 1.34) 0.479 
LDL (mM mean ± SD) 2.73 ± 1.42 1.75 ± 0.94 0.001** 
Malondialdehyde (µM mean ± SD)  2.48 ± 1.16 1.94 ± 1.04 0.039* 
Reduced ascorbate (µM)1 29.1 (2.2 to 67.6) 21.5 (0.0 to 60.0) 0.291 
Key: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; 1 median and range 
Whilst NTBI and LDL correlate across all cases (Figure 42), no significant difference 
in NTBI is seen across groups when controls with and without statins, and diabetes 
with and without statins are compared separately (P = 0.513) (Figure 68).  
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Figure 67.  Low density lipoprotein in Controls and Type 2 Diabetes, without 
and with statins medication  
Controls without and with statins (n = 14, and n = 9), Type 2 diabetes 
without and with statins medication (n = 15, and n = 38) (P < 0.001 
between Control No statin and Diabetes + Statin; P = 0.037 between 
Control + Statin and Diabetes + Statin). 
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Figure 68. NTBI in Controls and Type 2 Diabetes without and with statins 
medication  
Controls without and with statins (n = 14, and n = 9), Type 2 diabetes 
without and with statins (n = 15, and n = 38) 
 
To explore further the correlation between haemoglobin and LDL, significant only 
in diabetes, and negatively associated in controls, the data was stratified by HbA1c 
into tertiles and further correlations performed. The relationship strengthens 
significantly with HbA1c (Table 44, Figure 69, Figure 70, Figure 71).  
Table 44. Correlation tests between whole blood haemoglobin and LDL by 
HbA1c tertile 
 Correlation between haemoglobin and LDL by HbA1c 
tertile 
Tertile 
HbA1c (mmol/l) 
1 
(< 42.0)  
n = 24 
2 
(42.0 to 53.0)  
n = 24 
3 
(> 53.0)  
n = 24 
 r P r P r P 
Haemoglobin vs LDL -0.058 0.789 0.495* 0.014 0.538** 0.007 
Key: * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 
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Figure 69. Haemoglobin vs LDL stratified by HbA1c, Tertile 1  
(n = 24, r = -0.058, P = 0.789) 
 
 
Figure 70. Haemoglobin vs LDL stratified by HbA1c, Tertile 2  
(n = 24, r = 0.495*, P = 0.014) 
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Figure 71. Haemoglobin vs LDL stratified by HbA1c, Tertile 3 
(n = 24, r = 0.538**, P = 0.007) 
 
Increased HbA1c clearly associates with increased positive association between 
whole blood haemoglobin and LDL. If haemoglobin/haematocrit-correlated plasma 
LDL results from erythrocyte haemolysis and lipid release followed by hepatic LDL 
synthesis, then it is increased by some factor relating to glycaemia. Erythrocyte 
membrane alterations in diabetes have long been identified, including increased 
glycation across the range of membrane proteins (Miller et al 1980), with 952 
different erythrocyte membrane proteins found to be glycated, by mass 
spectrometry (Zhang et al 2011). Increased membrane lipid peroxidation occurs in 
diabetic erythrocytes, significantly correlating with HbA1c (Jain et al 1989), 
decreased deformability and unesterified membrane cholesterol (Garnier et al 
1990); and membrane spectrin glycation and oxidation (Schwartz et al 1991). 
Erythrocyte fragility increases with HbA1c in type 2 diabetic patients (Kung et al 
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2009), and similarly, erythrocyte fragility increases in patients with type 2 diabetes 
(Lippi et al 2012). A scenario of lipid and protein glycation, oxidation, and ROS-
driven oxidative damage would fit this picture, and the significant correlation seen 
between MDA and LDL in diabetes (r = 0.311, P = 0.026) may support this. 
Further support for this scenario of lipid and protein glycation, oxidation, and ROS-
driven oxidative damage may be provided by the results of correlations between 
HbA1c and reduced ascorbate in this study. With all cases pooled, a highly significant 
negative correlation is seen (r = -0.374, P = 0.001), however no correlation is seen 
in controls (r = -0.041, P = 0.850). In the diabetes group the negative correlation is 
significant (r = -0.303, P = 0.038) (Table 39, Figure 72, Figure 73, Figure 74). 
 
Figure 72. HbA1c vs ascorbate, all cases 
(n = 78, r = -0.374***, p = 0.001) 
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Figure 73. HbA1c vs ascorbate, Controls 
(n = 24, r = -0.041, P = 0.850) 
 
 
Figure 74. HbA1c vs ascorbate, Type 2 Diabetes 
(n = 47, r = -0.303*, P = 0.038) 
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The theory of glucose-linked erythrocyte membrane damage leading to plasma 
haemoglobin and haem suggests that the relationship between HbA1c and NTBI 
should strengthen with diabetes. This is not the case however, and the trend 
becomes negative in diabetes (Controls, r = 0.130, P = 0.544; Diabetes, r = -0.120, P 
= 0.408, Table 38). Likewise it seems surprising that NTBI is found here to be 
significantly correlated with LDL in controls (r = 0.481, P = 0.017), but not in 
diabetes (r = 0.187, P = 0.189), and not correlated with total cholesterol (r = 0.169, 
P = 0.147) (Table 38). Table 45, below, describes the mean and median levels of key 
parameters and their interaction by correlation. It can be seen that the mean level 
of LDL in controls is significantly higher than diabetes, probably due to the 
increased use of statins in the diabetes group. According to the theory, a 
proportion of plasma cholesterol will be derived from haemolysis, this proportion 
increasing with glycation in diabetes. Due to inflammatory anaemia, iron status and 
subsequently haemoglobin and haematocrit are lessened in diabetes, resulting in 
less free haemoglobin and haem (measured as NTBI) despite an increased rate of 
red cell lysis. Inflammation would also cause up-regulation of haptoglobin and 
hemopexin as acute phase proteins, reducing plasma haemoglobin and haem. 
Statins would up-regulate cholesterol take-up by the liver. The combination of 
inflammation and statins therapy results in no correlation between LDL and NTBI 
being seen. In controls, the strong correlation between LDL and NTBI would be due 
to higher levels of iron generally, greater haematocrit, more plasma cholesterol 
without statins to lessen cholesterol resulting from “normal” haemolysis, with a 
concomitant increase in NTBI due to lower levels of haptoglobin and hemopexin.  
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Table 45. Profile of selected results, showing mean and median values, and 
different associations between controls and diabetes, and without and with 
statins 
Key: NTBI, non-transferrin-bound iron; Hb, whole blood haemoglobin; MDA, malondialdehyde; 
LDL, low density lipoprotein; * P ≤ 0.05;  ** P ≤ 0.01; *** P ≤ 0.001. 
Controls, n = 24; Type2 diabetes, n = 53; No statins, n = 27; Statins, n = 46. 
See Table 38 and Table 39 for ranges and SD. 
 
Splitting the cases by use of statins therapy finds a non-significant difference in 
NTBI between groups (median 0.32 without statins compared to 0.22 µM with 
statins, P = 0.479; Table 43, and Table 45, above). In exploration of a possible 
protective effect on NTBI by statins, correlations were performed on the two 
groups (Table 39, and Table 45), finding a highly significant positive correlation 
between LDL and NTBI without statins (n = 27, r = 0.545, P = 0.003), which is lost 
with statins therapy (n = 46, r = 0.134, P = 0.373). The positive correlation between 
haemoglobin and NTBI remains constant, becoming significant in the statins group 
due to the larger group size. The significantly lower LDL with statins (P = 0.001) is 
reflected in a significantly lower MDA level (P = 0.039), and a non-significant trend 
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for less ascorbate (P = 0.291) (Table 43).  Correlation tests between NTBI and HbA1c 
with and without statins and diabetes, find no significance (Table 39). Further work 
needs to be done to understand the interaction between LDL and NTBI, which is 
disrupted by statins. 
The scenario of glycation, oxidation, and haemolysis implies an influence on plasma 
LDL level by haemolysis and hepatic LDL synthesis. However, when a rough 
calculation is performed to show the relative quantities of cholesterol potentially 
deriving from haemolysis, the figure is quite low. Total unesterified erythrocyte 
cholesterol per gram haemoglobin is 3.63 ± 0.21 mg/g (Farquhar 1962, in Beutler et 
al 2001), therefore if 10% of erythrocytes are lysed in the blood stream (Garby & 
Noyes 1959), plasma haemoglobin may equal 10% of all haemoglobin, i.e. ~ 1.4 
g/dl, then ~ 5.1 mg/dl cholesterol will also be present, with a molecular weight of 
385.65 g/mol, contributing ~ 132.0 µM to a typical plasma cholesterol level of ~ 5.0 
mM.  
From the rough calculation above lysed erythrocyte cholesterol may not appear to 
contribute significantly to overall cholesterol levels, unless haemolysis is greatly 
increased, and therefore further explanations may be needed to explain the 
correlation between haemoglobin and LDL in diabetes. Not all the mechanisms by 
which statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) 
operate are understood. Essentially, statins lower plasma LDL by increasing 
clearance from the circulation, and reducing the production of apoB-containing 
lipoproteins by the liver. This latter is altered in diabetes by the effect of insulin 
resistance; and additionally, insulin deficiency leads to reduced LDL receptors and 
altered LDL composition (for review see Ginsberg 2006). Other actions of statins 
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are known, such as inhibition of isoprenoids, which are intermediates of 
cholesterol synthesis, and required for subsequent signalling pathways and GTP-
binding protein function; also statins may induce peroxisome proliferators-
activated receptors (PPARs), which would have an anti-inflammatory effect (Zhou & 
Liao 2009). Endothelial function is also improved by statins independently of LDL 
level, possibly by up-regulation of endothelium nitric oxide synthase (eNOS) and 
therefore NO (Hamilton et al 2010). All statins have at least one hydroxyl group (as 
does cholesterol) and it is interesting to speculate on a possible iron-binding 
capacity contributing to its anti-inflammatory effects and other pleiotropic 
benefits.  
Interestingly, haemoglobin-bound cholesterol has been identified in erythrocytes in 
healthy people (Nikolic et al 2003), within both the cell membrane and the cell 
itself. Binding stoichiometry is two molecules each of cholesterol and phospholipid 
per haemoglobin molecule.  In haemolysate, haemoglobin-lipid adduct ranged from 
0.2% to 55.0% of total haemoglobin (n = 36), and correlated positively with plasma 
HDL (r = 0.57, P < 0.01). Lower levels of haemoglobin-lipid adduct are found in cell 
membranes. The authors speculate that erythrocytes may have a defensive role 
removing free cholesterol from circulation; however, in a diabetic and haemolytic 
scenario this grouping might be a potent source of ROS following glycation of the 
haemoglobin.  
In summary, the results for NTBI, LDL, haemoglobin, haematocrit, and MDA, found 
by this study may be explained by Figure 75, below. 
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Figure 75. The proposed role of protein glycation in plasma NTBI and LDL, and 
the protective effects of statins 
NTBI results from erythrocyte membrane glycation, oxidation, and 
subsequent haemolysis (purple pathways), with increased plasma 
MDA and decreased ascorbate indicating lipid peroxidation and 
oxidative damage. Plasma haemoglobin from haemolysis oxidizes to 
methaemoglobin, and degrades to haem, becoming vulnerable to 
incorporation in atherosclerotic plaques, where, alongside 
unesterified cholesterol, it can promote hydroxyl radicals and further 
oxidative damage. The use of statins lowers plasma LDL (red 
pathway), reducing the cholesterol available for erythrocyte 
membrane take up, and availability for lipid peroxidation, and 
thereby decreasing haemolysis and the appearance of NTBI.   
 
The scheme described by Figure 75 shows the plasma iron and plasma cholesterol 
products of haemolysis as occurring independently, however they might also be 
bound together, as found in haemolysate by Nikolic et al 2003). 
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4.6.1 Limitations 
There are several limitations to this study. Our assay includes NTA mobilisation, 
and therefore may not measure glycated albumin-bound iron, as found by Silva & 
Hider (2009). Our results may therefore underestimate total NTBI levels in people 
with diabetes. In addition, given the mechanisms discussed in Chapter 1, 
haptoglobin genotype will influence CVD risk in diabetes. This would be a valuable 
measure, but due to financial limitations this has not been possible. The 
measurement of serum ferritin is planned, but these results are not included in the 
thesis due to timing. 
The study is also limited by lack of numbers for the measurement of NTBI in renal 
disease. Measurement of urine iron would be an interesting contribution to the 
renal parameters. 
The use of statins is associated with decreased NTBI here. Angiotensin-converting-
enzyme (ACE) inhibitors and angiotensin II type I receptor blockers (ARB) were also 
compared, but found to have no effect on NTBI when tested (results not shown). 
Other medications taken by participants have not been considered however, and 
these may have an effect on results. 
4.6.2 Future work 
A theory to explain the correlations between NTBI and LDL; NTBI and haemoglobin; 
and LDL and haemoglobin in diabetes is suggested, but work needs to be carried 
out to test the theory and define the processes involved. In addition, the various 
statins compounds, and cholesterol, could be tested for iron binding function. Mass 
spectrometry has previously been used to examine erythrocyte membrane proteins 
for post-translational modifications by Zhang et al (2011) (see Chapter 3), who 
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found that erythrocyte proteins were more extensively glycated than plasma 
proteins in people with diabetes, in all 952 different membrane, and 853 cytosol 
proteins.  Spectrin alpha and beta chain were consistently up-regulated in diabetes 
amongst others – perhaps in response to glycation and oxidation-related losses? 
Increased lipid peroxidation significantly correlates with HbA1c in diabetes (Jain et al 
1989), and erythrocyte fragility increases in type 2 diabetes, with HbA1c (Lippi et al 
2012, Kung et al 2009), but further laboratory studies could be carried out on 
erythrocytes to link membrane protein glycation, lipid peroxidation, and the 
appearance of haemoglobin and haem.  
In addition, it has been shown that the formation of advanced glycation end-
products (AGE) on the surface of diabetic erythrocytes bind to specific AGE 
receptors on endothelial cells (Wautier et al 1994), and therefore haemolysis in situ 
should also be considered. 
4.7 Conclusions 
In people with type 2 diabetes and controls, with and without CVD and CKD, no 
association between NTBI and HbA1c is seen.  Utilizing HbA1c as a marker of protein 
glycation indicates that no correlation is found between NTBI and protein glycation. 
Unexpected correlations between NTBI and LDL, and LDL and haemoglobin with 
increasing protein glycation, are reported for the first time. NTBI is suggested to be 
iron sourced from haemoglobin or haem, from erythrocyte haemolysis prior to 
sample collection, possibly facilitated by nitrilotriacetic acid scavenging during 
laboratory assay. Reduction of LDL by statins therapy is associated with less NTBI in 
the diabetes group. NTBI is measured in people with pre-dialysis CKD stages I to III 
for the first time, finding no significant difference in NTBI level between groups, or 
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correlation with markers of renal function. No association between NTBI and 
kidney function at this stage of disease is proven. 
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Epilogue 
5.1 Prevention and intervention of non-transferrin-bound iron 
On the assumption that NTBI as measured here will be a contributing factor to iron 
build-up in atherosclerotic plaques, and potentially damaging to the sub-
endothelium prior to atherogenesis, efforts should be made to prevent or lessen it. 
The positive relationship described between LDL and NTBI, despite the lack of 
understanding of its nature, suggests that reducing high plasma LDL by statins is 
beneficial. The significant reduction in MDA in the statins group indicates that lipid 
peroxidation is occurring, correlating highly significantly with LDL without statins (P 
= 0.006), but not with statins (P = 0.388, Table 39), and therefore measures to 
protect against lipid peroxidation can be recommended, primarily by maintaining a 
good daily intake of dietary vitamin E.  
As individual requirements for vitamin E depend on dietary intake of 
polyunsaturated fatty acids (PUFA), no specific dietary reference values are 
published. However, minimum levels are set at > 4 mg/day for males (5.9 IU), and > 
3 mg/day for females (4.5 IU) (DH 1991), with safe upper levels set at 540 mg α-
tocopherol equivalents/day (805.9 IU) (EVM 2003). Most dietary vitamin E is 
consumed as fats (spreads, margarines and oils), fried snacks, cereal foods, and 
meat and meat products, with the most concentrated vitamin E levels being in seed 
and corn oils (Henderson et al 2003). As these are largely n-6 fatty acids, and the n-
6:n-3 fatty acid ratio is important for anti-inflammatory and cardio-protective 
effects (Appendix 1.v., Calder 2006, Kinsella et al 1990), oily fish should be included 
in the diet, with intakes of at least one 140 g portion/week recommended for the 
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general population (Mozaffarian et al 2008). For those with a prior cardiovascular 
event, intakes should be between two and four portions of oily fish per week, 
giving > 7 g of n-3 fatty acids (Kris-Etherton et al 2002). People with diabetes should 
include oily fish in their diet at least twice a week, in line with their raised risk for 
cardiovascular events. In addition to their known anti-arrhythmic and anti-
inflammatory properties, n-3 fatty acids are important structural components of 
cell membranes, and able to lower plasma cholesterol levels (Connor 2000).  
For people with diabetes, dietary iron intakes should follow normal 
recommendations unless iron status is outside the normal range (Section 1.4.3, and 
Appendix 1.iii). In general, a diet high in wholegrains, pulses, vegetables, fruit, low 
fat dairy and oily fish should be followed, limiting intakes of saturated and trans 
fatty acids (NCCCC 2008). 
5.2 Overview of work and conclusions 
This thesis has undertaken to explore the roles that iron might play in the 
development and pathologies of type 2 diabetes. From a review and discussion of 
the literature, in the development of type 2 diabetes a proportion of people with 
the metabolic syndrome, and non-alcoholic fatty liver disease, will have insulin 
resistance-associated hepatic iron overload, and, with the metabolic syndrome, will 
have an increased risk for diabetes. Whilst the build up of iron in the liver is 
thought to influence insulin resistance, it is not known by what mechanism this 
occurs. Hepatic-iron build up may take place in those with a predisposing genotype, 
occurring alongside the progressively increasing risk for diabetes with obesity, 
inflammation, dyslipidemia, and hypertension.  
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The literature for increased physiological iron status, as measured by serum 
ferritin, and soluble transferrin receptor to ferritin ratio, finds a positive association 
with risk for type 2 diabetes, which is not reduced by regular blood donation. 
Studies that assess physiological iron status and risk for diabetes by using serum 
ferritin alone, and which control for inflammation with CRP, may be inadequately 
controlling for inflammation.  
The literature for dietary iron intake and risk for type 2 diabetes suggests that 
processed red meat is associated with risk (Aune et al 2009, Micha et al 2010), with 
high intakes of red meat possibly also attached to a small increased risk.  There may 
be a role for iron in the development of advanced lipoxidation products (ALE) 
during processing, and a mechanism is described that might account for a link 
between ALE and pancreatic insulin secretion (Peppa et al 2002, Zhao et al 2009). 
Laboratory-based experiments should be undertaken to determine the 
involvement of iron in ALE development of different foods, with consideration of 
the lipid composition of the foods. 
In the development of diabetes-related pathologies, the effects of high plasma 
glucose levels are suggested by numerous authors to lead to functional damage to 
glycated proteins. Glycation of iron-related proteins, and haptoglobin genotypes, 
are discussed. Further research to determine risk of diabetes complications other 
than CVD by haptoglobin genotype, is needed.  
A sequence of in vitro experiments was carried out to test the functional capacity 
of glycated transferrin. These show that in vitro, glycated transferrin undergoes 
fragmentation, explaining the loss of function reported by earlier groups. Working 
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with the University of Bristol Proteomics Facility, in vitro glycated transferrin was 
examined by Thermo Orbitrap mass spectrometry (MS) to chart glycated amino 
acids in addition to lysine for the first time. A substantial number and range of 
residues were found to be subject to glycation, including Lys365 and Ile366, 
residues involved with transferrin receptor binding. Comparison with in vivo 
glycated transferrin MS by Waters suggests that many of the in vitro glycation sites 
are not glycated in vivo, and that many of the others involve methionine, therefore 
are potential MS artefacts, or likely to be repaired by methionine sulphoxide 
reductases in vivo. Further work by Orbitrap mass spectrometry of transferrin 
samples from people with and without diabetes should be undertaken to establish 
the extent and positioning of glycation in vivo. 
In collaboration with the Diabetes and Vascular Medicine Research Group, 
University of Exeter, a study has been made of a cohort of people with type 2 
diabetes, and controls, with and without cardiovascular disease (CVD) and chronic 
kidney disease (CKD). No association between non-transferrin-bound iron (NTBI) 
and HbA1c is seen, and therefore, utilizing HbA1c as a marker of protein glycation 
generally, no direct correlation with protein glycation. Unexpected correlations 
between NTBI and LDL, and LDL and haemoglobin with increasing protein glycation, 
are reported for the first time. NTBI is suggested to be iron sourced from 
haemoglobin or haem, from erythrocyte haemolysis prior to sample collection, 
possibly facilitated by nitrilotriacetic acid scavenging during laboratory assay. 
Erythrocyte membrane fragility may be increased by membrane protein glycation, 
and proximal lipoxidation. Reduction of LDL by statins therapy is associated with 
less NTBI in the diabetes group. NTBI is measured in people with pre-dialysis CKD 
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stages I to III for the first time, finding no significant difference in NTBI level 
between groups, or correlation with markers of renal function. No association 
between NTBI and kidney function at this stage of disease is proven. 
Further work should be undertaken to define the link between NTBI, haematocrit, 
and erythrocyte and plasma cholesterol. Statins, and cholesterol, should be 
investigated for iron binding function, and the role of cholesterol-bound-
haemoglobin or haem considered in the development of insulin resistance-
associated hepatic iron overload.  
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Appendices 
Appendix 1.i. Classification of stages in chronic kidney disease 
Table 1. NICE Guideline for classification of stages in chronic kidney disease 
 Stage I Stage II Stages III a & III b Stage IV Stage V 
Albuminuria 
(mg/24 h) 
<20 20-300 
 
≥300  
(up to 15 g/day) 
≥300 
(up to 15 g/day) 
≥300 
(Can fall) 
Glomerular filtration 
rate (ml/min/1.73 
m2) 
Normal/increased 
≥90 
Slight decrease 
 
60-89 
Moderate decrease 
a) 45-59 
b) 30-44 
Severe decrease 
 
15-29 
Established renal 
failure 
<15 
Serum creatinine 
(μmol/l) 
Normal  
60-100 
Normal  
60-100 
High normal 
80-120 
High 
120-400 
Very high 
>400 
Blood pressure  
(mm Hg) 
Normal 
90/60 to 120/80* 
Slightly increased 
120/80 to 140/90* 
Increased 
>140/90* 
Increased 
>140/90* 
Increased 
>140/90* 
Clinical signs 
 
None None Anaemia ± oedema  
Increased blood 
pressure 
May be none 
Anaemia ± oedema  
Increased blood 
pressure 
May be none 
Anaemia ± oedema  
Increased blood 
pressure 
Uraemic symptoms 
* General ranges, Blood Pressure Association 2008  
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Table 2. Diagnostic categories for microalbuminuria, macroalbuminuria, and proteinuria (adapted from Watkins 2003, and NICE 2008) 
 
 
 
References  
National Collaborating Centre for Chronic Conditions (2008) Clinical Guideline 73: Chronic Kidney Disease London: National Institute for Health and Clinical Excellence (NICE) 
Watkins, P. (2003) ABC of Diabetes Fifth edition London: BRITISH MEDICAL JOURNAL Publishing Group Ltd 
 
 
 
 
Microalbuminuria 
 Urinary albumin excretion rate 30-300 mg/24 h 
 Albumin creatinine ratio >2.5 mg/mmol/l (men) 
                                             >3.5 mg/mmol/l (women) 
 Urinary albumin concentration >20 mg/l 
 
Macroalbinumuria  
 Urinary albumin excretion rate >300 mg/24 h 
Proteinuria 
 Urinary protein excretion >500 mg/24 h 
 Albumin creatinine ratio >30 mg/mmol 
 Urinary albumin concentration >200 mg/l 
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Appendix 1.ii. Non-transferrin-bound iron in various conditions 
Table 1. Occurrence of non-transferrin-bound iron (NTBI)  in various conditions 
Patient group Study population 
Transferrin saturation  % 
mean (range) 
NTBI 
(µmol/L) mean (range) or SD 
NTBI measurement method used References 
Healthy controls 256 healthy male and female non-blood 
donors, aged 61.3 ± 5.7 yrs  
Range of means 30 to 34% 2.51 ± 0.80  Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Engberink et al 
(2008) 
17 healthy controls 25% (17 to 43%) -0.30 (-1.50 to 0.60) Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
De Valk et al 
(2000) 
63 healthy controls, aged 51 ± 12 yrs 35 ± 11% 0.154 ± 0.328 Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Le Lan et al 
(2005) 
47 healthy controls 32 ± 15.4%  0.04 ± 0.13. NTBI detected in 
10.6% of sample 
Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
Lee et al (2006) 
20 healthy controls, aged 34 ± 7 yrs Unknown 4.35 ± 0.85 S.E.M. (Fe2+ 
23%) 
Nilsson et al (2002) BPS 
spectrophotometry 
Prakash et al 
(2005) 
30 healthy controls, aged 24.5 ± 9.0 yrs 38.1 ± 11.5% -1.48 ± 0.48 Singh et al (1990) ultrafiltration. 
Modified by adding AlCl3 to prevent 
NTBI shuttling 
Walter et al 
(2008) 
17 healthy controls, aged 23 to 40 yrs 29% (19 to 41%) -0.87 (-1.27 to –0.75) Singh et al (1990), Porter et al (1996) 
NTA HPLC 
Cighetti et al 
(2002) 
Acute myocardial 
infarct 
322 patients within 24 hr of AMI Unknown 0.14 ± 0.23 Esposito et al (2003) DFO 
fluorescence 
Sulieman et al 
(2004) 
Ageing 41 healthy individuals  Unknown  Positive correlation labile 
cellular iron with ageing  
Flow cytometry Doulias et al 
(2008) 
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African iron 
overload 
25 African patients with iron overload, and 170 
relatives & neighbours 
Unknown 1.47 ± 1.75 (undetectable to 
7.9) 
Al-Refaie et al 1992 NTA HPLC Mcnamara et al 
(1999) 
Alcohol abusers a) 29 active drinkers with cirrhosis, aged 55 ± 
11 yrs 
a) 67 ± 27% a) 2.22 ± 2.49 Singh et al (1990), Porter et al (1996) 
NTA HPLC 
De Feo et al 2001 
b) 14 active drinkers without cirrhosis, aged 55 
± 9 yrs 
b) 46 ± 22% b) 0.59 ± 1.64 
Alcoholic cirrhosis 33 patients, with known absence of other 
causes of liver damage, aged 52 ± 10yrs 
56 ± 34% 0.385 ± 0.560 Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Le Lan et al 
(2005) 
β-Thalassemia & 
blood transfusion 
66 thalassemia patients receiving 2 different 
iron chelation treatments 
a) 89.1 ± 19.8%, b) 95.3 ± 
11.0% 
a) 3.19 ± 2.21, b) 4.81 ± 1.94  Singh et al (1990) ultrafiltration. 
Modified by adding AlCl3 to prevent 
NTBI shuttling 
Walter et al 
(2008) 
a) 21 thalassaemia major  a) 82% median (58 to 110%) a) 2.57 (0.08 to 6.73)  Singh et al (1990), Porter et al (1996) 
NTA HPLC 
Cighetti et al 
2002 
b) 13 thalassaemia intermedia b) 65% median (29 to 88%) b) 1.28 (-0.45 to 4.08) 
Blood donation n=443 healthy male and female blood donors, 
aged 59.1± 5.4 yrs   
30 ± 12% 2.33 ± 0.94  Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Engberink et al 
(2008)  
Chemo-therapy  40 bone marrow transplant patients, female to 
male ratio 1:11, aged 18 – 64 yrs. 18 received 
chemotherapy, 22 received radiochemotherapy 
98% (75 to 100%) 4.0 (1.90 – 6.90) day 0 Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
Durken et al 
(1997) 
Chronic renal 
failure without 
dialysis or iron 
supple-mentation 
24 patients aged 43 ± 14 yrs Unknown 15.93 ± 2.81 S.E.M. (Fe
2+
 
22.5%) 
Nilsson et al (2002) BPS 
spectrophotometry 
Prakash et al 
(2005) 
Coronary heart 
disease risk 
11,471 females aged 49-70 yrs were followed 
for ~4.3 yrs. 
Range of means 18.2 to 28.7% 
at baseline 
Range –2.06 to 3.51. An 
inverse relationship was 
found between increased 
NTBI & CHD risk 
Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Van Der A et al 
(2006) 
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Type 2 diabetes 49 newly diagnosed patients 29.4 ±11.7  0.24 ± 0.29. NTBI detected in 
59.2% of sample 
Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
Lee et al (2006) 
48 patients with >5 yrs duration diabetes 33 ± 11.2 0.62 ± 0.43. NTBI detected in 
91.7% of sample 
Type 1 & type 2 
diabetes 
Type 1 diabetes n=25,  
Type 2 diabetes n=51 
T1 DM 26.1 ± 1.7%,  
T2 DM 26.5 ± 1.6% 
0.53 ± 0.09, compared with 
0.10 ± 0.03 controls 
DFO-FE complex, with ultrafiltration, 
HPLC 
Leoncini et al 
(2008) 
Diabetes & acute 
myocardial 
infarction 
329 diabetes patients within 24 hr of AMI Unknown 0.43 ± 0.7  Esposito et al (2003) DFO 
flourescence 
Sulieman et al 
(2004) 
End stage renal 
disease receiving 
dialysis without 
iron 
supplementation or 
rHuEPO 
22 patients aged 46 ± 14 yrs Unknown 42.41 ± 20.72 S.E.M. (Fe
2+
 
19.8%) 
Nilsson et al (2002) BPS assay Prakash et al 
(2005) 
Dysmetabolic 
hepatosiderosis 
26 patients with high serum ferritin and insulin 
resistance syndrome, aged 55 ± 11 yrs 
47 ± 14% 0.381 ± 0.381 Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Le Lan et al 
(2005) 
Haemochromatosis: 
homozygous - 
treated 
27 patients, mostly receiving maintenance 
treatment 
27 to 85%, mean 57% 1.79 (-0.25 to 3.90) Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
De Valk et al 
(2000) 
14 male patients receiving maintenance 
treatment, aged 56 ± 11 yrs 
40 ± 14% 0.221 ± 0.559 Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Le Lan et al 
(2005) 
Haemochromatosis: 
homozygous - 
untreated 
23 male patients, with excess iron, pre-
treatment, aged 44 ± 10 yrs 
87 ± 16% 0.761 ± 0.504 Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Le Lan et al 
(2005) 
Haemochromatosis: 
heterozygous 
46 subjects, selected for low and high NTBI, 
aged 43 ± 15 yrs 
Range of means 19.6 to 51.0% Median 2.75 M, 2.30 F (0.44 
to 6.21)  
Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Van Tits et al 
(2006) 
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 22 symptom free individuals 14 to 40%, mean 27% 0.51 (-0.75 to 2.75) Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
De Valk et al 
(2000) 
Myeloablative 
treatment for stem 
cell transplant 
6 patients with haematological malignancy 91% (87 - 94%) Range 0.8 to 1.0 for all 6 
patients 
Evans & Halliwell (1994), bleomycin 
assay 
Sahlstedt et al 
(2002) 
Neonates 384 neonates, 195 found to have NTBI >1.16 
µmol/L 
  Range 1.16 to 15.2 Kime et al (1996) HPLC, chelation by 
disodium nitryloacetic acid & CP22 
Buonocore et al 
(2003) 
Premature 
neonates 
21 infants receiving blood transfusion, median 
gestational age 27 wks. 
Pre BT median 51.4%, Post BT 
54.1% 
Pre BT range 0.0 to 4.5 
(median 0), post BT 0.0 to 
20.7 (median 2.1) 
Gutteridge et al (1981) bleomycin 
assay 
Hirano et al 
(2001)  
Range of diseases 195 chemotherapy, haemochromatosis and 
other unspecified patients 
Unknown Range of findings 0 to 2 µM Colorimetric method: Zhang et al 
(1995); HPLC: Singh et al (1990) 
Kolb et al (2009) 
Table 2. The occurrence of non-transferrin-bound iron following iron supplementation (examples) 
Patient group Study population 
Transferrin saturation  % 
mean (range) 
NTBI 
(µmol/L) mean (range) or SD 
NTBI measurement method used References 
Oral iron 7 otherwise healthy anaemic women received 
200mg FeSO4 (65mg elemental iron) with food 
(a), without food (b) 
a) ~73% 3hr post iron b) ~58% 
3hr post iron 
a) 4.6 ± 0.5 SE, b) 3.9 ± 1.1 SE Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
Hutchinson et al 
(2004) 
Oral iron 35 unfasted pregnant females received 100mg 
ferrous calcium citrate 
Unknown 0.074 (SD 0.23) 1 hr post 
administration 
Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Gurumurthy et al 
(2008) 
Intravenous iron & 
healthy subjects 
20 healthy volunteers aged 18 - 38 yrs, received 
100mg ferrous saccharate (Venofer) 
40 ± 18% 3.3 ± 2.2, 4 hrs post iron Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
Rooyakkers et al 
(2002) 
Intravenous iron & 
pregnancy  
22 pregnant females received 100/5ml Venofer Unknown Mean 0.81 (SD 0.95) 1 hr 
post administration 
Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Gurumurthy et al 
(2008) 
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Intravenous iron & 
immune apheresis  
6 patients with autoimmune diseases, aged 42 
± 7.8yrs, received 50mg iron (III) sucrose 
(Venofer) 
45.2 ± 14.4%, 30 minutes post 
iron 
0.0 in 5 patients, 0.16 in 1 
patient, within 30 minutes 
post iron 
Gutteridge et al (1981) bleomycin 
assay 
Sengoelge et al 
(2004) 
6 patients with autoimmune diseases, aged 42 
± 7.8yrs, received 100mg iron (III) sucrose 
(Venofer) 
66.8 ± 25.7%, 5 minutes post 
iron 
Range 0.1 to 0.5 within 30 
minutes post iron 
  
Intravenous iron, 
haemodialysis, and 
peritoneal dialysis 
71 HD and CAPD patients aged 18-90 yrs, 
receiving either 100mg iron sucrose or sodium 
ferric gluconate 
29.5±14.4% Redox active NTBI detected 
in 19.7% of patients, mean 
2.2±1.75 
Breuer & Cabantchik (2001) 
Fluorescence based one step assay 
Esposito et al 
(2002) 
10 HD & rHuEPO treatment patients received 
100mg iron saccharate over 60 minutes (a) and 
6 minutes (b) 
Unknown a) 3.17 ± 1.18 1hr post iron, 
b) 2.42 ± 1.13 1hr post iron 
Singh et al (1990), Gosriwatana et al 
(1999), NTA/cobalt HPLC 
Kooistra et al 
(2002) 
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Appendix 2.i. Tables of results 
Table 46. Protein in filtrate, % of amount pre-filtration, Batches A to D  
  Glucose incubation (mM) 
Batch Run Fresh 0 500 750 1000 
A 1 1.41 4.38 3.60 3.80 11.20 
 2 0.00 0.00 5.62 3.75 6.54 
 3 0.68 0.00 1.23 7.34 12.91 
B 1 0.00 0.00 3.66 11.32 3.28 
 2 0.00 0.00 0.00 1.80 3.68 
 3 0.00 0.00 1.05 1.25 1.80 
C 1 0.00 0.00 0.00 1.09 0.00 
 2 0.00 0.00 3.07 0.00 3.17 
 3 0.00 0.00 3.62 0.00 0.00 
D 1 0.00 0.00 0.00 0.00 0.00 
 2 0.00 0.00 0.00 0.00 0.00 
 3 0.00 0.00 0.00 0.00 0.00 
 Mean 0.17 0.36 1.82 2.53 3.55 
 SD 0.44 1.26 1.98 3.56 4.49 
 P  0.626 0.043* 0.060 0.027* 
   P vs Fresh P vs 0 P vs 0 P vs 0 
SD: Standard deviation 
 
Table 47. Protein in retentate, % of amount pre-filtration, Batches A to D  
  Glucose incubation (mM) 
Batch Run Fresh 0 500 750 1000 
A 1 90.08 89.13 85.01 81.28 71.17 
 2 81.17 75.09 91.41 70.26 89.99 
 3 98.20 115.60 84.11 110.24 87.79 
B 1 107.43 97.17 75.73 68.98 62.72 
 2 107.36 92.63 76.14 71.64 74.85 
 3 97.22 96.86 86.04 59.52 75.96 
C 1 94.58 125.00 75.15 63.86 74.36 
 2 90.49 91.51 67.36 77.79 73.52 
 3 86.96 93.14 106.71 60.93 80.03 
D 1 82.36 80.94 84.72 81.04 83.78 
 2 98.35 96.21 93.06 75.68 74.71 
 3 94.92 84.59 90.29 83.17 83.00 
 Mean 94.09 94.82 84.64 75.37 77.66 
 SD 8.40 13.80 10.40 13.60 7.60 
 P  0.877 0.053 0.002** 0.001** 
   P vs Fresh P vs 0 P vs 0 P vs 0 
SD: Standard deviation 
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Table 48. Iron in filtrate, Batches A to D (μM) 
  Glucose incubation (mM) 
Batch Run Fresh 0 500 750 1000 
A 1 26.5 36.2 34.4 28.3 32.1 
 2 41.0 37.1 43.2 48.1 47.4 
 3 30.3 38.4 32.4 29.4 30.2 
B 1 34.3 38.4 43.2 41.7 43.9 
 2 34.7 37.9 47.0 47.2 48.6 
 3 36.5 38.4 50.9 43.9 49.8 
C 1 39.5 47.6 51.2 55.5 46.8 
 2 42.8 38.3 48.0 51.6 46.2 
 3 41.8 42.3 51.8 42.5 55.2 
D 1 50.9 54.4 48.8 46.1 43.7 
 2 33.7 33.5 55.8 40.4 46.0 
 3 33.1 43.3 46.7 42.5 56.5 
 Mean 37.1 40.5 46.1 43.1 45.5 
 SD 6.5 5.7 6.9 7.9 7.8 
 P  0.189 0.041* 0.362 0.084 
   P vs Fresh P vs 0 P vs 0 P vs 0 
SD: Standard deviation 
 
Table 49. Iron in retentate, Batches A to D (μM) 
  Glucose incubation (mM) 
Batch Run Fresh 0 500 750 1000 
A 1 24.37 16.54 15.34 16.78 14.13 
 2 19.07 17.63 10.88 8.83 9.92 
 3 15.81 20.31 12.06 11.69 13.31 
B 1 25.72 21.54 12.68 13.95 11.42 
 2 36.10 21.54 10.53 10.66 11.42 
 3 23.19 22.56 10.03 11.16 10.66 
C 1 20.08 15.45 10.33 8.33 9.83 
 2 18.33 19.20 12.70 10.20 9.95 
 3 17.45 16.58 8.58 13.45 8.20 
D 1 8.79 6.53 3.27 5.07 8.90 
 2 23.32 17.35 17.01 11.49 7.44 
 3 10.48 11.27 5.18 5.97 4.51 
 Mean 20.23 17.21 10.71 10.63 9.97 
 SD 7.24 4.60 3.84 3.31 2.59 
 P  0.2359 0.0011** 0.0006*** 0.0002*** 
   P vs Fresh P vs 0 P vs 0 P vs 0 
SD: Standard deviation
299 
 
Appendix 3.i. Materials and methods 
Materials purchasing 
1,2-dimethyl-3-hydroxy-4(1H)-pyridinone (DHP), nitrilotriacetic acid (NTA), butylated 
hydroxytoluene, and all other laboratory reagents were purchased from Sigma-Aldrich. Amicon 
Ultra filter units 30 kDa were purchased form Merke-Millipore.  
Equipment 
See section 2.3.1 for full laboratory equipment list. 
UV/Vis HPLC 
Dionex UVD170S detector.  
Hichrom C18 polyether ether ketone (PEEK) lined column, 100 mm x 4.6 mm, 5 µM particle 
size, with a PEEK-lined 2 µm inline filter. 
Gynkotec pump. Rheodyne injector port and sample loops, all PEEK-lined. 
Chromeleon software. 
Fluorescence HPLC 
Dionex Ultimate 3000 detector and pump 
Hichrom C18, 100 mm x 4.6 mm, 5 µM particle size column, with a 2 µm inline filter. 
Electrochemical HPLC 
BAS LCD 40 electrochemical detector 
Milton Roy Constametric pump  
150 mm x 5.0 mm Hichrom C18 column  
Protocols 
Measurement of non-transferrin-bound iron in plasma 
SOLUTIONS 
PHOSPHATE BUFFERED SALINE [PBS] pH 7.4 (0.154M NaCl) 
[137 mM NaCl; 2.7 mM KCl; 8 mM Na2HPO4; 1.46 mM KH2PO4] 
Using a 250 ml volumetric flask weight out the following: 
NaCl [MW 58.44]   2.0 g 
KCl [MW 74.56]   0.05 g 
Na2HPO4.12H2O  [MW 358.14] 0.716 g  
KH2PO4 [MW 136.09]               0.05 g 
Dissolve in about 200 ml H2O.  Take pH to 7.4.  Make up to 250 ml with H2O. 
Store in refrigerator. 
 
NITRILOTRIACETIC ACID [NTA] (0.8M) 
Weigh out 4.702 g of nitrilotriacetic acid disodium salt [MW 235.1] and place in 25 ml flask.  
Add about 20 ml H2O.  When dissolved, take pH to 7.0 with 100 mM NaOH.   Make up to 25 ml 
with H2O. Store in refrigerator 
 
3-HYDROXY-1,2-DIMETHYL-4(1H)-PYRIDONE [DHP].  IRON CHROMOPHORE  
[MW 139.15] Weigh out 0.014 g, add 2.0 ml of PBS.  This makes a 50 mM solution.  
 
STOCK FERRRIC ION STANDARDS 
Stock solution 1 mM FeCl3. [FeCl3.6H2O  MW 270.3] 
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Weigh out 0.027 g of FeCl3.6H2O and make up to 100 ml with HPLC grade H2O. 
Store in small volumes at -80oC. 
Prepare standards for calibration, ranging from 1 to 10 µM 
 
MOBILE PHASE 
5 mM PIPES buffer pH 7.0 containing 3.5 mM DHP and 5% acetonitrile 
1. Weigh out 0.866 g of PIPES disodium salt and place in a 500 ml flask 
2. Add 0.244 g of DHP.  
3. Make up to 500 ml with HPLC grade water 
4. Add 30 ml of acetonitrile 
5. Take to pH 7.0 with 1.0 M HCl 
6. Filter and degas 
 
PROCEDURE 
[1] Take 150 µl of plasma and add 15 µl 0.8M NTA solution.  Incubate at room 
temperature for 20 minutes. 
[2] Add 150 µl of phosphate buffered saline and mix well. 
[3] Place mixture in 30kDa Millipore amicon ultra filters 
[4] Centrifuge at 13,000 x g for 30 minutes at 4oC.   
[5] Remove ultrafiltrate, measure volume, to every 100l add 10 l of 50 mM DHP.   
[6] Incubate for 5 minutes at RT and then inject into the HPLC system. 
 
UV/Vis HPLC set-up 
Pump pressure 1 ml/min. Peaks measured between 3.5 and 5.0 minutes, at 450 nm. 
Measurement of ascorbate and urate  
Loosely based on method of Sato et al (2010) and Mitton & Trevithick (1994)  
SOLUTIONS 
Standard Ascorbate & Urate 
Ascorbate: 0.018 g/100 ml [0.009 g/50 ml] in H2O gives a 1.0 mM stock solution. Dilute in PBS 
to standards 10M to 50M. 
Urate: 0.019 g/100 ml [0.0095 g/50 ml] in H2O gives a 1.0 mM stock solution. 
Dilute in PBS to standards 10M to 50M. 
 
10% Metaphosphoric acid [MPA] containing 2mM EDTA 
Make up a solution of 2 mM EDTA in H2O.  e.g 0.186 g EDTA disodium salt made up in 250 ml 
H2O.  Use this to make up the MPA solution. 
5 g of MPA diluted with 50 ml of H2O containing 2 mM EDTA. 
 
5% MPA containing 1 mM EDTA 
A 1:2 dilution of the above in H2O 
 
Tris (2-carboxyethyl)phosphine hydrochloride [TCEP] 350 mM in 5% MPA containing 1 mM 
EDTA (Reducing agent). 
0.100 g made up in 1.0 ml of 5% MPA in 1 mM EDTA 
 
MOBILE PHASE 
50 mM phosphate buffer pH 2.8 containing 540 µM EDTA and 2% MeOH 
3.9 g NaH2PO4 
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0.1 g EDTA 
Make up to 400 ml, add 10 ml MeOH and make up to 500 ml with MilliQ H20 
pH to 2.8 with 1.0 M HCl 
Filter and degas 
 
PROCEDURE 
[1] Take 100 l of plasma and add to 100 l of 10% MPA containing 2.0 mM EDTA. Mix 
well and centrifuge at 20,000 x g at 4oC for 10 minutes. 
[2] Store ascorbate extract at -80°C until measured. 
[3] Take 2 x 45 l aliquots of supernatant.  
[4] To one add 10 l of 5% MPA containing 1 mM EDTA.  Add a further 100 l of 5% MPA 
containing 1 mM EDTA.  Mix well. This is for measurement of reduced ascorbate.  
From this sample remove 50 l and add to a tube containing 450 l 5% MPA 
containing 1 mM EDTA.  Mix well.  This is for measurement of urate. 
[5] To the other sample add 10l 350 mM TCEP in 5% MPA containing 1 mM EDTA.  
Incubate for 20 minutes at room temperature.  This is to reduce the oxidised 
dehydroascorbate back to ascorbate.  This measures total ascorbate  
 
Suggested procedure: Inject the reduced sample, and the sample for urate while the total 
ascorbate sample is incubating. Then inject the total sample. 
 
Standards:   Prepare standards as follows:  
1. Take 100 l of standard and add to 100 l of 10% MPA containing 2 mM EDTA.  
Mix well and centrifuge at 20,000 x g for 10 minutes at 4oC. 
2. Take a 45 l aliquot and add 10 l of 350 mM TCEP in 5% MPA containing 1 
mM EDTA. 
3. Incubate for 20 minutes at room temperature. 
4. Inject into HPLC system 
 
Electro-chemical HPLC set-up 
Pump: 1 ml/min; Volts: + 0.6; Range: 0.5 µA; Filter: 0.10 Hz 
Measurement of malondialdehyde (MDA) 
Based on the method of Agarwal & Chase (2002). 
SOLUTIONS 
Butylated hydroxytoluene (BHT) 0.05% in 95% ethanol 
Weigh out 0.0025 g add to 4.750 ml ethanol plus 250 µl dH20 
Phosphoric acid (0.44 M) 
Take 1.0 ml concentrated orthophosphoric acid and makeup to 100 ml with dH20 
Thiobarbituric acid (TBA) (42 mM) 
To 0.303 g of TBA make up to 50 ml with dH20. Heat at 50 to 55°C until dissolved 
Stock solution of MDA 
Weigh out 0.00313 g of MDA and make up to 10 ml with dH20. Dilute with PBS to make a range 
of standards from 500 nM to 10 µM 
Mobile phase 
Potassium dihydrogen phosphate (KH2PO4) (50 mM) 
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Weigh out 3.403 g of KH2PO4 dissolve in HPLC grade H2O to make 500 ml. Mix 80% 50 mM 
KH2PO4 (500 ml) and 20% HPLC grade MeOH (125 ml). Adjust pH to 6.8 using 5 M sodium 
hydroxide. Filter and degas. 
 
PROCEDURE 
In 2 ml centrifuge tubes with screw caps put 50 µl plasma, standard or blank. Add 50 µl of BHT 
solution then add 400 µl of phosphoric acid and 100 µl of TBA solution.  
 
1. Mix well on a vortex mixer. Heat for 1 hour at 100°C in a dry block 
2. Remove and place on ice to cool 
3. Add 300 µl of n-1-butanol. Mix on a vortex mixer for 15 seconds per sample, repeat for 
a further 15 seconds 
4. Centrifuge for 5 minutes at 13,000 x g to separate the aqueous and butanol phases 
5. Carefully remove 200 µl of the butanol extract. Inject directly into HPLC system  
6. Use methanol to wash system between each sample. 
 
Fluorescence HPLC SET-UP 
Pump: 1ml/min; Fluorescence HPLC Wavelengths - Excitation: 515 nm, Emission: 553 nm; 
Sensitivity: 4 
 
Total iron (Bothwell et al 1971), and Total iron binding capacity (Ramsay 1957), see Chapter 2. 
 
Refererences 
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W. (1971) Proposed Recommendations for Measurement of Serum Iron in Human Blood. 
Blood 37 (5): 598-600 
Mitton, K. Trevithick, J. (1994) High performance liquid chromatography-electrochemical 
detection of antioxidants in vertebrate lens: glutathione, tocopherol and ascorbate.  Methods 
in Enzymology 233: 523-39 
Ramsay, W. (1957) The determination of the total iron-binding capacity of serum Clinica 
Chimica Acta 2 (3): 221 - 226 
 
303 
 
Courses, conferences, and presentations  
Within the PhD period of study the following courses and conferences have been 
attended: 
December 2008, British Dietetics Association Research Symposium for Dietitian’s New 
to Research, poster presentation 
February 2009, Combating Obesity: Strategies for Prevention and Intervention 3: an 
Erasmus intensive two week programme, Austria, oral presentation 
June 2009, Postgraduate Research Day, Plymouth University, Faculty of Health, oral 
presentation 
June 2009, UK Genetic Haemochromatosis AGM, Royal Free Hospital, London 
December 2009, First International Conference on Metal Chelation in Biology and 
Medicine, Bath 
June 2010, South West Dietitian’s Research and Clinical Dietetics Study Day, Plymouth 
University, oral presentation  
June 2010, Postgraduate Research Day, Plymouth University, Faculty of Health, oral 
presentation 
June 2010, UK Genetic Haemochromatosis AGM, Royal Free Hospital, London, oral 
presentation 
July 2010, Division of Biosciences seminar, Brunel University, Middlesex, oral 
presentation 
July 2010, School of Health Professions Research Group meeting, oral presentation 
September 2010, The European Iron Club Annual Meeting, Building bridges with bio-
iron from bench to bedside, Nijmegen, The Netherlands, poster presentation 
November 2010, South Devon Health Care Foundation Trust, Riviera Research Day, 
Torbay, poster presentation 
March 2011, Cambridge University and ABCAM conference, Iron related diseases: A 
look to the future, Cambridge, poster presentation 
April 2011, Centre for Research in Translational Biomedicine Annual Research Day, 
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